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  Abstract 
 
c-Myb is a gene-specific transcription factor involved in the regulation of many target genes. 
As with other oncoproteins, an atypical function of the c-Myb may lead to uncontrolled cell 
growth and division that may cause many human cancers, where the c-Myb is over-expressed. 
Thus, it is observations like these that have established c-Myb as an attractive target for cancer 
therapy. 
 
Halting expression of the c-Myb transcription factor was done by inhibition of the DNA-
binding domain in c-Myb with small organic molecules. Compounds NSC87877 and 
NSC675460 (structures shown below) were previously identified as potential inhibitors of the 
DNA-binding domain in the c-Myb.  
 
Five analogs of NSC87877 were synthesized. The abilities of the five compounds towards 
inhibition of the c-Myb transcription factor were tested both in silico and in biological assays. 
 
In silico design of novel potential inhibitors based on the structure of NSC675460 was 
performed, resulting in 3 new lead compounds. Synthesis of compound NSC675460 was only 
partially completed. 
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Chapter 1 
 
Introduction 
 
1. The aim of the project 
 
• To investigate the nature of the transcription factor c-Myb in order to understand its role in many 
human cancers. 
 
• To inhibit the expression of the transcription factor c-Myb by blocking the DNA-binding domain in c-
Myb with small organic molecules. 
 
• To discover novel inhibitors of c-Myb and evaluate its activity against c-Myb through the use of the 
specialized software. 
 
• To investigate the possible metabolic routes of the newly discovered organic compounds.  
 
• Use the bioisosteric approach to enhance the robustness of the compounds towards the metabolic 
processes in human body and biological activity of the molecule of interest. 
 
• To investigate the selectivity of the newly discovered inhibitors towards the target molecule. 
 
• To synthesize the newly discovered inhibitors and send them for testing in biological assays at the 
MYB group, the Department of Molecular Biosciences, University of Oslo.  
 
• To compare results from the biological testing with results from computational studies. Evaluate how 
precise the software can predict the inhibition activity of the molecules of interest against the 
transcription factor c-Myb. 
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1.1 Introduction to the Myb family of transcription factors 
 
The material in this chapter will present general information about the transcription machinery in 
eukaryotic cells, an overview of the Myb family of transcription factors, the proto-oncoprotein c-Myb, 
its biochemistry and its role in oncogenesis. These topics are necessary for understanding the strategy of 
inhibition of transcription factors with small organic molecules. 
 
1.1.1 Transcription factors  
 
Transcription is a process where a DNA-sequence is copied into a 
complementary RNA-sequence.1 Enzymes that perform 
transcription of a DNA-segment are called RNA-polymerases. In 
eukaryotic organisms, there are three types of RNA-polymerases – 
I, II and III. RNA-polymerase II transcribes most genes, including 
those coding for proteins. A simplified process of a transcription 
can be viewed as follows: unwinding of a DNA-double helix, 
reading of a DNA segment and then catalysis of the formation of 
the phosphodiester bonds that link the nucleotides together to form 
a linear RNA chain. Initiation of transcription requires a vast array 
of general and specific transcription factors that bind to the 
promoters used by RNA-polymerase II, thereby making a sort of a 
platform for RNA-polymerase II.1 The overall process of initiation 
of transcription can be illustrated in this manner (figure 1). 
 
Gene-specific transcription factors are gene-regulating proteins 
that recognize DNA-sequences that code for particular proteins. 
They operate as a part of a bigger complex, where different co-
factors interact with transcription factors thereby allowing better  
control of gene expression. Specific transcription factors have  
different specialized domains that perform specific tasks during                   
transcription. A DNA-binding domain is responsible for recogni- 
tion of specific site(s) on DNA and binding to a particular region. 
Another typical domain is one that mediates proteins activity.1                      
                                                         
 
 
Fig. 1. Schematic representation of 
the transcription machinery. Fig. is 
taken from ref. 1.  
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1.1.2 The Myb family  
 
The Myb-family is a family of transcription factors that are commonly found in eukaryotic organisms, 
including animals, fungi and plants.2 The oncoprotein c-Myb is the best characterized member of the 
family that also consists of v-Myb, A-Myb and B-Myb. The main feature of the members of the Myb-
family is the presence of so called “Myb domains” that are highly conserved regions located inside 
protein.2 The Myb family was first discovered in its oncogenic form – v-Myb – in the AMV and the E26 
retroviruses that cause monoblastic leukemia (AMV) and erythroblastic and myeloid leukemia (E26) in 
chicken.2  
 
1.1.3 The c-Myb transcription factor 
 
c-Myb is a gene-specific transcription factor with a helix-turn-helix (HTH) DNA-binding domain.3 The 
protein weights 75 kD and contains 640 amino acids in three different domains: The N-terminal DNA-
binding domain (DBD), the central transactivational domain (TAD) and the C-terminal regulatory 
domain (CRD) (figure 2). These domains are highly conserved between members of the Myb-family 
and contain sites for interaction with DNA and other proteins. In the scope of this project, only the 
DNA-binding domain will be thoroughly discussed. 
 
 
Fig. 2 Schematic representation of c-Myb’s functional domains. The DNA-binding domain is located in N-terminus, in the 
central part lays transactivational domain and CRD is located in C-terminus. 
  
The DBD in c-Myb has a HTH-like motif and consists of three tandem repeats that are commonly 
referred to as R1, R2 and R3 starting from the N-terminal.4 Each repeat contains 51 – 52 amino acids 
including three tryptophan residues that are located after every 18-19 amino acids. The Trp residues are 
crucial for DBD’s ability to interact with the DNA since they maintain HTH-like structure that is critical 
for the correct positioning of the DNA sequence. In addition, acidic and hydrophobic regions are also 
found in the domain. 
 
The R1, R2 and R3 regions consist of three α-helixes that are folded and create a complex structure 
(figure 3).3,5 It has been shown that only the R2 and R3 repeats bind directly to the DNA, while the R1 
stabilize the protein/DNA structure through electrostatic interactions (figure 3). When DNA comes in 
contact with the R2 and R3, hydrogen bonds between the Asn183, Asn179 and Lys182 residues from 
the R3 region are formed with the following bases from DNA: A18, A19 and G8. In the R2 region 
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hydrogen bonds are created between Glu132 and Lys128 and bases G22 and C20 respectively (figure 
4).3 
 
 
 
Fig. 3 Complex between R1, R2, R3 and DNA. R2 is green, R3 is blue and R1 is red. As it can be seen, R1 does not make direct 
contact with the DNA chain. Fig. is taken from ref. 6. 
 
 
 
Fig. 4 Hydrogen bonds (blue) between DNA (yellow) and the residues from the R2R3 (green). Image was generated with MMV.       
 
1.1.4 The role of the c-Myb in oncogenesis  
 
Bone marrow, large intestine and mammary glands are primary targets of the c-Mybs oncogenic activity 
in humans.2 The oncogenic activity of c-Myb can be activated by over-expression or inappropriate 
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expression, structural alteration and/or genomic rearrangements.7 The genomic locus of the c-Myb gene 
is often rearranged in human acute myelogenous leukemias, melanomas and carcinomas. This 
rearrangement of the locus results in an amplification of the expression of the c-Myb gene. Increased 
expression of c-Myb has also been detected in other cancers, such as breast and colon cancer. Genomic 
rearrangements in the c-Myb gene have also been identified in T-cell acute lymphoblastic leukemia, 
where duplication of the c-Myb gene and translocation of the c-Myb locus led to increased proliferation 
and blocking of differentiation. 
 
c-Myb is crucial in several processes required for carcinogenesis.7 It has been shown that high levels of 
c-Myb expression are necessary for survival and expansion of several types of human cancers. 
Leukemia cells are also more sensitive towards inhibition of c-Myb than normal hematopoietic cells. All 
these features make c-Myb an attractive target for the development of potential medicinal agents against 
human cancers.   
 
1.1.5 Inhibition of transcription factors with small organic molecules  
 
The general transcription machinery is used by all transcriptional factors, meaning that inhibition of 
some part of this machinery will have an affect on the whole system.8, 9 In order to modulate the activity 
of a chosen transcription factor, a small organic molecule must bind itself to an area on a surface of 
transcription factor that is critical for its normal functioning. The mode of action of small molecules as 
inhibitors can be divided into several classes:9 
 
- Small molecules that bind to the DNA binding domain of transcription factor(s). 
- Small molecules that bind to the DNA sequence targeted by transcription factor(s).  
- Small molecules that prevent dimerization of the transcription factor(s). 
- Small molecules that prevent contact between co-activators and transcription factor(s) by 
binding to the protein-protein interaction domain. 
 
c-Myb acts as monomer, making prevention of dimerization pointless in this case. Martinez et al. chose 
inhibition of the DNA binding domain in c-Myb as the approach of his choice and this approach was 
followed in this study also.68 The general idea was to find small organic molecules that can make a tight 
complex with residues involved in binding of the DNA strand, thus preventing contact between the 
DNA binding domain in the c-Myb and the DNA.      
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Chapter 2 
 
Design and analysis of novel pharmaceutical agents 
 
In this chapter, some background information about drug design is given. It includes an overview of 
major guidelines that are followed during the design of molecules with drug-like properties using in 
silico tools. 
 
2.1 Background information 
 
A drug is usually a small molecule that binds to, interacts with and affects the activity of a target 
molecule. Drugs are commonly used to identify, prevent or treat a disease. Pharmaceutical companies 
spend billions of dollars on discovery of novel drugs – a process that can easily take up to 10 years.11 
Discovery of new drugs has historically been a trial and error process where hundreds of chemical 
compounds have been screened in biological assays.11 The analysis of a drug candidate can be separated 
into several parts: examination of biological activities and ADMET parameters of a drug. The discovery 
of a possible drug is a multistep process that can roughly be divided into three stages: target 
identification, lead discovery and clinical trials.11 
 
The drug target is a macromolecule that is critical for a disease to function. Target molecule may be an 
enzyme, receptor or a transcriptional factor.10 Detailed knowledge about the target comes from 
biological and genetic investigations, X-ray and NMR studies. Lead discovery has been a very 
expensive stage of drug discovery process until 1980’s since it required very large amount of 
experimental work and time. In the 1980’s, computer aided drug design began to expand and grow due 
to progress made in the field of chemo- and bioinformatics as well as computer power. Today, large 
pharmaceutical companies have chemoinformatic departments, which enable them to screen millions of 
potential organic compounds.11 Chemoinformatic tools saves both time and money, it also helps 
researchers to avoid experimental dead ends that are not trivial to predict. There are several approaches 
towards discovery of new potential drug candidates using computer aided drug design. Structure based 
drug design (SBDD) is one of the approaches and it also the one that was used in this project.  
 
2.2 Structure-based drug design 
 
Structure based drug design relies on a fact that the structure of the target molecule is known.10 A 
potential drug candidate can then be discovered by screening of large databases of organic compounds. 
The initial process of finding a new drug candidate consists of two main parts: docking and scoring. 
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Docking is the generation of many different orientations of a drug candidate in and around the binding 
site of the target molecule. Using software language, it is a genetic algorithm that performs the docking. 
During docking, the software makes many spatial transformations of drug and receptor, trying to find 
most energetically favourable orientations. Scoring is the prediction of how well a particular orientation 
of a drug will be bonded to the target. Since inhibitor potency is directly related to the degree of target 
molecule–drug binding, it means that scoring is one of the main tasks in accurate prediction of the 
target-inhibitor affinities. The conformation with the lowest energy is usually the one that is predicted as 
the binding mode. 
 
2.3 Interactions between drug and target site 
 
The material in this section (section 2.3) is based on previously published works.1, 11, 73 
 
When a molecule binds to a target substrate, vast arrays of interactions arise.11 Water molecules get 
expelled upon binding, making it possible for functional groups to interact with each other. The binding 
of a drug to a target and how strong it will be depends solely on what type of bonds are being formed. 
The four most common types of bonds are covalent, ionic, hydrogen and London-forces (figure 5). 
 
 
Fig. 5. Schematic representation of the interactions. A – covalent bond, B – ionic bond, C – hydrogen bond, D – London-forces 
 
The strongest bond that can be found in drug-target interactions is covalent bond, where an atom from 
drug shares a pair of electrons with an atom from target molecule. Covalent bond is very strong 
(typically 50 – 100 kcal/mol) and often results in irreversible binding of drug to receptor. 
  
The next-strongest bond that can be formed between drug and target molecule is ionic bond. The 
strength of the ionic bond lies between 5 and 10 kcal/mol and its strength decreases proportionally to the 
square of the distance of two atoms that are involved in bonding. Ionic interactions increase 
significantly when drug differs closer to target. Ionic bond does not result in irreversible binding – a 
drug molecule can at some point diffuse away from the target.  
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Hydrogen bonds are formed when a hydrogen atom is shared between two atoms, an electronegative 
donor and a basic acceptor atom. The most important hydrogen bonds are those involving the oxygen 
and nitrogen atoms of the carboxyl, hydroxyl, carbonyl, amino, imino and amido groups. A single 
hydrogen bond has on average strength of 2 – 5 kcal/mol, which is usually not sufficient enough to 
stabilize a drug-target complex on its own. More commonly a typical interaction between a drug and a 
target includes several H-bonds, that all confer to the stability of the drug-receptor complex. 
 
The weakest interactions that can be found in drug-target complex are London and hydrophobic 
interactions. London-forces appear from fluctuations in electron density around atoms. Unsymmetrical / 
disturbed electron densities around atom(s) causes a similar electron density to occur on neighboring 
atom(s) resulting in an attraction. These forces become significant as distance between clouds of atoms 
decreases. Hydrophobic interactions are forces that can be quite significant in aqueous solutions – they 
are formed when water molecules are expelled from the surface between drug and target molecules 
upon binding. Hydrophobic interactions are entropy driven – expelling water results in increase in 
entropy and decrease in energy.      
 
2.4 Software used in in silico design and analysis of molecules with drug-like properties      
 
There are many programs that are designed for the screening and evaluation of small molecules as 
potential drug candidates. The main difference between the programs comes from what type of function 
is being used for the scoring of ligands. Various scoring functions offer different accuracies in the 
scoring process, meaning that some programs provide theoretical results that are close to experimental 
values, while other software programs do not. In the past 20 years, numerous scoring functions have 
been developed and they can be divided into three major groups: force field,12 empirical13 and 
knowledge-based scoring functions.14 The choice of the software is regretfully not always based on their 
scoring accuracy. Factors like economic cost and user-friendliness are major concerns. Many programs 
do not have a GUI, so users very often spend more time learning codes and programming languages 
than actually performing scientific research. The compatibility of the software with CPUs, graphic 
cards, OSs etc is another major issue.      
 
Computational part of this project was based on a previous work done by Martinez et al.68 The software 
for docking studies that was used both in this and the previous project is AutoDock 4.2.15 Reasons for 
keeping AutoDock as our software of choice, is that it is a free software package that can be installed 
both on Mac OS X, Linux and Windows platforms and thus results from our and previous studies68 
could to some extent be compared. 
 
	  	  15	  
Chapter 3 
 
AutoDock and AutoDock Tools 
 
In this chapter, a presentation of the AutoDock package will be given. General steps in docking process 
will be reviewed. A short introduction on how to use the software will also be given. 
  
3.1 AutoDock 
 
AutoDock is a software package consisting of AutoDock (AD) and AutoDock Tools (ADT). The latest 
stable versions of AD and ADT are 4.2 and 1.5.4. AutoDock is a program that predicts the optimal 
bound conformation of a ligand-protein complex. AutoDock uses a semi-empirical free energy force 
field for scoring combined with a suitable genetic algorithm for generation of potential orientations of a 
drug molecule. A number of approximations are used during the process of finding and evaluating 
conformations to minimize computational time.  
 
3.2 Force field function 
 
The semi-empirical free energy force field estimates energy of binding of two (or more) molecules in a 
water environment by using pair-wise terms to evaluate the interaction between two molecules and an 
empirical method to estimate contribution of the surrounding water.16 The goal of this force field is to 
capture enthalpic and entropic contributions to the drug-target complex in a limited number of easily 
evaluated terms. The free energy of binding is the difference between the energy of ligand and the 
protein in an unbound sate and the energy of ligand-protein complex. This difference is broken further 
in to two pieces/steps: evaluation of intramolecular energies of the transition from the unbound state to 
the bound one for each of the molecules separately, and then evaluate the intermolecular energetics of 
bringing two molecules together into a bound complex (figure 6).  
 
 
Fig. 6. Schematic representation of scoring process in AutoDock 4. Fig. is taken from ref. 16.  
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The estimation process of the free energy of bonding of one particular conformation includes six pair-
wise evaluations (V) and estimation of the lost conformational entropy upon binding (ΔSconf), L stands 
for ligand and P for protein (equation 1):16 
 
Equation 1 
 
Every evaluation V is then composed of evaluations for dispersion/repulsion, hydrogen bonding, 
electrostatics and desolvation (equation 2):16 
 
 
Equation 2 
 
Constants – W etc. – have been calibrated by using a large dataset of known ligand-target complexes, 
where the free energy of binding and other parametres have been obtained experimentally. 
 
3.3 Genetic algorithm        
 
The second major part of AutoDock software is the genetic algorithm (GA) used for docking. As it was 
mentioned before, docking is a process of finding new conformations of protein and target molecules. 
Exploration of possible conformations through the use of genetic algorithm is inspired by natural 
genetics and biological evolution. As implied by the name, the problem of discovery of new 
energetically favorable orientations of ligand and target molecule must be encoded using “genetic 
language” – as a genome or chromosome. Genomes or chromosomes undergo common evolutionary 
“events” - mutations, crossovers etc – slightly improving its “properties” – finding conformation with 
lowest energy. Lamarckian genetic algorithm proved to be one of the best genetic algorithms for use in 
docking experiments with large conformational space. The material in this section is based on 
previously published material.17   
 
The first step in a docking process is to define a particular arrangement of ligand and protein using state 
variables: translation of the ligand  (x,y and z coordinates in space), orientation and conformation of 
ligand with respect to the target molecule. Each state variable of ligand corresponds to a “gene”, so all 
state variables form ligand’s “genotype”, while atomic coordinates of ligand correspond to the 
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“phenotype”. When the process of docking starts, each genotype is evaluated by a scoring function that 
gives total interaction energy of ligand and target molecule – using language of GA this process is 
called fitness. Another important term used in GA is “chromosome” – a set of all parameters that 
describe both ligand and target molecule – its genotype and phenotype. 
 
In a docking experiment, the “chromosome” of a compound is thus made of several genes: three 
Cartesian coordinates for the ligand translation, four variables defining the ligand orientation and one 
value for each torsion of the ligand. Once the genes have been defined, the genetic algorithm starts by 
creating a population of individuals where the number of individuals in the population is defined by the 
user. Process of crossover and mutation are applied to create new individuals in a population by 
changing one or more of the state variables – three translation genes for x, y and z is given a random 
value between the minimum and maximum x, y and z extents of the grid map, the four genes describing 
the orientation are given a random quaternion, consisting of a random unit vector and a random rotation 
angle between -180° and +180°. Then a process of “fitness” of every individual is applied using the 
scoring function. Like in biology, not all “individuals” survives – only the best go to the next step in the 
process of docking/scoring in accordance with (equation 3): 
 
 
Equation 3 
 
In equation 3 n0 is the integer number of offspring to be allocated to the individual; fi is the fitness of the 
individual, that is, the energy score of the individual; fw is the fitness of the worst individual (highest 
energy) in the last N generations (i.e., N is a user-definable parameter, typically 10) and 〈 f 〉 is the mean 
fitness of the population. Since fw will always have a higher energy than both fi and 〈 f 〉, except for when 
fw = fi). For individuals who have a fitness lower than the mean fi < 〈 f 〉, the numerator in this equation, 
fw - fi , will always be greater than the denominator fw - 〈 f 〉, and therefore such individuals will be 
allowed at least one offspring, and thus will be able to reproduce. In this way the more “fit” individuals 
will be allowed to carry their “genes” into the next generation, whilst the least “fit” will eventually 
become “extinct”. Finally if fw = 〈 f 〉, the population is assumed to have converged and the docking is 
terminated. 
 
When individuals for the next generation are selected, the process of crossover, mutation and scoring 
starts all over again. This process is repeated for a number of generations that is user-defined. 
Sometimes random mutations and crossovers may drive the search for a global minimum in a wrong 
direction. Lamarckian GA deals with this issue by replacing state variables in the genotype with those 
obtained in the last docking run that corresponds to the lowest energy.  
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3.4 Grid maps and approximations 
        
A fast evaluation of interactions between ligand and target molecule is achieved through the use of grid 
maps (figure 7).18 It means that affinity potentials are pre-calculated for each atom of a ligand. The 
target protein is set in a three dimensional grid and a probe atom is placed at each grid point. The energy 
of interaction is assigned to this point. An affinity map is calculated for every atom and every single 
grid point that is present in the potential drug candidate. A grid map of electrostatic potentials is pre-
calculated too. Subsequently these maps are used as a look-up table in order to perform a rapid energy 
evaluation.  
 
                  Fig. 7. Representation of the grid box concept. Fig. is taken from ref. 21.  
 
In order to provide accurate results in a reasonable amount of time, a number of approximations must be 
included in the method of docking. Treating the target molecule as rigid is one of the most common 
simplifications. However, it is known that upon binding of a ligand to a target molecule some 
conformational changes occur, ranging from local side chain movements to large domain changes. The 
target molecule itself is not a rigid structure where all atoms and chains are fixed at some position. 
There is always some amount of flexibility and structural fluctuations. This type of motion can be 
visualied / quantified upon performing NMR analysis of a macromolecule – all 20 structures from 20 
“runs” will slightly differ from each other in terms of bond lengths and angles between side chains. As it 
was mentioned above, AD’s “grid map” approach implicates that the target molecule is a rigid structure 
with zero degrees of freedom. One way to overcome this problem is to put specific side-chains outside 
of the grid box and treat them as flexible. 
 
3.5 Essential concepts to note during analysis of docking results 
 
Experimental affinities between a drug-like molecule and a target molecule usually differ from those 
obtained from docking software. So, if docking software cannot accurately predict experimental values, 
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it must at least rank the compounds to be screened in the correct order. Reproducibility of the binding 
mode and location is also important. AD has standard deviation of free energy prediction of about 2 - 3 
kcal/mol.17 Unfortunately it is not sufficient precision to enable ranking of the compounds as the best. 
Often, best hits from the first round of docking have to be “re-docked” to ensure that the pose and 
affinity is not just a statistical coincidence. 
       
One of the most important steps in docking analysis of potential drug candidates is the evaluation of the 
docking results. First of all, the software and the docking algorithm must be tested on a known system 
where the actual drug has subsequently been investigated by X-ray crystallography to ensure that the 
binding pose suggested by the software does not differ much from the experimental one. IC 50 values 
may also be compared. AD ranges docked compounds in order of increasing free energy of binding, 
which is a good criterion for a fast overview of results. Additionally, analyses of consistency of docked 
conformations by clustering of compounds based on RMSD (root mean square deviation) of the 
coordinates may provide additional proof. Conformations that are found many times in the same region 
of the target molecule are grouped into clusters. Clusters are then separated from each other according 
to their free energy of binding. So, when a drug-like molecule binds to a target molecule, it becomes 
less mobile and loses its entropy, which opposes binding forces between target and ligand.19, 20 It means 
that a cluster with a large quantity of molecules is more likely to induce favorable entropy changes in 
the system. If a cluster with a small amount of molecules has a lower free energy than a big cluster with 
higher free energy, then it is more probable that a large cluster will represent a more or less “true” 
picture of binding pose. Another important factor is the so-called ligand efficiency criteria.22 Large 
molecules tend to have better predicted affinity than smaller ones due to the fact that the binding affinity 
is somewhat proportional to the number of atoms in the ligand. Ligand efficiency calculates free energy 
of binding per non-hydrogen atom, giving a rough estimate of how “efficient” the molecule is. This 
being said, a large molecule with an affinity that is only 1 kcal/mol lower than another molecule that is 
twice as small, is not necessarily a better drug candidate.       
 
3.6 Representative procedure for in silico analysis of potential drug compounds 
 
A single docking is a process where a single molecule is docked against a target molecule. From this 
point on, the word “docking” will be used about the whole process of evaluation of molecule with AD 
and ADT. To perform a single docking, one needs 4 files: 
 
1. A file describing the ligand 
2. A file describing the macromolecule 
3. A file describing the search parameter file 
4. A file describing the parameters of the search 
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Preparation of the macromolecule file 
 
The structure of c-Myb DBD can be downloaded from the PDB’s databank website http://pdb.org. The 
file name is 1GV2.pdb. Open ADT 1.5.4 either by clicking on an icon or by typing in terminal:  
/Library/MGLTools/1.5.4/bin/adt & and press enter (figure 8). PDB-files are not perfect – sometimes 
they include water molecules and other atoms that must be removed prior to use. Click on File → Read 
molecule, open 1GV2.pdb (figures 8, 9, 10). 
                  
                                        Fig. 8                                                                                                      Fig. 9 
 
                   
                                            Fig. 10                                                                                             Fig. 11 
 
In order to remove the Na+ ions and water, click Select → Select from string (figure 11). Type HOH* in 
the Residue entry and * in the Atom entry. Click Add, this will select 60 atoms (figure 12). 
 
                
                                          Fig. 12                                                                   Fig. 13 
 
Click on clear form and type NA in the Atom entry. Click Add. You will see Selected: 62 residues 
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(figure 13). Then click Dismiss in the Select From a String window and click Edit → Delete → Delete 
Atom Set (figure 14). You will get a warning message, click on CONTINUE. This will delete all water 
molecules and the 2 Na+ ions. Then click Edit → Hydrogens → Add, choose to add All Hydrogens using 
method noBondOrder with yes to renumbering. Click OK to add all hydrogens. Then click File → Save 
→ Write PDB. Click OK to write the file. Then click Grid → Macromolecule → Choose, choose 1GV2 
→ Select Molecule. A new window will be opened where you will be asked to save your macromolecule 
file in the PDBQT-format. 
 
 
Fig. 14 
 
If the molecule already has charges, the program will ask you if you want to preserve the charges 
instead of adding Gasteiger charges. Click Yes. Then click Edit → Delete → Delete all molecules and 
click continue 
 
Preparation of the ligand file 
 
Click Ligand → Input → Open and choose the .pdb file corresponding to the molecule you want to 
dock. Upon opening the ligand molecule, ADT automatically computes Gasteiger charges, merges non-
polar hydrogens, lists how many rotational bonds molecule of your choice has, and detect aromatic 
carbons. It also colors atoms according to their type (carbon, oxygen etc) (figures 15, 16). 
 
                         
                                             Fig. 15                                      Fig. 16 
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Then the ligand must be saved as a PDQT-file. Click Ligand → Output → Save as .pdbqt (figure 17).  
 
                          
                                        Fig. 17                                                                                                       Fig. 18 
 
Press Edit → Delete → Delete all molecules and click Continue (figure 18). Right now both the 
macromolecule and the ligand files are prepared. The next step is to prepare the grid parameter file and 
the parameters search file. Click Grid → Macromolecule → Open and find 1GV2.pdbqt, then click 
Open (figure 19). 
 
                 
                                                      Fig. 19                                                                                    Fig. 20 
 
You will get a warning message where you will be asked if you want to preserve the already added 
charges etc. Click No. Then Click Grid → Set Map types → Open Ligand, find ligand.pdbqt file and 
click Open (figure 20). If everything was done according to this procedure, you will see both the ligand 
and the macromolecule in the ADT window. Next step is to generate a grid affinity map for the R2 or 
R3 region. As it was pointed before, the residues that are important for DNA binding in the R2 region 
are Glu132 and Lys 128 and for the R3 region - Ser187, Asn183, Asn179, Lys183 and Asn186. The grid 
boxes must be centered on those residues and have a sufficient size so ligand molecules can be rotated 
in all directions. Lys 128 and other residues can be located by clicking on Select → Select from string, 
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in the Residue field type Lys128 and click add. Lys128 will then be highlighted with small yellow 
asterisks. Based on those criteria, the center and the size of the R2 grid box are x: 22.153, y: 13.581, z: 
14.192; size: 50 x 40 x 60. The center and the size of the R3 grid box are: x: -0.503, y: 15.076, z: 7.389; 
size: 74 x 44 x 40. In order to understand those numbers and what they mean, we shall proceed to the 
“construction” of the grid box. In order to dock our drug like molecule against the R2 region, click Grid 
→ Grid Box… and the Grid Options Window will come up together with a box (figure 21). 
 
   
    Fig. 21                                                     Fig. 22. GPF-file can be opened with any emacs editor. 
 
There are several important things to notice here. By clicking on Center → Pick an atom and picking an 
atom that belongs to for e. g. Lys128, the grid box will center on the Lys128. The number of points in 
the x, y and z dimensions correspond to the size of the grid box. Typing the coordinates above in the 
center grid box fields can also center the grid box. Adjust number of points in the x, y and z direction to 
50 (x), 40 (y) and 60(z) by moving the “wheels” (the ones with the number 40 typed on them). Then 
type 22.153, 13.581 and 14.192 in the Center Grid Box fields (figure 23). If everything was done 
correctly, then the Grid Options Window will look like it does in the figure 23. Then click (in the Grid 
Options Window) File → Close Saving Current. Then close the Grid Options Window. Then click Grid 
→ Output → Save gpf and give the .GPF-file an appropriate name. A GPF-file is actually a text file 
(figure 22). 
 
Preparation of the search parameter file 
 
Click on Docking → Macromolecule → Set rigid file name...  choose 1GV2.pdbqt. Click on Docking → 
Ligand → Choose…, choose “ligand.pdbqt” and click Close in the window that will appear. Click on 
Docking → Search parameters → Genetic algorithm..., this will open a window called Genetic 
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Algorithm Parameters. According to the literature one should make an output file with 100 GA runs, a 
value of 150 in population size and 10 million of energy evaluations.23 To reduce the time of the 
calculations, use 5 million of energy evaluations. Click Accept. Click Docking → Docking parameters, 
this will open a window called Set Docking parameters, change translation step to 1.0. Click Accept. 
Then both windows will look like they do in figure 23. Click on Docking → Output → Lamarckian GA 
and give the DPF-file an appropriate name. 
 
 
Fig. 23 
 
Docking of the ligand against the DBD of the c-Myb 
 
The actual docking process using the AutoDock software is done at the Titan cluster. The first thing to 
do is to log on at http://bioportal.uio.no, click on Projects and create one with an appropriate name 
(figure 24). 
 
         
                                                 Fig. 24                                        Fig. 25 
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Upload all the 4 files to the project in File Admin (figure 25). Click on Submit job, click on appropriate 
project in the Choose project field and mark your desired input files. In the Resource roll-menu click on 
titan. In Application, choose autodock4@titan and enter the name of the job in Job name (figure 26). 
Click on Submit. This will lead you to the screen depicted in figure 27. 
 
           
                                                Fig. 26                                                                          Fig. 27 
 
Specify your macromolecule, the ligand and the DPF-file in the Inputfiles section, in the Select 
available queue select bioportal and unmark Low priority queue. Then click on Start computation. Now 
the docking process / computation will start. It takes about 6 - 8 hours to run a docking of one 
compound in one region.  
 
When the job is done, all the files associated with the docking run can be downloaded as a .zip file. 
Unzip the files to the same directory the input files are located. Then, in ADT, click on Analyze → 
Dockings → Open…, find the unzipped output files and open the file autodockOut.dlg and click on OK 
(figure 28). 
            
                                        Fig. 28                                                                                     Fig. 29 
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Then open the macromolecule file 1GV2.pdbqt – Click on Analyze → Macromolecule → Open… 
If everything was done correctly, both the macromolecule and the ligand will appear in the ADT 
window. The next step is to load the most important thing – the docked conformations and affinities, 
Click on a circle under MS and on a square under Atom that corresponds to the macromolecule in order 
to visualize the molecular surfaces and colour them by atom type. Click on Analyze → Conformations 
→ Load, this will bring up the Autodock conformation chooser window (figure 30). 
 
 
Fig. 30 
 
By clicking on ABAD66 1_1, the conformation with the lowest binding energy will come up in the ADT 
window together with its corresponding inhibition constant. In number 1_1, the first digit corresponds to 
the number of the cluster based on the RMSD, the second digit corresponds to the molecule with the 
lowest energy – ABAD66 2_2 means that it is cluster number 2 and this docked conformation has the 
second lowest energy. Clustering based on the RMSD values can also be viewed by clicking on Analyze 
→ Clusterings → Show. Two windows will appear – one called ABAD66: rms = 2.0 clustering and 
another – ABAD66. Second window – ABAD66 – is a conformational player that allows going through 
different conformations by clicking on the arrows. In order to view additional information about the 
different docked ligands, the following can be done. 
Click on the   button and the Set Play options window will come up, in that window click on Show 
Info and Build H-bonds. Two more windows will come up, one called Conformation X_X info and 
another called Hydrogen bonds. In the first window, all information about energies, efficiency etc. can 
be found. In the Hydrogen bonds window the residues on the macromolecule that are involved in 
hydrogen bonds with the ligand are displayed. The hydrogen bonds themselves are shown as small 
green spheres in the main ADT window (figure 31). 
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Fig. 31 
 
There are many more tutorials and manuals that describe the process of docking, preparation of the 
GPF- and the DPF-files in more detail.24 The preparation and the docking analysis of the docked 
compounds was done on a Macbook Pro mid 2010 model running OS X 10.6.8 with Python 2.5.  
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Chapter 4 
 
Overview and pharmacological analysis of NSC87877 and NSC675460 
 
In this part, a very general overview of the compounds NSC87877 and NSC675460 will be given. An 
in-depth look into the potential metabolic transformations of both compounds is provided. 
 
4.1 NSC87877 
 
Compound NSC87877 (figure 32) from the NCI (National Cancer Institute) library was identified by 
Martinez et al. as a potential inhibitor of the DBD in the c-Myb after virtual screening of the NCI 
library. 68  
 
 
 
Fig. 32. NSC87877 
 
The IUPAC name of the compound is (E)-8-hydroxy-7-((6-sulfonaphthalen-2-yl)diazenyl)quinoline-5-
sulfonic acid. It is a known compound that was synthesized in the late 50’s – early 60’s.25 Originally this 
compound and related ones were used as indicators for metal ions in complexometric titrations.26 
 
Compound NSC87877 can be viewed as consisting of two parts – the 8-hydroxyquinoline-5-sulfonic 
acid and the 6-aminona- phthalene-2-sulfonic acid – that are connected by an azo-bridge. Chemical 
compounds that have two large, fused aromatic systems (not always) on each end of an azo-group are 
often called azo-dyes. Most azo-dyes contain one azo-group, but there are numerous examples of dyes 
that have two or three azo-groups. The azo-group itself is not stable unless it is a part of an aromatic 
system that stabilizes it through electron delocalization. The azo-dyes can display a vast array of colors 
by changing the substituents on the diimide group. The cost of production of the azo-dyes are rather 
low, a factor that makes them attractive colorants in the industry.27, 41, 43 
 
During the past two decades, concerns have been expressed related to the use and production of azo-
colorants. Dyes are used in the industry on an everyday basis to dye different textiles, papers, plastics, 
leathers and other products. As a matter of fact, like from any industrial plant, some dyes are released 
N
SO3H
OH
N N
SO3H
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into the environment. For some dyes, starting materials for the production of the colorants, especially 
ones based on benzidine analogues and biotransformation products were shown to be carcinogenic or 
mutagenic and were subsequently banned.27 
 
4.2 Metabolism of drugs 
 
The material in this section, sections 4.3 and 4.4 is based on the reference.11 
   
Pharmaceutical agents and other chemicals are foreign objects (xenobiotics) that the human body tries to 
deal with through a number of responses. Ideally, when a drug is given to a patient, it must reach its 
target site, cure the disease and leave the body without doing anything else. However, most drugs must 
undergo some sort of chemical reaction to aid excretion.          
 
Drugs and other chemicals undergo a variety of transformations when they enter a human body. 
Enzymes that metabolize them are commonly located in liver, kidneys and lungs. Metabolism of drugs 
and chemicals also occurs in the gastrointestinal tract where the bacterial flora transforms xenobiotics 
into more / less harmful metabolites. Chemical reactions that occur during metabolism are usually 
divided into two big groups – phase I (P I) and phase II (P II) reactions.  
 
The P I reactions are hydroxylation, reduction, oxidation and hydrolysis. Generally speaking, during the 
P I metabolism, new functional groups may be introduced / changed or exposed to P II pathways. The 
main idea behind P I processes is to make a molecule more polar so it can be excreted faster. The P II 
reactions can generally be called conjugation reactions – where an existing functional group (alcohol, 
phenol, amine etc.) is masked by the addition of a new group (acetyl, sulfate, amino acids etc.), there by 
making the molecule even more polar. There are also chemicals/drugs that do not undergo metabolic 
reactions when they enter/go through the body – these compounds are usually excreted to a certain 
extent unchanged. 
 
4.3 Pharmacological analysis of NSC87877       
 
An analysis of potential metabolic pathways of compound NSC87877 begins with the identification of 
structural features in the molecule that might be substrates for P I/II reactions. The first and the most 
obvious feature, is the presence of the azo-bridge that is easily cleaved by the enzyme azoreductase, a 
NADPH-dependent system in the liver microsomes, converting the azo-bridge substituents into primary 
amines (P I reaction) (scheme 1): 
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Scheme 1. Cleavage of the azo-bridge by the enzyme azoreductase 
 
The products themselves can undergo further biotransformations (schemes 2 and 3):  
 
 
Scheme 2. Theoretical metabolic pathways of the 7-amino-8-hydroxyquinole-5sulfonic acid. 
  
 
 
OAT: O – acyltransferase; NAT: N – acetyltransferase; FMO: flavin – monooxygenase system; NMT: N – methyltransferase; P 
– 450: cytochrome CYP – 450 system; UGT: UDP – glucuronosyl transferase; STF: Sulfotransferase; P I: phase one reaction; 
P II: phase two reaction. 
Scheme 3. Theoretical metabolic pathways of the 6-aminonaphthalene-2-sulfonic acid. 
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It is difficult to predict whether the different metabolic products will cause harm or detoxification. 
Despite the fact that there exists much knowledge about the metabolism of the drugs, there is no 
guarantee that these particular transformations will take place. On the basis of the notions from scheme 
1, 2 and 3, one can assume that the NSC87877 will most probably loose its activity relatively fast once 
it enters the body. On the other hand, the way of administration of a drug can be subject to change and 
thus one can avoid certain metabolic pathways – an orally administrated drug may undergo metabolic 
reactions in the gastrointestinal tract, while drugs administrated intravenously avoid a given pathway. 
Another concern is the possibility of interactions between the pharmaceutical agent and metabolic 
products that can cause inhibition of a drug or serious side effects. Physiological and pathological 
factors such as age, heart condition etc. can as well result in different metabolic fates than the ones 
predicted – patients with a poorly functioning liver or kidneys may accumulate larger doses of toxic 
metabolites than healthy ones. Genetic differences may also give different rate of metabolism in certain 
pathways since some individuals may have different isoforms or even lack certain enzymes  
 
4.4 Pharmacological analysis of NSC675460 
 
Martinez et al. discovered compound NSC675460 after screening of the NCI library for compounds that 
exhibited electronic similarities with NSC87877. 68 It had a more favorable energy of binding than other 
compounds similar to NSC87877. After an extensive search, it became clear that the compound exists 
only “virtually” in NCI databank. NSC675460 has several functional groups that most probably will 
undergo metabolic transformations inside human body (scheme 2,4 and 5):  
 
 
 
Scheme 4. Cleavage of the azo-bridge by the enzyme azoreductase 
 
All the proposed metabolic pathways for NSC675460 are purely theoretical and have not been 
corroborated. But one fact is clear – NSC675460 has many structural features that can serve as 
substrates for different enzymes present in the body. Most probably NSC675460 will lose its activity as 
a drug relatively fast due to conjugation pathways etc. One way to cope with this problem is to replace 
functional groups with biologically similar ones that do not undergo the same metabolic 
transformations. Investigation and docking analysis of different bioisosteres of NSC675460 was 
performed (for details see chapter 6, section 6.3 and 6.4).    
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NAT: N – acetyltransferase; FMO: flavin – monooxygenase system; NMT: N – methyltransferase; P – 450: cytochrome CYP – 
450 system; UGT: UDP – glucuronosyl transferase; AS: Acyl synthetase; ACS: Acyl CoA synthetase; MOG: monooxygenase; 
EH: epoxide hydrolase; P I: phase one reaction; P II: phase two reaction. 
 
Scheme 5. Theoretical metabolic pathways of the (Z)-5-amino-2-(4-carboxystyryl)benzoic acid  
 
4.5 Lipinski’s rule of 5 
 
Lipinski’s rule of 528 is four criteria that increase the chances of a drug to be highly soluble, cell 
permeable and thus, orally-active: 
 
- Molecular weight < 500  
- logP < 5 
- Number of hydrogen donors < 5  
- Number of hydrogen acceptors < 10 
 
The criteria are based on calculated properties. The criteria have been established after experimental 
observations, for instance, studies have shown that a larger molecular weight of a compound results in 
poorer intestinal and blood brain barrier permeability.29 The lipophilicity of a compound is expressed as 
a ratio (log P) of octanol solubility to aqueous solubility. The higher the log P value is, the more 
lipophilic and thus, less hydrophilic the compound is. An excessive number of hydrogen bonds in a 
compound harm the permeability across a membrane bi-layer. There are orally active therapeutic 
categories that violate the rule of 5 such as antibiotics, antifungals, vitamins and cardiac glycosides. 
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Chapter 5 
 
The docking studies of NSC87877 and its analogues 
 
In this chapter, the docking analysis of the five analogues of NSC87877 that were about to be 
synthesized will be presented. The synthesis of the five analogues will be presented in chapter 9.  
 
5.1 Docking studies of NSC87877 and its analogues against the R2 region of the DBD in 
the c-Myb 
  
It was decided to synthesize a series of the analogues of NSC87877 with an azo-bridge and a sulfonic 
acid group placed at different positions in a naphthalene system. The decision of which analogues were 
synthesized was based purely on the availability of the starting material – X-aminonapthalen-Y-sulfonic 
acid – with an amino and a sulfonic acid groups in the different positions (figure 33). A docking 
analysis of NSC87877 and the analogues was performed. Special attention was drawn to how significant 
the sulfonic acid groups, the hydroxyl groups etc. are for binding with the DBD in c-Myb. 
                             
                                         
X = NH2, Y = SO3H                                  AB 75                                     AB 76                                           AB74 
 
                                      
                        AB 77                                                                    AB 81 / NSC87877                                                 AB 78                                                                        
                                                                                                       
Fig. 33. Structures of the six compounds that were docked against the DBD in c-Myb. 
 
From previous studies it was known that the sulfonic acid group in NSC87877 makes hydrogen bonds 
with the residues involved in the DNA binding.68 Assuming that it was true, an in silico experiment in 
which the ligand molecule lacks functional groups capable of making hydrogen bonds, will most 
probably result in a less favourable free energy of binding and a higher inhibition constant. Both 
NSC87877 and the rest of the analogues have two sulfonic acid groups, an sp2-hybridized nitrogen in a 
quinoline-like moiety, a hydroxyl group and an azo-bridge that can function both as hydrogen donors 
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and acceptors. Removal of one or several functional groups must affect the binding energy etc. The 
binding pose and the location of the ligand will probably differ after deletion of a hydroxyl group etc.     
 
Compounds NSC87877 and AB74 – 78 were docked against the residues Lys128 and Glu132 that are 
involved in hydrogen bonding with the c-Myb recognition element in the DNA. All chemical structures 
were drawn using JChemPaint, converted to the PDB-format using Avogadro and geometry optimized 
using iBabel, ff MMFF 94s force field, 250000 iterations with the steepest decent. The size of the grid 
box was 50 x 50 x 60, the grid spacing was default (0.375Å) and the grid box was centered on the 
Lys128 (22.153, 13.581 and 14.192). The search parameters were the following: 100 GA runs, 150 in 
population size, 5 million energy evaluations, translation step 1.0 Å, elitism 1, mutation and crossover 
rates of 0.02 and 0.8 respectively, and a local search rate of 0.06. The final docked conformations were 
clustered using a root-mean-square deviation of 2.0 Å. The results are summarized in table 1, while the 
complete table can be found in attachment 3, table 11. 
 
Name of 
the 
compound 
Free en. of 
bind.   
(kcal/mol) 
R2 - Ki 
Name of 
the 
compound 
Free en. of 
bind.   
(kcal/mol) 
R2 - Ki 
AB81 - 9.91 53.99 nM AB76 - 9.32 148.38 nM 
AB81-1 - 8.45 645.09 nM AB76-1 - 8.38 715.6 nM 
AB81-2 - 9.25 165.66 nM AB76-2 - 9.78 68.02 nM 
AB81-3 - 8.47 620.97 nM AB76-3 - 8.31 805.19 nM 
AB81-4 - 9.99 47.68 nM AB76-4 - 10.03 44.45 nM 
AB81-5 - 9.68 79.66 nM AB76-5 - 10.03 44.38 nM 
AB74 - 10.94 9.5 nM AB77 - 9.9 55.67 nM 
AB74-1 - 8.91 296.19 nM AB77-1 - 7.74 2.14 µM 
AB74-2 - 10.27 29.84 nM AB77-2 - 8.68 437.63 nM 
AB74-3 - 8.47 622.47 nM AB77-3 - 8.12 1.11 µM 
AB74-4 - 10.6 17 nM AB77-4 - 8.96 268.58 nM 
AB74-5 - 10.85 11.12 nM AB77-5 - 9.95 50.75 nM 
AB75 - 9.08 221.08 nM AB78 - 9.97 48.92 nM 
AB75-1 - 8.97 266.27 nM AB78-1 - 8.15 1.07 µM 
AB75-2 - 8.68 436.7 nM AB78-2 - 9.12 204.84 nM 
AB75-3 - 8.6 497.86 nM AB78-3 - 8.29 835.69 nM 
AB75-4 - 9.31 151.1 nM AB78-4 - 10.05 43.27 nM 
AB75-5 - 9.18 187.14 nM AB78-5 -10.04 43.45 nM 
 
Table 1. Docking of NSC87877 and AB74 – 78 against the R2 region of the DBD in c-Myb. Ki stands for inhibition constant. 
 
Compounds AB74, 75, 76, 77, 78 and AB81 showed similar binding energies upon docking to the R2 
region of the DBD in c-Myb. Keeping in mind that the standard error in docking is around 2 – 3 
kcal/mol, the results can’t point which of the analogues would work better in a biological assays. 
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According to the literature, compounds with energies lower than -7 kcal/mol will most probably be 
specific, strong binding ligands – all of the analogues fall into that category.30 Analysis of the top 5 
conformations of every analogue showed that they bind to the two specific areas in the R2 region (figure 
34). 
 
Fig. 34. The target molecule R2R3 is visualized with molecular surface (vdW). Residue Lys128 is marked. Top 5 conformations 
of AB 81 is green, AB74 – red, AB75 – purple, AB76 – yellow, AB77 – turquoise, AB78 – black. Image generated with ADT 
1.5.4. 
 
Electronic factors in the target molecule made one site particularly favorable for AB74 and 76. If this 
result would mean anything for the experimental analysis of in vitro activity was not clear. The top 5 
conformations of AB75, 77, 78 and 81 were all docked inside some sort of a pocket. From one point of 
view it is a goal of the docking process to be sure that the ligand binds to the target in a pocket. 
AutoDock, as it was mentioned before, treats the target molecule as a rigid structure although it is a 
common assumption that this is false. Proteins and macromolecules are dynamic structures that undergo 
conformational changes due to molecules that interact with them, solvent effects or interchanging 
hydrogen bonds. Fluctuations in the electronic environment make it impossible to predict with high 
degree of accuracy where the ligand will bind or not. The solvent molecules may impede the process of 
binding by more strongly solvating functional groups that could make hydrogen bonds with a ligand. 
Based on these notions, the binding site of AB75, 77, 78 and 81 is favored from one point of view, yet 
from another, some uncertainty regarding the dynamical behavior of the substrate must be addressed. 
 
An investigation of how the elimination of the different functional groups in AB74 - 78 and 81 will 
affect the free energy of binding showed some general trends. Upon elimination of the sulfonic acid 
group from either the naphthalene or the quinoline moieties, the free energy of binding increased across 
all the analogues (approximately from -9 kcal/mol to -8 kcal/mol). Factors such as the absence of 
hydrogen bonds, electrostatic interactions between the sulfonic acid group and the residues in the R2 
region may account for the trend. Elimination of the hydroxyl group showed a similar tendency for the 
same reasons. Substitution of the azo-bridge with a trans carbon-carbon double bond did not give any 
significant change in the free energy, neither substitution of the sp2-nitrogen in the quinoline moiety. 
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The loss of the free electron pair on the nitrogen atom may account for a very small drop in the free 
energy in some analogues. 
 
All analogues including those missing hydroxyl group etc. showed the same trends in their binding 
pattern. Majority of the analogues bind exactly in the same region as AB74 – 78 and 81. The top scoring 
conformation of the compounds AB81, 81-1 – 81-5 bind in the same place (figures 35, 36). Upon 
visualization of the docked conformations of AB81, 81-1 – 81-5, it becomes clear that the substrates 
bind to the DBD in the two specific regions (figure 37). 
 
                           
                  Fig. 35. AB81 – 81-5 bind at the same place.                     Fig. 36. Visualization of AB81 – 81-5 on the VdW surface 
              Hydrogen bonds are visualized with small green dots.                                       of the R2 and R3. 
 
 
Fig. 37. 600 docked conformation of AB81 – 81-5 in the R2 region represented with small green spheres. 
 
This indicates that the chemical skeleton (position of the carbon or nitrogen bridge may vary) of the 
analogues - (E)-7-(2-(naphthalen-2-yl)vinyl)quinoline – has a geometric and electronic structure that 
make it possible to induce hydrophobic interactions in these regions. Similar conclusions can be drawn 
from the investigation of AB74 – 78 and its analogues missing functional groups (attachment 4, p. 175). 
 
5.2 Docking studies of NSC87877 and its analogues against the R3 region of the DBD in c-
Myb  
 
The compounds NSC87877 and AB74 – 78 were docked against the residues Lys183, Ser187, Asn183, 
Asn179 and Asn186 that are involved in hydrogen bonding with the c-Myb recognition element in 
DNA. All the chemical structures were drawn using JChemPaint, converted to the PDB-format using 
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Avogadro and geometry optimized using iBabel, ff MMFF 94s force field, 250000 iterations with the 
steepest decent. The size of the grid box was 74 x 44 x 40, the grid spacing was default (0.375Å) and the 
grid box was centred on Asn183 (-0.503, 15.076 and 7.389). The search parameters were following: 100 
GA runs, 150 in population size, 5 million energy evaluations, translation step 1.0 Å, elitism 1, mutation 
and crossover rates of 0.02 and 0.8 respectively, and local search rate of 0.06. The final docked 
conformations were clustered using a root-mean-square deviation of 2.0 Å. The results are summarized 
in table 2 and the complete tables can be found in attachment 3, table 12. 
 
Name of 
the 
compound 
Free en. of 
bind.   
(kcal/mol) 
R3 - Ki 
Name of 
the 
compoun
d 
Free en. of 
bind.   
(kcal/mol) 
R3 - Ki 
AB81 - 6.63 13.73 µM AB76 - 7.5 3.19 µM 
AB81-1 - 7.75 2.08 µM AB76-1 - 7.71 2.23 µM 
AB81-2 - 6.74 11.56 µM AB76-2 - 7.12 6.03 µM 
AB81-3 - 6.83 9.87 µM AB76-3 - 7.11 6.12 µM 
AB81-4 -6.9 8.69 µM AB76-4 - 7.6 7.71 µM 
AB81-5 - 6.61 14.27 µM AB76-5 - 7.65 2.47 µM 
AB74 -7.23 5 µM AB77 - 7.85 1.77 µM 
AB74-1 - 7.06 6.73 µM AB77-1 - 7.19 5.14 µM 
AB74-2 - 7.09 6.36 µM AB77-2 - 6.88 9 µM 
AB74-3 - 6.76 11.09 µM AB77-3 - 6.87 9.2 µM 
AB74-4 - 7.11 6.09 µM AB77-4 - 6.87 9.17 µM 
AB74-5 - 7.04 6.86 µM AB77-5 - 7.84 1.8 µM 
AB75 - 6.49 17.35 µM AB78 - 6.81 10.24 µM 
AB75-1 - 7.9 1.61 µM AB78-1 - 7.64 2.52 µM 
AB75-2 - 6.29 24.68 µM AB78-2 - 7.71 2.21 µM 
AB75-3 - 6.47 18.21 µM AB78-3 - 7.21 7.35 µM 
AB75-4 - 6.63 13.77 µM AB78-4 - 7.03 6.99 µM 
AB75-5 - 6.79 10.47 µM AB78-5 - 6.93 8.36 µM 
 
Table 2. Docking of NSC87877 and AB74 – 78 against the R2 region of the DBD in c-Myb. Ki stands for inhibition constant. 
 
The same trends continue to appear in the R3 region also. The free energy of binding is less favorable 
than in the R2 region, equally so with the binding affinity values. Elimination of the functional groups 
causes identical effects as in the R2 region. The top conformations of AB81 – AB81-5 all bind in the 
same place in the R3 and make hydrogen bonds with the residues involved in interactions with DNA 
(figure 38). Visualization of all conformations of AB81 – 81-5 shows that all the molecules were 
docked into a small area (figure 39). The top 5 conformations of AB74, 75, 76, 77, 78 and 81 all showed 
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a similar pattern in the docking (figure 40). Better visualizations of the docked conformations of AB74 - 
78 and AB81 in the R3 region can be found in attachment 4, table 12.  
 
            
 Fig. 38. Visualization of top scoring conform. of AB81 – AB81-5.   Fig. 39. 600 docked conformation of AB81 – AB81-5. 
 
 
Fig. 40. The R3 region of the DBD in c-Myb. Top 5 conformations of AB81 is colored green, AB74 – red, AB75 – purple, AB76 
– yellow, AB77 – turquoise, AB78 – black. Image was generated with ADT 1.5.4. 
 
The elimination of the functional groups capable of making hydrogen bonds in compounds AB74 – 78, 
81 resulted in less favorable free energy of binding between the compounds and the DBD in c-Myb. The 
trend shows the significance of the sulfonic acid and hydroxyl groups in induction of the favorable 
interactions between the target and the drug molecules.       
 
From the docking studies of AB81 and its 5 analogues it became clear that these compounds might also 
be potent inhibitors of the DBD in c-Myb. From the previous work conducted by Martinez et al., it was 
known that compound NSC87877 had an IC50 value of 1 µM.68 Theoretically, the compounds similar to 
NSC87877, that had better in silico results, could have even lower IC 50 values.  
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Chapter 6  
 
Computational studies of NSC675460 and its analogues  
 
In this chapter, the bioisosteric approach in drug discovery will be discussed. The same methodology 
will be used in the modification of compound NSC675460. Docking studies of the designed compounds 
against the R2 and R3 region of the DBD in c-Myb will also be discussed.    
 
6.1 Docking of NSC675460 against the R2 and R3 region in the DBD in c-Myb 
 
Compound NSC675460, discovered by Martinez et al., was re-docked against the R2 and R3 region in 
the DBD of c-Myb to verify the previously obtained results.68 The free energies of binding differed from 
the ones obtained by Martinez et al. (table 3). 
 
Compound Results from Martinez Results from this study 
R2 R3 R2 R3 
NSC675460 
-10.98 kcal/mol - 8.52 kcal/mol - 9.19 kcal/mol - 6.57 kcal/mol 
 
Table 3. Comparison of the docking results. 
 
It is unclear how Martinez et al. obtained such good results, but this will not be discussed further. 
Visualization of the top 5 conformations of NSC675460 in the R2 and R3 regions gives the following 
picture (figures 41 – 44).  
 
 
Fig 41. Residue Lys128 is marked with text. Red areas represent areas on the surface of the R2 region that have affinity for 
oxygen. The sulfonic and carboxylic acid groups are buried inside regions with oxygen affinity. It explains the big energy of 
binding.    
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Fig 42. Residue Lys128 is marked with text. Blue areas represent areas on the surface of the R2 region in the DBD that have 
affinity for nitrogen. The same areas with affinity for oxygen, also have affinity for nitrogen 
 
 
Fig. 43.The nitrogen affinity map in the R3 region of the DBD in the c-Myb. 
 
 
Fig. 44. Oxygen affinity map in the R3 region of the DBD in c-Myb. One can see that only the sulfonic acid group is buried 
inside the area with affinity for oxygen, the carboxylic acid groups do not make contact with these areas. It explains the quite 
small energy of binding of NSC 675469 in the R3 region. 
 
The most important piece of information from figures 41 – 44 is that the same areas on the surface of 
the DBD in c-Myb have affinity both for oxygen and nitrogen. Theoretically, if the sulfonic or 
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carboxylic acid groups are substituted with other functional groups that bear nitrogen atoms instead of 
the oxygens, they will bind to the same area. This substitution may result in more favorable free 
energies of binding and give a more “potent” in silico drug candidate. This theory was investigated 
further. 
 
6.2 The bioisosteric approach in the discovery of novel potential drugs 
 
As was mentioned before, compound NSC675460 may undergo metabolic transformations. Its time of 
action as an active drug might be very short and will not lead to the desired effect. One way to deal with 
this type of concerns is to replace the functional groups in the molecule with similar ones that do not 
undergo metabolic degradation that easily. The substitution may also modify the toxicity, the chemical 
properties and the activity of the molecule of interest. A common term used about the substitution of 
functional groups with other groups presenting similar physical and chemical properties, is referred to as 
an isosteric replacement. The concept of chemical isosterism was first developed and described by 
Langmuir in 1919. 31 It was used to describe physical similarities between atoms, molecules and 
functional groups. Langmuir’s theory was primarily based on the fact that atoms with the same number 
of valence electrons, from the same column in the periodic table had similar physicochemical properties. 
This idea was limited only to some atoms and molecules and was later developed further by Grimm and 
Hinsberg.11 
 
Substitution of functional groups and atoms in biologically active molecules is not simple since a drug 
molecule usually has a lot of different interactions with a target molecule/biological system that cannot 
be analyzed straightforwardly. The physicochemical properties of functional groups are somehow 
related to biological properties, but it is not easy to generalize this comparison across biological systems 
– a successful substitution in one system can give an adverse effect in another. The concept itself – 
bioisosterism – was pioneered by Friedman.11 Later, Burger expanded the original definition by saying 
that: “Bioisosteres are compounds or groups that possess near equal molecular shapes and volumes, 
approximately the same distribution of electrons, and which exhibit similar physical properties such as 
hydrophobicity. Bioisosteric compounds affect the same biochemically associated systems as agonist or 
antagonists and thereby produce biological properties that are related to each other”.32 
 
Bioisosteric compounds are commonly divided into two subclasses: classical and non-classical. 
Classical bioisosteres are functional groups that obey the guidelines presented by Langmuir and Grimm. 
Non-classical bioisosteres do not follow the same rules as classical ones and often have different 
numbers of atoms than the group(s) they replace. Examples of classical bioisosteric replacement are 
substitution of a hydrogen atom with a fluorine or substitution of an amino group with a hydroxyl 
group.33 An example of a non-classical replacement can be found in the development of the drug 
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isoproterenol (figure 45).11 The phenolic hydroxyl and the sulfonamido group do not have same number 
of atoms, electrons or size. But they are both capable of donating a hydrogen atom and interacting with 
the target receptor as anions or as hydrogen bond donors. The groups also have roughly the same pKa. 
Another crucial factor is that the sulfonamide group is not metabolized by the O-methyltransferase, 
thereby increasing the time of action of the drug.  
         
                                                   Fig. 45                                                                                                 Fig. 46 
 
6.3 Bioisosteric replacement of the functional groups in NSC675460  
 
To simplify the discussion about the bioisosteric replacement of the existing functional groups in 
NSC675460, the aromatic rings will be named as it is depicted in the figure 46. One of the first and 
most obvious replacements is the substitution of the azo-bridge with a C=C trans double bond between 
the rings C and B, to prevent cleavage by the enzyme azoreductase. A comparison of the geometries of 
the substrates with N=N or C=C bonds showed that the overall orientation of the functional groups has 
only undergone minor changes (figure 47 – 50). The chemical structures were drawn using JChemPaint, 
converted to the PDB-format using Avogadro and geometry optimized using iBabel, ff MMFF 94s force 
field, 250000 iterations with the steepest decent, visualized with Avogadro and the bond lengths and 
angles were measured using Avogadro. 
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                                                 Fig. 49                            Fig. 50 
 
6.4 Tetrazoles as bioisosteres of carboxylic acids 
 
Substitution of the carboxylic acid group at the rings A and B with another functional group is the next 
step towards the design of a more robust molecule. 5-Substituted tetrazole rings are considered as 
bioisosteres of carboxylic acids – they often preserve or improve the biological activity of the parent 
drug.32, 34 
  
Tetrazole rings are 6π-azopyrrole type ring systems that are usually classified as aromatic systems due 
to their reactivity. 5-Substituted tetrazoles are commonly referred to as tetrazolic acids if they have a 
free N-H bond. They exist as two tautomeric forms in nearly 1:1 ratio – 1H and 2H – that interconvert 
rapidly (figure 51). 
 
 
Fig. 51. Two tautomeric forms of the 5-substituted tetrazoles. 
 
The acidity of the N-H is largely dependent on the substituent at the 5´-position. Both 5-alkyl- and 5-
aryltetrazoles have a pKa that is similar to that of carboxylic acids due to their ability to stabilize 
negative charge by electron delocalization.35 Tetrazoles, like carboxylic acids, are ionized at 
physiological pH and have a planar structure. Tetrazoles in their ionized state are more lipophilic than 
the corresponding carboxylic acids – which can make it easier for a drug molecule to penetrate the cell 
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membrane. Delocalization of a negative charge over the larger surface area of tetrazole rings, compared 
to carboxylic acids, may both enhance and diminish binding affinity of a drug containing a tetrazole 
ring. It is difficult to predict how the biological activity will vary upon substitution with the tetrazole 
moiety. Recent studies show that in the cases where a tetrazole ring improved in vitro results, it was due 
its capability to make hydrogen bonds with the residues at the target molecule.36  
        
Both the carboxylic and tetrazole groups may function as CYP-450 substrates for oxidative metabolic 
processes, but the tetrazole analogues do not react in the phase II conjugation pathways. Unfortunately it 
has been shown that 5-aryltetrazoles undergo conjugation reactions and form β-N-glucuronides (figure 
52).37  
 
 
Fig. 52. The phase II conjugation reaction of tetrazoles. 
 
The second step of the bioisosteric replacement process in NSC675460 consisted of the substitution of 
the carboxylic acid groups at rings A and B with tetrazole rings:  
 
 
 
                                                                          ABAD2 
    
From the docking analysis of compound ABAD2 against the residues in the R2 and R3 region, 
promising results were obtained. In the R2 region: The free energy of binding: -11.79 kcal/mol; Ki = 
2.26 nM. In the R3: The free energy of binding: -10.54 kcal/mol; Ki = 18.64 nM. Encouraged by these 
results, several (68) bioisosteres and analogues of compound ABAD2 were designed and docked against 
the residues in the R2 and R3 regions.   
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6.5 Docking of NSC675460 analogues against the R2 region of the DBD in c-Myb 
 
Compounds ABAD1 – 68 were docked against residues Lys128 and Glu132 that are involved in the 
hydrogen bonding with the c-Myb recognition element in DNA (table 4). All chemical structures were 
drawn using JChemPaint, converted to the PDB-format using Avogadro and geometry optimized using 
iBabel, ff MMFF 94s force field, 250000 iterations with the steepest decent. The size of the grid box 
was 50 x 50 x 60, the grid spacing was default (0.375Å) and the grid box was centered on Lys128 
(22.153, 13.581 and 14.192). The search parameters were the following: 100 GA runs, 150 in 
population size, 5 million energy evaluations, translation step 1.0 Å, elitism 1, mutation and crossover 
rates of 0.02 and 0.8 respectively, and local search rate of 0.06. The final docked conformations were 
clustered using a root-mean-square deviation of 2.0 Å. The results are summarized in table 4 and the 
complete tables can be found in attachment 3, table 13.  
 
Name of 
the 
compound 
Free en. of 
bind.   
(kcal/mol) 
R2 - Ki 
Name of 
the 
compound 
Free en. 
of bind.   
(kcal/mol) 
R2 - Ki 
ABAD 1 - 10.83 11.43 nM ABAD35 - 7.66 2.43 µM 
ABAD2 - 11.79 2.26 nM ABAD36 - 7.91 1.6 µM 
ABAD3 -8.17 1.03 µM ABAD37 - 8.76 379.6 nM 
ABAD4 - 10.22 32.19 nM ABAD38 - 8.49 602.21 nM 
ABAD5 - 7.98 1.41 µM ABAD39 - 10.38 24.57 nM 
ABAD6 - 8.07 1.22 µM ABAD40 - 6.57 15.25 µM 
ABAD7 - 5.58 81.62 µM ABAD41 - 6.29 24.2 µM 
ABAD8 - 8.1 1.15 µM ABAD42 - 8.83 338.03 nM 
ABAD9 - 8.01 1.35 µM ABAD43 - 9.13 202.59 nM 
ABAD10 - 11.2 6.17 nM ABAD44 - 10.87 10.82 nM 
ABAD11 - 9.07 226.45 nM ABAD45 - 9.84 61.63 nM 
ABAD12 - 10.78 12.52 nM ABAD46 - 10.35 25.7 nM 
ABAD13 - 7.41 3.67 µM ABAD47 - 10.09 40.51 nM 
ABAD14 - 8.67 438.4 nM ABAD48 -10.01 45.79 nM 
ABAD15 - 7.02 7.16 µM ABAD49 - 6.68 12.59  µM 
ABAD16 - 9.17 190.88 nM ABAD50 - 8.5 301.42 nM 
ABAD18 - 10.35 26.06 nM ABAD51 -10.41 23.31 nM 
ABAD19 - 3.8 1.63 mM ABAD52 - 8.52 573.08 nM 
ABAD20 - 8.25 903.44 nM ABAD53 - 10.47 21.29 nM 
ABAD21 - 10.84 11.32 nM ABAD54 - 12.87 367.91 pM 
ABAD22 - 8.29 285.43 nM ABAD55 - 10.04 43.46 nM 
ABAD23 - 9.61 89.95 nM ABAD56 - 8.58 511.22 nM 
ABAD24 - 9.55 100.22 nM ABAD57 - 9.7 77.94 nM 
ABAD25 - 8.83 335.53 nM ABAD58 - 9.25 167.2 nM 
ABAD26 - 7.17 5.58 µM ABAD59 - 10.94 9.6 nM 
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ABAD27 - 9.51 107.16 nM ABAD60 - 7.79 1.95 µM 
ABAD28 - 10.24 31.34 nM ABAD61 - 7.4 3.77 µM 
ABAD29 - 8.92 290.06 nM ABAD62 -4.84 282.95 µM 
ABAD30 - 8.61 491.93 nM ABAD63 -10.27 29.69 nM 
ABAD31 - 8.7 420.28 nM ABAD64 -9.57 96.35 nM 
ABAD32 - 9.87 58.17 nM ABAD65 -10.31 27.87 nM 
ABAD33 -8.89 306.97 nM ABAD67 -8.12 1.12 µM 
ABAD34 - 9.3 151.41 nM ABAD68 -8.16 1.05 µM 
 
Table 4. Docking of compounds ABAD1 – 68 against the R2 region in c-Myb. Ki stands for inhibition constant. 
 
6.6 Docking of NSC675460 analogues against the R3 region of the DBD in c-Myb 
 
Compounds ABAD1 – 68 were docked against residues Lys183, Ser187, Asn183, Asn179 and Asn186 
that are involved in the hydrogen bonding with the c-Myb recognition element in DNA (table 5). All 
chemical structures were drawn using JChemPaint, converted to the PDB-format using Avogadro and 
geometry optimized using iBabel, ff MMFF 94s force field, 250000 iterations with steepest decent. The 
size of the grid box was 74 x 44 x 40, the grid spacing was default (0.375Å) and the grid box was 
centred on Asn183 (-0.503, 15.076 and 7.389). The search parameters were following: 100 GA runs, 
150 in population size, 5 million energy evaluations, translation step 1.0 Å, elitism 1, mutation and 
crossover rates of 0.02 and 0.8 respectively, and local search rate of 0.06. The final docked 
conformations were clustered using a root-mean-square deviation of 2.0 Å. The results are summarized 
in table 5 and the complete tables can be found in attachment 3, table 14. 
 
Name of 
the 
compound 
Free en. of 
bind.   
(kcal/mol) 
R3 - Ki 
Name of 
the 
compound 
Free en. 
of bind.   
(kcal/mol) 
R3 - Ki 
ABAD 1 - 10.16 35.98 nM ABAD35 - 6.36 21.87 µM 
ABAD2 - 10.54 18.64 nM ABAD36 - 6.01 39.27 µM 
ABAD3 - 7.76 2.05 µM ABAD37 - 8.54 552.15 nM 
ABAD4 - 7.53 3 µM ABAD38 - 7.13 5.93 µM 
ABAD5 - 8.21 952.32 nM ABAD39 - 8.69 426.76 nM 
ABAD6 - 6.14 31.65 µM ABAD40 - 7.13 5.97 µM 
ABAD7 - 5.21 150.7 µM ABAD41 - 5.78 57.95 µM 
ABAD8 - 6.54 15.99 µM ABAD42 - 7.43 3.57 µM 
ABAD9 - 6.79 10.46 µM ABAD43 - 9.89 56.41 nM 
ABAD10 - 10.26 30.21 nM ABAD44 - 10.67 14.98 nM 
ABAD11 - 5.36 118 µM ABAD45 - 11.47 3.9 nM 
ABAD12 -10.56 18.06 nM ABAD46 - 6.43 19.41 µM 
ABAD13 - 6.38 21.21 µM ABAD47 - 7.49 3.26 µM 
ABAD14 - 8.33 786.81 nM ABAD48 - 6.83 9.8 µM 
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ABAD15 - 6.35 22.34 µM ABAD49 - 6.9 8.8 µM 
ABAD16 - 6.97 7.76 µM ABAD50 - 9.12 207.19 nM 
ABAD18 - 7.41 3.68 µM ABAD51 - 10.41 23.22 nM 
ABAD19 - 4.1 992.9 µM ABAD52 - 9.97 48.82 nM 
ABAD20 - 7.83 1.82 µM ABAD53 - 10.44 22.16 nM 
ABAD21 - 9.15 197.17 nM ABAD54 - 9.56 98.61 nM 
ABAD22 - 5.7 58.3 µM ABAD55 - 9.89 55.88 nM 
ABAD23 - 10.03 44.59 nM ABAD56 - 8.56 532.06 nM 
ABAD24 - 7.82 1.86 µM ABAD57 - 8.65 457.09 nM 
ABAD25 - 6.61 14.21 µM ABAD58 - 8.2 972.63 nM 
ABAD26 - 7.07 6.55 µM ABAD59 - 8.43 658.44 nM 
ABAD27 - 8.93 282.6 nM ABAD60 - 8.34 772.42 nM 
ABAD28 - 10.52 19.42 nM ABAD61 - 5.69 67.23 µM 
ABAD29 - 7.49 3.21 µM ABAD62 -4.64 398.44 µM 
ABAD30 - 9.18 186.68 nM ABAD63 -7.14 5.85 µM 
ABAD31 - 7.53 3.02 µM ABAD64 -7.01 7.16 µM 
ABAD32 - 6.59 14.77 µM ABAD65 -7.78 1.97 µM 
ABAD33 - 6.42 19.55 µM ABAD67 -6.65 13.46 µM 
ABAD34 - 6.08 35.18 µM ABAD68 -7.82 1.87 µM 
 
Table 5. Docking of compounds ABAD1 – 68 against the R2 region in c-Myb. Ki stands for inhibition constant. 
 
6.7 Re-docking  
 
Compounds ABAD1, 2, 10, 12, 45, 51 and 53 showed the best binding affinities after docking against 
the residues in the R2 and R3 regions in the DBD in c-Myb. Every compound was re-docked in the 
same regions with the same parameters 25 more times, giving a total amount of docking runs per region 
per compound of 26. A short summary with average values of the free energies of binding and the 
inhibition constants is given in table 6 and the complete tables can be found in attachment 3, table 15. 
 
Compound 
Free energy of bind. 
R2 (kcal/mol) 
Ki R2 (nM) 
Free energy of bind. 
R3 (kcal/mol) 
Ki R3 (nM) 
ABAD1 
Average: - 10.03 
Std.: 0.51 
Average: 61.93 
Std.: 51.72 
Average: - 10.05 
Std.: 0.48 
Average: 56.02 
Std.: 41.05 
ABAD2 
Average: - 10.79 
Std.: 0.53 
Average: 17.66 
Std.: 15.03 
Average: - 10.57 
Std.: 0.23 
Average: 19.08 
Std.: 7.17 
ABAD10 
Average: - 9.23 
Std.: 0.77 
Average: 328.62 
Std.: 406.6 
Average: - 8.98 
Std.: 0.65 
Average: 503.27 
Std.: 1012 
ABAD12 
Average: - 10.92 
Std.: 0.31 
Average: 11.55 
Std.: 8.03 
Average: - 10.33 
Std.: 0.31 
Average: 30.77 
Std.: 17.47 
ABAD45 
Average: - 10.17 
Std.: 0.38 
Average: 42.32 
Std.: 26.96 
Average: - 11.50 
Std.: 0.36 
Average: 4.48 
Std.: 2.8 
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ABAD51 
Average: - 10.24 
Std.: 0.37 
Average: 37.27 
Std.: 24.39 
Average: - 10.45 
Std.: 0.31 
Average: 23.40 
Std.: 10.66 
ABAD53 
Average: - 10.59 
Std.: 0.57 
Average: 27.14 
Std.: 28.52 
Average: - 11.08 
Std.: 0.28 
Average: 8.47 
Std.: 4.49 
 
Table 6. Re-docking of compound ABAD1, 2, 10, 12, 45 and 53 against the R2 and R3 regions in c-Myb. 
 
Analysis of the binding poses of the compounds revealed some general trends. Taking the re-
docking/statistical analysis of compound ABAD1 as an example, the 2600 conformations in the R2 and 
R3 regions can be visualized as in figures 53 and 54. 
 
                                         
 Fig. 53. 2600 conformations of ABAD1 docked in the R2.          Fig. 54. 2600 conformations of ABAD1 docked in the R3. 
 
As it can be seen from the figures 53 and 54, the conformations are grouped around residues Lys128, 
Ser187, Asn183 and Asn179 that are the primary target sites for the interactions/binding with the DNA 
chain. Another way to view the binding mode of ABAD1 is to visualize the top-ranking conformations 
from every single run (26 conformations at all) based on the binding affinities and the RMSD values 
(figures 55 and 56). 
 
     
Fig. 55. The top-ranking conformations of the ABAD1            Fig. 56. The top-ranking conformations of the ABAD1in the R3 
in the R2 region.                                                                        region.                                                                 
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Based on these criteria, the compounds ABAD2, 45 and 53 were the best hits after analysis of the 
bioisosteres of compound NSC675460. An analysis of the top conformations of compound ABAD2 in 
the R2 region showed that the orientation of the conformations are similar – the sulfonic acid group and 
the tetrazole rings are placed in areas with high affinities for oxygen and nitrogen atoms respectively 
(figure 57). Analysis of all 2600 conformations of the compound ABAD 2 in the R2 region showed 
specific grouping around Lys128 residue (figure 58). 
 
  
   Fig. 57. Top conformation of the ABAD2 in the R2.                Fig. 58. 2600 conformation of ABAD2 in the R3 region. 
 
The same conclusions can be drawn after analysis of the top conformations of ABAD2 in the R3 region 
(figures 59 – 61). 
 
   
     Fig. 59. Top conform. of ABAD2 from every run. Tetrazole                 Fig. 60. All 2600 docked conformations of ABAD2 
     rings and sulf. acid groups have the same orientation.                         represented with small green spheres.             
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Fig. 61. Top conformations of ABAD2 from every single run (total 26 conformations). Red and blue areas represent regions on 
the surface of the DBD that have affinity for nitrogen and oxygen. Sulfonic acid groups and tetrazole rings are positioned right 
beside areas with high oxygen/nitrogen affinity.     
 
Visualizations similar to these that show bindings/conformations of the compounds ABAD45 and 
ABAD53 can be found in attachment 4, p. 187. It is not possible to predict which of the three 
compounds will show the best results in biological testing since the affinity values lie very closely. One 
way to improve in silico results is to employ software programs such as CHARMM, GOLD, eHiTS etc. 
that use different scoring and docking functions than AutoDock 4, for the analysis of the top lead 
compounds.74      
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Chapter 7 
 
In silico analysis of the specificity of the compounds for the DBD in c-Myb  
 
The docking of the selected compounds against the DBD of the Sp1 protein to probe for selectivity will 
be presented. 
 
7.1 Docking of selected compounds against the ZF2/ZF3 in the DBD of the Sp1 protein 
 
During the design of novel drug candidates, one of the main requirements is the specificity of a drug for 
a target. Interactions of a drug with other proteins or processes can lead to serious side effects and/or a 
decreased time of action as a drug. The aim of the project was to discover a compound that would bind 
only to the R2 and R3 in c-Myb and inhibit its DNA binding activity without interfering with other 
proteins. The DBD in the Sp1 protein was chosen as a domain for testing the specificity of compounds 
AB74 – 78, 81 and ABAD2, 45, 53. The DBD in the Sp1 protein consists of three regions called zinc 
finger 1, 2 and 3 (ZF 1, ZF 2 and ZF3). Only the ZF2/ZF3 play a major role in the binding to the DNA 
chain.38 The selected compounds were docked against the ZF2/ZF3 (table 7). 
 
Compound Free en. of bind. ZF 2 
(kcal/mol) 
ZF 2 – Ki 
(nM) 
Free en. of bind. ZF 3 
(kcal/mol) 
ZF 3 – Ki 
(nM) 
AB 81 - 10.56 18.24 nM - 9.85 59.99 nM 
AB 74 - 9.79 66.99 nM - 7.93 1.53 µM 
AB 75 - 8.95 274.5 nM - 8.3 826.82 nM 
AB 76 - 11.01 11.72 nM - 9.6 92.57 nM 
AB 77 - 10.29 28.84 nM - 10.47 21.28 nM 
AB 78 - 10.19 33.95 nM - 8.8 310.86 nM 
ABAD 2 - 12.16 1.22 nM - 11.03 8.29 nM 
ABAD 45  - 11.23 5.9 nM - 10.87 10.83 nM 
ABAD 53 - 10.71 14.14 nM - 10.0 46.47 nM 
 
Table 7. Docking of AB74 – 78, 81 and ABAD2, 45, 53 against the ZF2/ZF3 in the DBD of the Sp1 protein. 
 
As it can be seen from the table, all values are below -7 kcal/mol, which is a typical threshold value for 
distinguishing molecules will likely bind to a target. Unfortunately this means that none of the 
compounds will bind specifically to the DBD in c-Myb – there will also be some degree of inhibition of 
the DBD in the Sp1 protein. On the other hand, the compounds were first docked against the ZF2 and 
then against the ZF3 – although it is known that the ZF1 – 3 exist as a single complex.39 Factors as 
overlap of regions, a different 3D-structure when the three fingers exist in a complex etc. have not been 
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included, making the docking results not completely accurate. Compounds AB74 – 78, AB81 have been 
tested in the electrophoretic mobility shift assay against the DBD of the Sp1 protein and were found to 
inhibit it with IC 50 values in micromolar region – meaning that the docking results for the tested 
compounds predicted the experimental results relatively accurately.69   
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Chapter 8   
 
Biological testing of compounds AB74 – 78, AB81 
    
In this chapter, the biological testing will be discussed briefly. The biological testing was done by 
members from the MYB group under the supervision of Professor Odd S. Gabrielsen at the Department 
of Molecular, University of Oslo. Comparison of the biological results and the in silico analysis will 
also be given. A detailed procedure for the tests that were performed has been previously published.69 
 
8.1 EMSA-analysis  
 
EMSA – electrophoretic mobility shift assay – is a method for studying interactions between DNA and 
proteins. The method is very sensitive and makes it possible to detect and analyze very small amounts of 
protein. A solution of a protein that is suspected to bind to DNA, is mixed with a 32P-labeled DNA 
sequence that contains a binding domain for that protein. Subsequently, the solution is subjected to 
electrophoresis through a polyacrylamide gel to separate a protein/DNA complex from the DNA strains 
that have not been bound by the protein. The molecules are separated according to their charge and size, 
so the protein/DNA complex will move slower than the unbound DNA because of its charge and size. 
The protein/DNA complex will be found closer to the cathode end; the free DNA will be located closer 
to the anode end (figure 62). The distribution of the different species is usually determined by an 
autoradiography technique.  
 
Fig. 62. Electrophoretic Mobility Shift Assay. The example shows the binding reaction between the R2/R3 regions of the DBD 
in c-Myb and 32P labeled DNA sequence that binds to these two regions. The protein/DNA complex is separated from unbound 
DNA by electrophoresis (well 2). The upper band is the protein/DNA complex, while the lower one is the unbound DNA. To 
well 1 is added only DNA. The arrow shows the direction of migration of the molecules. Fig. is taken from ref. 69. 
 
Every compound was first mixed with the R2 and R3 regions of the DBD in c-Myb and then added to 
the 32P-labeled DNA sequence GCATTATAACGGTTT. Then, the EMSA has been performed in order 
to separate the complexes from the unbound molecules. The results can be found in figure 63. 
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Fig. 63. Inhibition effect of AB74 - 78 and AB81. The R2/R3 regions and 0.1,       
1, 10, 100 and 1000 µM of every compound was incubated with 32P labeled 
mim-probe for 10 min. The protein/DNA complex was then separated from the 
unbound probe by electrophoresis. Visualization was done by 
autoradiography. Arrows show the protein/DNA complex, the stars show the 
unbound probe. The figure is taken from ref. 69. 
       Fig. 64. Fig. is taken from ref. 69. 
  
An IC 50 (half maximum inhibitory concentration) value is a numerical tool that indicates the 
concentration of a drug molecule that is needed to inhibit a given biological process by 50 %. In our 
case, it is the inhibition of the binding of the R2 and R3 regions to DNA. Based on the EMSA analysis 
of the 6 compounds, the following IC 50 values have been found (table 8). 
 
Compound Free en. of bind. 
in R2  (kcal/mol) 
R2 - Ki Free en. of bind. 
in R3  (kcal/mol) 
R3 - Ki IC 50 
AB 74 - 10.94 9.5 nM - 7.23 5 µM 0.1 – 3 µM 
AB 75 - 9.08 221.08 nM - 6.49 17.35 µM 100 – 1000 µM 
AB 76 - 9.32 148.38 nM - 7.5 3.19 µM 0.1 – 10 µM 
AB 77 - 9.9 55.67 nM - 7.85 1.77 µM 50 – 100 µM 
AB 78 - 9.97 48.92 nM - 6.81 10.24 µM 100 – 200 µM 
AB 81 - 9.91 53.99 nM - 6.63 13.73 µM 100 – 1000 µM 
 
Table 8. Comparison of the docking results with the experimental IC 50 values. 
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The IC 50 values differ significantly from the ones obtained in the docking studies. A closer 
investigation shows that the binding affinities from the docking in the R3 region correspond somewhat 
with the results from the EMSA-analysis. AB74, 76 and 77 have the best free energies of binding, 
however only AB74 and AB76 showed similar low IC 50 values. As it was shown before (figure 34), 
AutoDock predicted that all the top conformations of the 6 compounds that were tested would bind in 
the same area in the R3 region. On the contrary, in the R2 region, compounds AB74 and AB76 had the 
predicted mode of binding in a different region than the other four (figure 34). It is unsure whether this 
observation actually has something to do with the experimental IC 50 values. 
 
All the six compounds contain two sulfonic acid groups that are capable of making hydrogen bonds with 
molecules that have a hydrogen donor or acceptor sites. When the compounds were synthesized, 1H 
NMR analysis showed the presence of a large amount of water. One way to explain this observation is 
that the compounds upon precipitation co-crystallize with water molecules. Techniques such as freeze-
drying did not remove water from the solid material. Most probably it is the sulfonic acid groups that 
are responsible for binding of water molecules. Keeping that assumption in mind, the process of the 
binding of the ligand to the target molecule can be viewed as follows; In order to bind to the target site, 
water molecules surrounding both the substrate and the drug must to some extent be expelled from the 
surface between the drug and the target molecule in order for interactions between the functional groups 
to take place - hydrogen bonds between the sulfonic acid group and e.g. the residue Lys128 must be 
formed. The sulfonic acid groups are very hygroscopic and make hydrogen bonds with water molecules. 
Theoretically, water molecules surrounding the sulfonic acid groups might not be expelled when the 
molecule approaches the R2 and R3 regions in c-Myb, resulting in the absence of the interactions 
between the drug and the residues in the target molecule. In terms of entropy, making hydrogen bonds 
with water molecules gives a larger positive change in entropy than binding to the target site, thus 
making interactions with the target site not sufficiently favorable to occur. Whether this is indeed the 
case, is not sure. 
 
Another interesting fact is the results from the EMSA analysis of compound AB81. Compound AB81 
was synthesized, characterized and checked by HPLC for purity, which indicated that the material was 
92 % pure. Compound AB81 is the same compound as NSC87877. A small sample of NSC87877 was 
purchased and tested earlier by Martinez et al.68, 69 In an EMSA analysis, the NSC87877 that was 
purchased gave an IC 50 value of 1 µM (p. 54, figure 64), while the “synthesized version of NSC87877” 
– AB81 – had an IC 50 between 100 and 1000 µM. The purchased sample of NSC87877 was checked 
by HPLC using the same conditions as used for controlling the purity of AB81. This analysis showed 
that the purchased sample of NSC87877 contained substances other than the desired compound – 
making it impossible to say what actually caused the inhibition of the R2 and R3 regions in c-Myb at the 
1 µM level.  
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Chapter 9 
        
 Synthesis of compounds AB 81, 74, 75, 76, 77 and 78 
 
As was mentioned before, all of the compounds listed in figure 33 belong to a group of chemical 
compounds called azo-dyes. After conducting a literature search, it was decided that an azo-coupling 
would eventually lead to the desired products in two synthetic steps. 
 
9.1 Theoretical aspects behind azo-coupling reaction 
 
The material in this section is based on previously published work.40–43  
 
Azo-dyes are compounds containing azo-groups that are linked to sp2-hybridized carbon atoms. Usually 
the azo-groups are bound to benzene or naphthalene rings, but in some cases they can also be attached 
to aromatic heterocycles or enolizable aliphatic groups. Diazotization was first reported by Griess in 
1858. The first azo-dyes were manufactured by Mene in 1861 and by Matius in 1863. The first dyes 
produced by diazotization and azo-coupling in two distinct steps were performed in 1875 by Caro and 
Witt.40–43 
           
The diazotization of an aromatic or heteroaromatic primary amine is the first of the two reactions steps 
by which practically all of the azo-dyes are produced. Diazotization is usually carried out by the action 
of sodium nitrite on an aqueous solution of an amine in the presence of a mineral acid at 0°C (scheme 
6). Since the reaction is performed in an aqueous solution, the reactants or the products exist fully or 
partly in their ionized forms: the acid, the nitrite and the diazonium salt exist as H+X- (aq), Na+NO2- (aq) 
and Na+X- (aq), while the amine is in equilibrium with the corresponding ammonium ion Ar ⎯ NH3+.  
 
According to the reaction scheme 6, at least 2 equivalents of mineral acid must be used since the pH of 
the solution during the diazotization must be below 2. This is necessary for several reasons: 
1) At higher pH, the equilibrium Ar ⎯ NH2   ↔  Ar ⎯ NH3+ is shifted in the direction of the free base, 
which is usually less soluble in aqueous solution. 
2) At low concentrations of H+ ions, the diazonium ion formed reacts non-productively with the free 
base of an unattacked amine: Ar ⎯N2X + Ar ⎯ NH2  →  Ar ⎯ N=N ⎯ NH ⎯ Ar 
3) The reactive forms of the diazotizing agent are converted into ineffective ones such as HNO2 and 
NO2-. 
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Excess nitrite must also be avoided, since it would exert an unfavorable effect on the stability of the 
diazonium ions. 
 
 
Scheme 6. Generation of the diazonium salt. 
 
Diazonium ions are Lewis acids in which the β-nitrogen atom is the center of their electrophilic 
character. The addition of nucleophiles at the β-nitrogen is called an azo- (or diazo-) coupling reaction 
and depending on the atom that provides the lone pair of electrons, C-, N-, O-, P- or S-coupling can 
occur. In our case the coupling partner is 8-hydroxyquinoline-5-sulfonic acid, and the coupling reaction 
is performed under basic conditions in order to bring sufficient nucleophilic character to the carbon 
atom in the ortho-position to the hydroxyl group (scheme 7). The sulfonic acid group occupies the para-
position, so the ortho-position is the only potential position where the coupling can take place. 
 
 
 
Scheme 7. The mechanism of the azo-coupling step. 
 
It is likely that in the azo-coupling reactions the diazonium ion is added to the nucleophilic center of the 
substrate in such way that the σ-complex has a trans-configuration (scheme 8). Although there is no 
strict evidence against a primary formation of a compound with a cis-configuration, Zollinger showed 
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that all additions of “hard” nucleophiles to the β-nitrogen of a diazonium ion (e.g. OH-) have an early 
transition state and the cis-configuration is the primary product. With “soft” nucleophiles (C- and N- 
coupling) a later transition state is feasible; trans-isomers are formed. The cis-isomers are available only 
by photochemical isomerisation of the trans-compounds. 
  
Another argument can be drawn from the steric considerations of the transition state leading to the 
formation of the desired diazo-compound. As it can be seen in scheme 8, the transition state leading to 
the formation of the cis-product do not provide enough space for the base to come in and eliminate the 
hydrogen atom which is ortho to the hydroxyl/keto group. The transition state leading to the formation 
of the trans-product does provide enough space for the base to come in and abstract the proton. An 
additional argument can be drawn from the possible stabilization of the transition state leading to the 
trans-product by electrostatic forces between the hydrogen atom ortho to the hydroxyl/keto group and 
the lone pair of electrons on the α-nitrogen.  
 
 
 
Scheme 8. Representation of the two possible transition states leading to the formation of the diazo-compounds.  
 
The diazo-compounds in solution exist most likely as different tautomeres, as it is shown (scheme 9). 
Which of the forms that is most favorable, depends on the pH of the solution. 
 
 
 
Scheme 9. Tautomerization of the diazo-compounds. 
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9.2 Synthesis, results and discussion 
 
Synthesis of the series of the compounds AB81 - 78 began with the preparation of compound AB81 that 
has the IUPAC name of 8-oxo-7- [(6-sulfonaphthalen-2-yl)hydrazinylidene]quinoline-5-sulfonic acid. 
As it can be seen from the name, the two coupling partners for the azo-coupling reaction were the 8-
hydroxyquinoline-5-sulfonic acid and the 6-aminonaphthalene-2-sulfonic acid. The overall reaction 
procedure can be viewed in scheme 10. 
 
 
Scheme 10. The overall reaction procedure leading to the formation of the diazo-product. 
 
From the literature it was known that azo-dyes containing the sulfonic acid groups could be precipitated 
from a crude reaction mixture at a pH of 10 - 12 by addition of concentrated hydrochloric acid.40-43 
Unfortunately, during the first attempts of the synthesis of AB81, absolutely no material could be 
precipitated by addition of acid (the reaction mixture was allowed to stay at room temperature for 2 
hours after addition of the acid). A first thought was that the diazotation step did not go as planned – the 
diazonium salts are not stable and commonly decompose at temperatures above 5 or 10 oC. Upon 
repetition of the experiment, the solution of sodium nitrite in water was added over 10 min to the 
solution of amine in water that had a temperature of -5 oC. The color change from clear to yellow 
indicated that the diazonium salt was formed – when an aromatic system such as naphthalene is 
extended by the addition of a triple bond, a color change usually follows in the direction of colors that 
have longer wavelengths. Upon warming of the solution to room temperature, bubbling was noticed 
which can be explained in terms of a decomposition of the diazonium salt and release of nitrogen gas. 
Acting upon this, attention was focused on the second step of the reaction – the coupling process itself. 
Three experiments were set up to test the coupling step at pH 8, 10 and 12. Upon addition of the 8-
hydroxyquinoline-5-sulfonic acid dissolved in 1M NaOH to the solution of diazonium salt at -5 oC, an 
intensive color change towards red-purple was observed at all three pH values. Using the same 
arguments about extension of the conjugated system and color change, it can be argued that the coupling 
reaction had occurred. However, upon addition of the concentrated hydrochloric acid, no precipitation 
was observed. 
 
Further investigation of the literature uncovered a very interesting detail: prior to the diazotation, 1 eq. 
of sodium carbonate was added to the solution of the amine in water. If formation of the sodium salt of 
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the amine would somehow affect the reaction, was not clear, so an experiment was set up where sodium 
carbonate was added to the solution of the amine – the other experimental parameters were left 
unchanged. Surprisingly, precipitation of the crude product upon addition of hydrochloric acid 
proceeded smoothly, making it possible to filter off the crude product. Purification of the crude product 
was carried out by dissolving it in hot water, followed by hot filtration and precipitation of the product 
with dioxane. But since dioxane is a toxic solvent, it was decided to purify the crude product instead by 
dissolving it in 1M NaOH and then adding concentrated hydrochloric acid to reprecipitate the product. 
An 1H NMR showed the absence of signals from the starting materials after this purification protocol 
was carried out 2 - 3 times.  
 
The synthesis of the other 5 compounds followed the same reaction protocol as for AB81. Some amines 
were not soluble in water at room temperature and required heating to 60 or 70 oC in order to dissolve. 
Precipitation of the desired products with concentrated hydrochloric acid commonly took from 5 
minutes to 1 hour, but in some cases it took up to 12 hours. 
 
The yields of the azo-coupling reaction were very low – between 15 and 35%. It is not clear whether 
this is caused by side reactions or decomposition of the diazonium salt. Also the recoveries from the 
reprecipitation technique were low, so it is plausible that some percentage of the desired product was 
lost during purification.  
 
An investigation of the crude and pure products by TLC technique proved to be very challenging. TLC 
analysis on the normal phase silica plates using water/acetic acid (1:1) gave a very strong tailing. Eluent 
systems as methanol/water, methanol/acetic acid, acetonitrile/water also did not work. When TLC 
analysis was performed using reverse phase silica plates in acetonitrile/acetic acid (5:2), less tailing was 
observed than in the previous cases, but it was not enough for a clear distinction of the different spots.  
 
The purity of the synthesized azo-compounds was checked using a reverse phase HPLC system with 
acetonitrile/ammonium acetate buffer (pH 10) as eluent system. HPLC conditions were obtained from 
TOCRIS Bioscience.70       
 
NMR characterization of the synthesized compounds included 1H NMR spectra of the compounds 
purified both by precipitation with dioxane and hydrochloric acid. In the 1H NMR spectra a sharp peak 
at 3.55 ppm and in 13C NMR a peak at 66 ppm corresponded to dioxane. When the purification was 
done using only 1M NaOH and concentrated hydrochloric acid, the sharp peak at 3.55 ppm disappeared. 
A very broad peak around 4 ppm corresponded to water present in the sample. It was attempted to 
remove water by freeze drying techniques, but even after 3 days on a freeze dryer, water was still 
present in the samples in high concentrations.     
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Chapter 10     
 
Synthesis of the compound NSC675460 
 
10.1 Introduction 
 
The target compound NSC675460 was identified as a potential inhibitor of the DBD in c-MYB after 
screening of the NCI library for substances that exhibit structural and electronic similarities with 
NSC87877.68 After a literature research, it became clear that the compound has never been synthesized 
before and exists only as a “virtual” compound in the NCI library. Therefore, it was decided to explore 
different strategies to synthesize NSC675460. 
 
10.2 Overview of NSC675460 
 
NSC675460 consists of two aromatic phenyl rings, both bearing carboxylic acid groups. The phenyl 
rings are connected by a C=C cis–double bond and one of the rings is connected to a functionalized 
quinoline moiety by an azo-bridge. One of the first concerns was the stability of the cis-double bond. 
The possibility of spontaneous isomerisation to the more stable trans-analogue had to be taken into 
account by avoiding chemicals and conditions that could facilitate isomerisation. Another aspect was the 
polarity of the final product, which could make purification by standard methods like flash 
chromatography quite challenging.  
 
 
NSC675460 
 
10.3 The retrosynthetic analysis 
 
The retrosynthetic analysis began by considering possible disconnections in the target compound 
(scheme 11). It became clear that a disconnection of the quinoline moiety from the rest (step XIII) 
would simplify the synthesis to a great extent. The availability of the 8-hydroxyquinoline-5-sulfonic 
acid from commercial sources and the fact that the azo-bridge can be made in a two-step reaction 
avoiding harsh reactions conditions were the main thoughts behind the disconnection. This 
disconnection gave the next retrosynthetic intermediate with the IUPAC-name (Z)-5-amino-2-(4-
N
OH
SO3H
N
N
COOH
COOH
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carboxystyryl)benzoic acid (compound 3, scheme 11). After an extensive literature search it became 
clear that the compound had not been previously reported. The compound contains an internal cis-
double bond – one of the key features in the target molecule of our interest. It was decided that the 
replacement of the cis-double bond with an internal triple bond would provide a more synthetically 
robust intermediate. 
 
 
Scheme 11. The retrosynthetic analysis of NSC675460. 
COOH
COOH
N
NN
SO3H
OH
COOH
COOH
H2N
N
SO3H
OH
Azo - coupling Hydrolysis of ester
COOMe
COOMe
H2N
Cis - reduction
 of internal 
alkyne bond
COOMe
H2N COOMe
Reduction of the 
nitro group
COOMe
O2N COOMe
Sonogoshira coupling
I
COOMe
NO2
COOMe
Fisher esterification
I
COOH
NO2
I
COOH
Nitration
COOMe
COOMe
Step I
Step II
Step III
Step IV
Step VIII
Step X
Step XI
Step XIIStep XIII
Br
Br
O
"Wittig 
reaction"
Dehydro -
halogenation
Reduction of the 
nitro group
Step VII
I
COOMe
NH2
COOMe
+
Sonogashira coupling Step IX
COOMe
I
+
H
SiMe3
Sonogashira 
couplingStep V
COOMe
TMS
Removal of the TMS group
Step VI
Compound 1 Compound 2 Compound 3 Compound 4
Compound 5Compound 6
Compound 7Compound 8 Compound 9Compound 9Compound 10
Compound 11 Compound 12
Compound 13
Compound 14
Compound 15
Compound 16
+
+
	  	  63	  
The two carboxylic acid groups present in the target molecule could readily be derived from the methyl- 
or ethyl esters, which are easier to work with than carboxylic acids with respect to purification by flash 
chromatography and identification of synthetic intermediates by NMR- and TLC-analyses – esters 
provide easily recognizable peaks in 1H NMR spectra and do not give tailing on TLC plates when using 
common eluent systems. This brings us to the compound 5 in scheme 11, with the IUPAC-name methyl 
5-amino-2-((4-(methoxycarbonyl)phenyl)ethynyl)benzoate. A literature search showed that this 
compound had not been reported before. Thus, the next step was the analysis of possible methods for 
constructing an internal alkyne bond – the Sonogashira coupling reaction became our method of choice 
since it often provides desired alkyne product in good yields, does not require harsh reaction conditions 
and also tolerates the presence of different functional groups. This retrosynthetic step gave two 
intermediates; methyl 5-amino-2-iodobenzoate and methyl 4-ethynylbenzoate. The former of which has 
not been prepared before while the latter is a known compound. The methyl 5-amino-2-iodobenzoate 
could be prepared from the 2-iodobenzoic acid by nitration, followed by methylation of the carboxylic 
acid and reduction of the nitro group, as shown in the scheme 11. The synthesis of the methyl 4-
ethenylbenzoate by the original route shown in the scheme 12 proved to be very problematic, and thus 
the compound was later synthesized by another procedure. 
 
The retrosynthetic analysis was carried out before the experimental work was started. As such, parts of 
the analysis and the order of some of the steps proved to be wrong or misleading, as it always happens. 
The synthesis of the metyl 4-ethynylbenzoate by the original route proved to be difficult and it was thus 
prepared by another procedure. The order of some of the synthetic steps was also changed in order to 
obtain a more convergent synthetic pathway leading to the desired compound. 
 
10.4 Syntheses, results and discussion 
 
10.4.1 Corey-Fuchs reaction 
 
The synthetic work began with the synthesis of the methyl 4-ethynylbenzoate (compound 9, scheme 11). 
The first idea was to synthesize it from methyl 4-formylbenzoate by performing Corey–Fuchs 
reaction.71 The Corey–Fuchs reaction is a two-step reaction where an aldehyde is transformed into a 
terminal alkyne by a one-carbon homologation. The first step of the reaction can be compared to the 
Wittig reaction and leads to a dibromoolefin (scheme 12). Treatment of the dibromoolefin with a lithium 
base, in the second step, leads via dehydrohalogenation to the bromoalkyne intermediate, which then 
undergoes a metal-halogen exchange which yields the terminal alkyne upon aqueous work-up (scheme 
12).44  
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Scheme 12. Corey – Fuchs reaction 
 
The first step in the reaction proceeded smoothly and gave the desired product in good yields (scheme 
13). The second step of the reaction – the dehydrohalogenation of the dibromoalkene with subsequent 
metal-halogen exchange and generation of the terminal alkyne – did not work. Several techniques and 
reagents were tested (scheme 13). None of them gave the desired product. The dehydrohalogenation 
with different amounts of n-BuLi at different temperatures, followed by an aqueous work-up gave 
product mixtures that could not be identified or purified by flash chromatography. 1H NMR of the crude 
product mixture showed the absence of the methyl ester signals. This suggested that n-BuLi, even at low 
temperatures had attacked the electrophilic methyl ester group in favor of abstracting the weakly acidic 
proton on the dibromoalkene. Another experimental procedure was tested in order to see if it would give 
the terminal alkyne. It is possible to perform the second step of the reaction – the dehydrohalogenation – 
by refluxing the dibromoalkene in THF at 120 °C in the presence of activated magnesium metal.72 But 
despite all the efforts, a 1H NMR-analysis of the crude mixture indicated that no reaction took place.       
  
 
 
a) Mg, activated with I2, THF, 120 °C, 2 hours; b) Mg, activated with C2H2Br2, THF, 120 °C, 2 hours; c) Mg, activated by 
washing with 1 M HCl, then heating under vacuum, THF, 120 °C, 2 hours; d) 2 eq. n-BuLi, -78 °C → 0 °C → r.t., H2O, 4 h.; e) 
3 eq. n-BuLi, -78 °C, H20, 4 h. 
Scheme 13. Attempted Corey – Fuchs reaction.  
 
As a result of this failure, it was decided to synthesize the methyl 4-ethynylbenzoate in two steps. The 
first step was the Sonogashira coupling of the methyl 4-iodobenzoate with the ethynyltrimethylsilane, 
giving the methyl 4-((trimethylsilyl)ethynyl)benzoate.  
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10.4.2 The Sonogashira coupling reaction 
 
The palladium catalyzed C-C homologation reaction that couples terminal sp-hybridized carbon atom of 
an alkyne with an sp2 hybridized atom of an aryl or vinyl halide is typically referred to as the 
Sonogashira coupling reaction. There are many variations of this reaction, but the most general synthetic 
protocol uses copper as a co-catalyst, in addition to the palladium catalyst. During the last two decades, 
the Sonogashira reaction has seen an incredible growth in its versatility, proving its role as an important 
tool in organic synthesis. There are many examples of applications of the Sonogashira coupling in 
syntheses of natural products, biologically active molecules and technologically advanced materials. An 
arylalkyne may provide a molecule with a rigid structure and a specific shape, but it also gives an 
unsaturated, high-energy moiety that can undergo further synthetic transformations.  
 
The first example of an sp2–sp cross–coupling between two carbon atoms was reported in 1963 by 
Stephens and Castro.45 A general overview of the reaction protocol can be seen in scheme 14. 
 
 
 
Scheme 14. Stephens and Castro’s coupling method. 
 
During the following years, a number of other synthetic protocols appeared dealing with the cross–
coupling of sp2–sp hybridized carbon atoms (schemes 15 - 17). 
 
Cassar’s method:46 
 
 
Scheme 15. Cassar’s  coupling method. 
 
Heck’s method:47 
 
 
Scheme 16. Heck’s coupling method. 
 
Sonogashira’s method:48 
 
Scheme 17. Sonogashira’s coupling method. 
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Sonogashira’s protocol may be seen as a combination of three other protocols. As a matter of fact, the 
catalytical amount of CuI increased the reaction yield and made it possible to conduct reactions at lower 
temperatures. One of the main differences between the Sonogashira reaction and other C–C 
homologation reactions involving a palladium catalyst, is that the alkyne does not need to be activated 
by a halide or a metal. The alkyne itself serves as a good ligand for the palladium catalyst because of the 
shape of its d-orbitals and the absence of steric bulk. It has also been shown that the Sonogashira 
reaction tolerates nearly all common functional groups as a consequence of the mild reaction 
conditions.49 Such a wide functional group tolerance makes it an attractive procedure for the 
construction of alkyne moieties in syntheses of complex molecules. 
 
Mechanism 
 
The accepted mechanism of the Sonogashira reaction does not differ that much from the original one 
proposed by Sonogashira and Hagira (scheme 18).50 However, there are some evidence that suggests a 
more complex reaction mechanism.50a, 51 
 
 
 
a: Transmetallation; b: Reductive elimination; c: Oxidative addition 
 
Scheme 18. The accepted mechanism of the Sonogashira coupling reaction 
 
The most commonly used catalyst for the reaction is either Pd(0)(PPh3)4 or Pd(II)(PPh3)2Cl2. The 
catalyst loading is typically 2 – 5 mol%, the amount of the CuI is usually twice as high. There are also 
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reported reactions where the loading of the palladium catalyst is lower and the reaction proceeds 
without a copper co-catalyst. Demanding substrates may require a different catalyst system that is 
electronically and sterically tuned to the specific reaction.  
     
In the Sonogashira coupling reaction, the catalytically active complex is Pd(0)L2 (3, scheme 18). 
Following the classical reaction mechanism, this species is generated from Pd(0)(PPh3)4 by dissociation 
of the two phosphine ligands. It can be also generated from Pd(II)(PPh3)2Cl2 via transmetallation of an 
alkynyl copper adduct, followed by reductive elimination of (1) in scheme 18 to (3) and (2). The amount 
of the by-product (2) can be minimized by removing oxygen from the reaction mixture by purging the 
reaction mixture with an inert gas before and during the slow addition of the alkyne coupling partner. 
Running the reaction under inert atmosphere also diminishes amount of the by–product (2). After the 
formation of complex (3), oxidative addition of the aryl or vinyl halide occurs giving complex (4). 
Transmetallation of complex (4) with the alkynyl copper adduct gives (5), followed by reductive 
elimination that furnishes the cross–coupled product and regenerates the catalytically active complex 
(3). 
    
There are many factors that govern the efficiency of the catalytic system. These factors usually evolve 
around the ligands on the palladium-center, the amine base, the copper co-catalyst, the solvent effects 
and the steric and electronic environments of the aryl/vinyl halide and the alkyne. Organohalides 
containing electron-withdrawing groups are commonly more reactive in the Sonogashira coupling 
reaction than ones with electron-donating groups. For alkynes the opposite is true.52      
      
As it can be seen from scheme 18, the amine base is an important component of the Sonogashira 
reaction. Et3N, Et2NH and iPr2NH are commonly used bases and often give good results. It must, 
however, be pointed out that the choice of base is sometimes substrate dependent and is usually a result 
of trial and error. Stronger bases may give an increase both in the reaction rate and the yield according 
to some publications.53 In the classical Sonogashira protocol, the amine acted both as the base and the 
solvent. Later research indicated that use of co-solvent – mostly THF – gave increases in the reaction 
rates and yields. It is difficult to give a detailed explanation of this effect – substrate and catalyst 
solubility might be a major factor. 
 
10.4.3 The Sonogashira coupling of the methyl 4-iodobenzoate with the 
ethynyltrimethylsilane 
     
The first attempts on the synthesis of methyl 4-((trimethylsilyl)ethynyl)benzoate were performed using 
the “classical” protocol in which the active catalyst – Pd(0)(PPh3)4 – was generated in situ from 
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Pd(OAc)2 and PPh3. Et3N was used both as a solvent and a reagent (scheme 19, entry b). 1H NMR 
analysis of the crude reaction mixture did not show any conversion of the starting material. The use of 
DMF as a solvent and the addition of a smaller amount of Et3N also did not give any conversion 
(scheme 19, entry a). After the first unsuccessful attempts, the attention was moved to another catalyst 
which is commonly used in the Sonogashira reaction – Pd(II)Cl2(PPh3)2. The first attempt (scheme 19, 
entry c) was unsuccessful, but the second one gave the desired product in 50 % yield (scheme 19, entry 
d). After further investigation of the reaction protocols, two slightly different approaches were 
employed for the synthesis of methyl 4-((trimethylsilyl)ethynyl)benzoate, giving the desired product in 
good to excellent yields (schemes 20 and 21). The reaction protocol shown in scheme 21 provided the 
product in less time than the other methods, with a lower loading of the palladium catalyst. The 
procedure was reproducible and as such it was chosen for the synthesis of methyl 4-((trimethylsilyl)- 
ethynyl)benzoate.  
 
 
 
Entries: a) Pd(OAc)2 (5 mol%), CuI (10 mol%), PPh3 (20 mol%), TMSA (1 eq.), TEA (0.7 eq.), DMF, r.t., N2 - atm., 16 h.;  
              b) Pd(OAc)2 (5 mol%), CuI (10 mol%), PPh3 (20 mol%), TMSA (1 eq.), TEA (10 eq.), 80 oC, N2 - atm., 6 h.;  
              c) PdCl2(PPh3)2 (2 mol%), CuI (1 mol%), TMSA (1.2 eq.), TEA (5 eq.), r.t., N2 - atm., 20 h.;  
              d) PdCl2(PPh3)2 (3 mol%), CuI (6 mol%), TMSA (1.3 eq.), TEA (7 eq.), r.t., N2 - atm., 20 h. 
 
Scheme 19. The attempted Sonogashira coupling reactions between the methyl 4-iodobenzoate and the TMSA.  
 
                      
 
Scheme 20. Modified protocol of the Sonogashira couplig 
reaction.  
Scheme 21. Optimized protocol of the Sonogashira coupling 
reaction. 
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There are several factors that might explain the failed reactions in scheme 19. Generation of the 
Pd(PPh3)4 in situ might be problematic – any air present in the solvent or reaction flask will prevent the 
formation of the catalyst or destroy one already formed. PdCl2(PPh3)2 on another hand is an air stable 
catalyst and can be purchased from commercial sources. Employing THF as the solvent and adding the 
required amount of the amine (1.5 – 4 eq.), instead of running the reactions in neat Et3N might also have 
contributed to the increase in the yields. Careful deoxygenation of the solid reactants, purging of the 
solvents and liquid reactants with argon before mixing was performed in order to provide an inert 
atmosphere during the reaction. The reaction itself was done under continuous flow of argon.  
 
10.4.4 Removal of the TMS group 
 
The next step was the removal of the TMS group from the methyl 4-((trimethylsilyl)ethynyl)benzoate. 
There are many procedures and techniques for carrying out this step (scheme 22).76  
 
 
 
a) K2CO3, MeOH, r.t.;76a b) DBU, H2O, MeCN, 60 oC;76b c) K2CO3, MeOH, CH2Cl2, r.t.;76c d) CsF, MeCN, H2O, r.t.;76d e) t-
Bu4NF, THF, r.t.76e 
 
Scheme 22. Methods dealing with removal of the TMS group based on the literature.  
 
K2CO3 in MeOH usually cleaves the TMS group selectively and in good yields. With respect to the 
elimination of the TMS group, some attention must be addressed to the amount of K2CO3 present in the 
reaction mixture. Experiments showed that when a large excess of K2CO3 is used, hydrolysis of the 
methyl ester might occur, especially when the reaction is performed over prolonged periods of time.  
It is also known that KF and TBAF readily cleaves carbon-silicon bonds and do not affect base labile 
groups, but there are some serious drawbacks when it comes to handling KF and TBAF. In addition to 
their toxicity, their hygroscopic nature also provides some additional difficulties since it is not a trivial 
task to measure amount of water present thus making it difficult to weight out precise amounts of the 
reagents. After some experimental work and a literature search, a procedure for a fast and reliable 
removal of the TMS group was set up. K2CO3 (0.6 eq.) in MeOH/CH2Cl2 (3:1) furnished the desired 
product after 1 hour at room temperature (scheme 23).  
COOMe
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Scheme 23. Procedure for fast and reliable removal of the TMS-group.  
 
The yields were very good: 95 – 99%. Pure methyl 4-ethynylbenzoate is a white solid, but in some cases 
it had either yellow or reddish color. Upon storage at 0 oC overnight under an argon atmosphere, a black 
substance appeared inside the flask in most cases. It was easily removed by flash chromatography, 
resulting in a 5 – 8% loss of the compound. In most cases, the methyl 4-ethynylbenzoate was used 
directly in the next reaction.      
            
With one of the major building blocks synthesized, the focus was changed towards the preparation of 
another building block – the methyl 5-amino-2-iodobenzoate. At this point there were some doubts 
regarding how well the Sonogashira coupling of the methyl 4-ethynylbenzoate with the methyl 5-amino-
2-iodo-benzoate would work since the amino group is a strongly electron-donating group. It was thus 
decided to synthesize the methyl 2-iodo-5-nitrobenzoate instead, couple it with the methyl 4-
ethynylbenzoate and then reduce the nitro-group. 
 
10.4.5 Preparation of the methyl 2-iodo-5-nitrobenzoate 
      
Methyl 2-iodo-5-nitrobenzoate has been prepared in two steps as shown in scheme 24. The first step is 
the nitration of 2-iodobenzoic acid and the second step is the esterification of the carboxylic acid group.  
 
 
 
Scheme 24. A general protocol for the nitration and esterification of the 2-iodobenzoic acid. 
 
Nitration of the 2-iodobenzoic acid is a classical example of electrophilic aromatic substitution (scheme 
25).  
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                                    Scheme 25. The mechanism of nitration.                                  Fig. 65. Potential positions of nitration. 
 
Both the iodine and the carboxylic acid group are deactivating substituents, with the iodine being an 
ortho-, para-directing group and the carboxylic acid being meta-directing functional group. Taking these 
considerations into account, the 2-iodobenzoic acid could in theory be nitrated both in the 3´- and 5´-
position (figure 65). Since the iodine atom and the nitro group are quite bulky substituents, nitration in 
the 3´-position was considered highly unrealistic and thus the nitrated product would have the nitro 
group in the 5´-position. As was mentioned earlier, the iodine and carboxylic acid are deactivating 
substituents, so high reaction temperatures and long reaction times were required for the formation of 
the 2-iodo-5-nitrobenzoic acid. This reaction was performed by mixing the starting material with 
concentrated H2SO4 at 0°C, adding cold 99% HNO3 mixed with concentrated H2SO4 and then stirring 
the reaction mixture at 130°C for 2 hours. This furnished the desired product in 75 – 85% yield. 
Experiments where 66% HNO3 was used did not furnish the desired product.     
 
Esterification of the carboxylic acid group was performed using a classical method – the Fischer 
esterification. Refluxation of the crude 2-iodo-5-nitrocarboxylic acid in the mixture of the H2SO4 and 
MeOH at 110 oC for 18 hours. The yields were around 75 – 85%. Separation of the crude 2-iodo-5-
nitrobenzoic acid was carried out by pouring the cold reaction mixture over ice/water and then filtering 
the solution on a Büchner-funnel. The crude product contained large amounts of water that could affect 
the next step – the esterification in methanol with concentrated H2SO4. According to most reaction 
protocols, the compound to be esterificated had to be dry since water quenches the catalytic activity of 
H2SO4. However, after drying the crude 2-iodo-5-nitrobenzoic acid with either phophorus pentaoxide 
overnight or under open air for 2-3 days, the esterification did not proceed. This indicated that the 2-
iodo-5-nitrocarboxylic acid was unstable and therefore the crude product had to be used in a wet state in 
the esterification step. In the “classical” esterification protocol, only a catalytical amount of H2SO4 is 
added to the reaction mixture, while the alcohol is present in excess. In this case, methanol could not 
dissolve the crude 2-iodo-5-nitrobenzoic acid alone, even at 110 oC. However, after the addition of a 
large amount of H2SO4 (MeOH/H2SO4, 2 – 3:1), the crude 2-iodo-5-nitrobenzoic acid finally dissolved 
at 110 oC and the reaction furnished the desired product in 75 – 85 % yield. An interesting fact is that 
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the methyl 2-iodo-5-nitro-benzoate precipitates immediately upon cooling of the reaction mixture in an 
ice bath.  
        
The next steps were the Sonogashira coupling reaction of the methyl 4-ethynylbenzoate both with the 
methyl 2-iodo-5-nitrobenzoate and the methyl 5-amino-2-iodobenzoate as well as the reduction of the 
nitro group to an amino group in the case of methyl 2-iodo-5-nitrobenzoate. As mentioned, most 
probably the reduction would be performed on the coupled product, methyl 2-(4-(methoxycarbonyl)- 
styryl)-5-nitrobenzoate. 
 
10.4.6 The synthesis of methyl 2-(4-(methoxycarbonyl)styryl)-5-nitrobenzoate 
 
The Sonogashira coupling between methyl 4-ethynylbenzoate and methyl 2-iodo-5-nitrobenzoate was 
carried out using the same methods as the coupling between the methyl 4-iodobenzoate and the 
ethynyltrimethylsilane (schemes 26 and 27). 
 
 
Scheme 26. Method 1. The Sonogashira coupling between the methyl 4-ethynylbenzoate and methyl 2-iodo-5-nitrobenzoate. 
 
 
Scheme 27. Method 2. The optimized Sonogashira coupling protocol. 
 
Use of less than 1.2 equivalents of the ethynyl coupling partner resulted in a major decrease in yield. As 
was pointed out before, pure methyl 4-ehynylbenozate sometimes had reddish colour – in these cases 
coupling did not proceed smoothly with either of the two methods and yields were 10 – 15 % lower. 
Methyl 4-ethynyl-benzoate is not a stable compound (section 10.4.4), an observation that may explain 
the lower yields caused by the longer reaction times of method 1 (scheme 26). On the other hand, the 
reaction temperature in method 2 is higher, making it unrealistic that the methyl 4-ethynylbenzoate 
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would decompose slower than the method 1. Possibly however, the rate of coupling in method 2 could 
have been higher than the rate of decomposition of the starting material, giving higher reaction yields. 
Reaction temperatures above 58 oC did not increase the yield. 
 
10.4.7 The reduction of the nitro group and hydrolyses of the ester groups 
 
There are numerous reaction protocols dealing with the reduction of both aromatic and aliphatic nitro 
groups.54 Some methods were chosen for further investigation and testing on our substrates of interest 
(scheme 28). The methods employing metals and acids seemed to be the most appropriate since 
protocols where a palladium catalyst and hydrogen gas was being used could potentially react with the 
triple bond and give unwanted reduction products. The protocol involving the use of sodium dithionite 
in water/THF solution was the first to be tested, since it is a known and very mild procedure for the 
reduction of aromatic nitro groups. An excess of the sodium dithionite (10 – 15 eq.) was used in the 
reduction of the nitro group on both substrates, giving the desired products in 35 – 50 % yield (schemes 
29 and 30). Attention was thus moved to the other methods employing metals and acids.  
 
 
 
 
a) SnCl2, HCl, solv. / reag.; b) Zn, NH4Cl (aq), H2O, THF, r.t., 6 – 24 h.; c) Pd, CO2, H2, 180 bar, elevated temperature; d) 1. 
FeSO4, H2O, MeOH, reflux. 2. NH4OH, H2O, reflux; e) Zn, NH4Cl, MeOH, H2O, r.t., 6 – 24 h.; f) Na2S2O4, H2O, THF, r.t., 8 – 
24 h.; g) Fe, CaCl2, EtOH, H2O, THF, reflux, 1.5 – 4 h..  
 
Scheme 28. Possible routes of the reduction of the aromatic nitro group based on the literature. 
 
 
Scheme 29. The reduction of nitro group employing sodium dithionite. 
R
NO2
R
NH2
a
b
c
d
e
f
g
COOMe
COOMe
R:
I
COOMe
or
I
NO2
COOMe
I
NH2
COOMe
Yield: 35 - 45 %
Na2S2O4 (10 – 15 eq.), 
           THF, H2O
r.t., 16 h.
	  	  74	  
 
 
Scheme 30. The reduction of the nitro group employing sodium dithionite. 
 
The reduction of an aromatic nitro group with a metal in an acidic solution is a classical method that is 
commonly employed in organic synthesis. The accepted mechanism for this type of reduction is a single 
electron transfer mechanism that can be illustrated as a two-electron transfer, in the following manner: 
 
 
 
Scheme 31. The accepted mechanism of the reduction of the nitro group using metal in an acidic solution. 
 
The metal functions as an electron donor and the acid as a proton donor. The most commonly used 
metals are Sn, Fe or Zn. The reduction of the substrates of interest was attempted with FeSO4 in a 
water/MeOH system that gave a mixture of products that could not be separated. Reduction with Zn (8 
eq.) using a concentrated aqueous solution of NH4Cl and THF as a solvent furnished the desired 
products in 45 – 55 % yield. Contrary to this result, most reported procedures using the aqueous 
Zn/THF/NH4Cl system had obtained yields over 80 %. Increasing the amount of the metal did not give 
an improvement in the yields. It was noticed that a yellow slurry was formed during the reaction. It 
dissolved slightly in THF, EtOAc or CH2Cl2. After further investigation of the reaction parameters, it 
became clear that if the Zn was added at room temperature to a solution of the substrate and the acid, an 
exothermic reaction resulting in the formation of insoluble compounds ensued, from which the substrate 
would not undergo further reduction to the amine. If the Zn was added in small portions over a 
prolonged period of time to a pre-cooled solution of the substrate, the formation of insoluble compounds 
was minimized, resulting in increased yields. A TLC analysis showed almost complete conversion of 
the starting material. Yields after flash chromatography were 85 – 95 % (schemes 32 and 33).  
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Scheme 32. The reduction of the nitro group employing Zn and sat. aq. NH4Cl. 
 
 
 
Scheme 33. The reduction of the nitro group employing Zn and sat. aq. NH4Cl. 
 
The Sonogashira coupling between the methyl 4-ethynylbenzoate and the methyl 5-amino-2-iodo- 
benzoate was also tested (scheme 34), furnishing the desired product in 70 – 75 % yield. 
  
 
 
Scheme 34. The Sonogashira coupling between the methyl 4-ethynylbenzoate and the methyl 5-amino-2-iodobenzoate. 
 
However, having established an excellent method for the reduction of the nitro group, the attention 
directed to the hydrolysis of the two methyl ester groups in methyl 5-amino-2-((4-(methoxycarbonyl)-
phenyl)ethynyl)benzoate. Utilizing 3 eq. of LiOH in THF/water furnished the hydrolyzed product in 
90% yield. Our attention was then shifted to the step that proved to be the most challenging – the cis-
reduction of the triple bond between the two aromatic rings. 
 
10.4.8 Introduction to the selective cis-reduction of the triple bond 
 
The reduction of the triple bond could be performed either on compound 1, 2 or 3 (see figure 66). 
Compound 3, with the carboxylic acid groups, would make purification of a theoretical analogue with a 
cis-double bond by flash chromatography complicated and it was thus not treated as a potential substrate 
for the cis-reduction. Compounds 1 and 2 were perfect substrates for the cis-reduction reaction, but the 
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amino group in the compound 2 could react in an unpredictable manner. Through the rest of the text, the 
two hydrogens that sit on the double bond will be referred to as Ha and Hb (figure 67).  
 
                            
  Comp. 1                                Comp. 2                                  Comp. 3 
                                                                                                 
                           Fig. 66. Substrates of the interest.                                                   Fig. 67. Nomenclature of the two hydrogens. 
 
The cis-double bond can be synthesized by a variety of methods. It can either be obtained from a triple 
bond by reduction or it can be synthesized stereoselectively as a Z-olefin from suitable substrates. A 
short overview of the strategies can be found in schemes 35 – 39. 
 
                                                 
 
    Scheme 35. Cis-reduction of the triple bond.                                          Scheme 36. Cis-reduction of the triple bond. 
 
 
 
Scheme 37. Cis-reduction of the triple bond using an addition/elimination approach. 
 
 
 
Scheme 38. Stereoselective synthesis of the cis-double. 
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Scheme 39. Two-step synthesis of the cis-double bond using Stille and Heck coupling reactions. 
 
The schemes 38 and 39 illustrate a method where the cis-double bond is synthesized stereoselectively, 
avoiding going via a triple bond intermediate which subsequently must be reduced. In the scheme 39, 
tributyl(vinyl)stannane is being used as a coupling reagent, giving tributyl(bromo or iodo)stannane as a 
by-product. The same by-product can be found in scheme 38. It is known that it is not trivial to remove 
this by-product from a reaction mixture. It is highly toxic and since the aim of this project is to prepare 
the novel pharmaceutical agents, it will not be optimal to have traces of this material in the final 
product. When it comes to use of the tributyl(vinyl)stannane, extremely rigorous safety routines must be 
followed. Therefore, the synthesis of the Z-olefin linkage by these two protocols was not considered as a 
safe nor attractive route. The schemes 35 and 36 illustrate the reduction of the triple bond using a 
catalyst and hydrogen gas. The reaction protocol in the scheme 37 differs from the other procedures 
since it does not involve a reducing agent – it is more of a “stereoselective addition-elimination 
reaction”. Based on the literature and the availability of the reagents, the following methods were 
chosen for testing either on the compound 1 or 2 (scheme 40). 
 
 
Scheme 40. The cis-reduction techniques that were tested either on compound 1 or 2. 
 
10.4.9 Reduction of the triple bond using the Pd(OAc)2/KOH/DMF-system 
 
In 2010, an interesting article appeared by Li J. et al.55 dealing with the transfer hydrogenation of 
diarylacetylenes to cis-stilbenes. A variety of diaryl compounds with a triple bond were reduced to their 
cis-double bond analogues in excellent yields and with high stereoselectivities. The catalytic 
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system/reagents used were Pd(OAc)2/KOH/DMF. According to the article, the proposed mechanism for 
the transfer hydrogenation reaction is depicted in scheme 41, the optimal stochiometry and reaction 
conditions are illustrated in scheme 42.  
 
                      
 Scheme 41. The mechanism of reduction of the triple bond.         Scheme 42. The optimal stochiometry and reaction conditions.  
 
Despite of the quite harsh reaction conditions, this protocol was tested on the methyl 5-amino-2-((4-
(methoxycarbonyl)phenyl)ethynyl)benzoate. As it can be seen from scheme 41, hydrolysis of the DMF 
in the presence of KOH generates HCOOH in situ in an appropriate concentration that later functions as 
a hydrogen source. Keeping in mind that the substrate carries two methyl ester groups, it would be right 
to think that the hydrolysis of the methyl ester groups will be a major side-reaction at such high 
temperatures. Assuming that the provided mechanism provides an accurate picture of the reaction, the 
carboxylic acids formed from the hydrolysis of the methyl esters could undergo oxidative addition to the 
Pd(0) species and further transformations. The first attempts on the cis-reduction using an optimized 
reaction protocol (scheme 42) that according to the authors gave the best yield and stereoselectivity, 
furnished the desired product in 24 % yield with 70% purity. As it was pointed out in the article, old and 
undried DMF had been used. TLC-analysis and purification of the crude material by flash 
chromatography showed that the starting material and the desired product had very similar Rf-values. 
The desired compound could not be obtained completely pure as per 1H NMR. Changing the reaction 
parameters or stochiometries of reagents/catalyst did not improve the reaction yields (scheme 43, table 
8).         
 
 
 
Scheme 43. A general procedure for the reduction of the triple bond using the Pd(OAc)2/KOH/DMF-system. 
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Entry Pd(OAc)2 KOH 
DMF (X ml pr. 
0.5 
mmol substr.) 
React. temp. 
(oC) 
React. time 
(h.) 
Yield: 
1 2 mol % 1.5 eq. 3 145 6 0 % 
2 4 mol % 1.5 eq. 1 145 6 24 %, ca 60 % pure 
3 6 mol % 1.5 eq. 1 100 12 26 %, ca 65 % pure 
     
Table 8. The stochiometries of the reagents and catalyst in the reaction depicted in scheme 43. 
 
Despite the low yields and an extremely tedious work up, some very important facts were unveiled. The 
most obvious of them is that it is possible to cis-reduce the triple bond. An investigation of the data 
from the 1H MNR analysis revealed that J Ha-Hb in (Z)-methyl 5-amino-2-(4-(methoxycarbonyl)- 
styryl)benzoate had coupling constant of 12.0 – 12.2 Hz (attachment 2, spectra 1 and 2, doublets at 
7.073 – 7.033 and 6.540 – 6.500 ppm). The coupling constant was the only proof that the reduction of 
the triple bond had proceeded according to plan, giving the cis-product. Theoretically, the J Ha-Hb in a 
trans analogue of (Z)-methyl 5-amino-2-(4-(methoxy-carbonyl)styryl)benzoate would have coupling 
constant of approximately 15 Hz.75 Neither the (Z)-methyl 5-amino-2-(4-(methoxycarbonyl)styryl)- 
benzoate nor its trans analogue - (E)-methyl 5-amino-2-(4-(methoxycarbonyl)- styryl)benzoate were 
previously reported. 
 
10.4.10 Reduction of the triple bond using the Pd(OAc)2/PPh3/NaOMe/THF-system 
 
Another system for the stereoselective reduction of substituted diarylacetylenes was proposed by Wei et 
al.56 The system was tested on the methyl 5-amino-2-((4-(methoxycarbonyl) phenyl)ethynyl)benzoate, 
unfortunately giving only the starting material, that was recovered in 80 – 90% yield after the flash 
chromatography (scheme 44, table 9). 
 
 
 
 
 
Scheme 44. A general procedure for the reduction of the triple bond using the Pd(OAc)2/PPh3/NaOMe/THF-system. 
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2 10 mol % 10 mol % 10 eq. r.t. 48 75 – 80 
3 10 mol % 10 mol % 10 eq. 45 12 0 
 
Table 9. The stochiometries of the reagents and catalyst in the reaction depicted in scheme 44. 
 
After observing the difficulty in the reduction of the triple bond using two different protocols, it was 
decided to employ a distinct approach towards the synthesis of the analogue with the cis-double bond. 
 
10.4.11 Synthesis of the cis-double bond using an addition/elimination approach 
 
The transformation of a triple bond to a cis-double bond can be achieved in two steps using the 
addition/elimination approach that is illustrated in scheme 45. 
 
 
 
Scheme 45. Two-step reduction of the triple bond using an addition/elimination approach. 
 
10.4.12 Synthesis of the cis-double bond using a hydroboration/protonolysis approach 
 
One of the classical methods for this type of synthesis of a cis-double bonds is the hydroboration/ 
protonolysis protocol discovered by Brown et al.57 The whole reaction sequence can be viewed in 
scheme 46. 
 
 
 
Scheme 46. A schematic representation of the hydroboration/protonolysis approach. 
 
The hydroboration reagent is a disubstituted borane adduct of the type R2BH. Some of these reagents 
can be bought from commercial sources; others can easily be prepared in situ. The disubstituted borane 
adduct acts as an electrophile in the hydroboration step since the borane atom has a free p-orbital that 
undergoes a nucleophilic attack by the triple bond. The addition goes through a four-center transition 
state resulting in a vinylborane adduct (scheme 47).  
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Scheme 47. Mechanism of addition of the disubstituted borane adduct to the triple bond. 
 
The protonolysis of the vinylborane adduct with formic acid proceeds with the retention of the 
stereochemistry giving a cis-olefin. The choice of disubstituted borane adduct to be used in the 
hydroboration step is governed by the sterical environment of the substrate - heavily hindered alkynes 
will not react with borane reagents bearing large aromatic groups. The vinylborane adduct itself may 
react with the hydroborating agent, but this happens only with relatively unhindered alkynes bearing 
alkane side chains. Both the hydroboration and protonolysis are commonly performed at 0 oC since the 
vinylborane adducts are not stable and may decompose – as a consequence of this, the vinylborane 
adducts are not isolated and are used directly in the next step. 
 
Going back to our substrates of interest, it was decided to adopt the experimental procedures that used 
dicyclohexylborane as the hydroborating agent.58 The hydroboration/protonolysis sequence was tested 
on the methyl 5-amino-2-((4-(methoxycarbonyl)phenyl)ethynyl)benzoate since it is soluble in THF at 
low temperatures (down to -20 oC), while the methyl 2-((4-(methoxycarbonyl)phenyl)ethynyl)-5-
nitrobenzoate is not. During the hydroboration step, the disubstituted borane reagent reacts in an anti-
Markovnikov fashion, adding to the most hindered carbon of the two that constitute the triple bond. For 
our purposes, addition to either of the carbons in the triple bond would suffice. During the protonolysis 
step with formic acid, hydrolysis of the methyl ester groups was a possible side reaction, but since the 
step is commonly done at 0 oC, the hydrolysis would be very slow or should not take place at all. The 
overall reaction sequence can be viewed in scheme 48. 
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Scheme 48. A general procedure for the synthesis of the cis-double bond using the hydroboration/protonolysis approach. 
 
As can be seen from the scheme 48, the dicyclohexylborane was generated in situ from the cyclohexene 
and the BH3•THF complex. Unfortunately, a 1H NMR analysis of the crude mixture showed no 
formation of the desired product, the starting material was always recovered after flash chromatography 
in 90 – 95% yield. Attempts with larger excesses of the dicyclohexylborane, prolonged reaction times 
etc. (scheme 49, table 10) did not give any conversion of the starting material. An interesting 
observation is that in all cases, the white solid (dicyclohexylborane) disappeared after the addition of the 
substrate – maybe due to formation of the vinylborane adduct, but since there was no product formed, 
this interpretation goes unsubstantiated. No hydrolysis of the methyl ester groups was observed in any 
of the cases. 
 
 
 
Scheme 49. A general procedure for the synthesis of the cis-double bond using the hydroboration/protonolysis approach. 
 
Entry HBCy2 AcOH 
React. time (hydrobor. 
+ protonolysis, h) 
% conversion to 
alkenyl adduct 
1 2 eq. 12 eq. 1 + 0.5 0 
2 4 eq. 24 eq. 2 + 1 0 
3 10 eq. 60 eq. 2 + 2 0 
4 15 eq. 80 eq. 2 + 3 0 
5 20 eq. 120 eq. 3 + 2 0 
 
Table 10. The stochiometries of the reagents and catalyst in the reaction depicted in scheme 49. 
 
10.4.13 Synthesis of the cis-double bond using hydrosilylation/protodesilylation approach 
 
The next approach that was attempted to effect the cis-reduction of the triple bond was based on the 
research done by Hamze A. et al.59 The main idea was exactly the same as with the hydroboration/ 
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protonolysis approach – an addition of a H–Si bond to the sp-carbons in the triple bond in a cis-selective 
fashion, followed by the removal of the silane adduct, leaving behind a cis-double bond (scheme 50). 
This approach was used in the synthesis of analogues of combretastatin.59a An addition of a H–Si bond 
to the carbon-carbon triple bond can give 4 different products (scheme 51). 
 
 
 
Scheme 50. The main concept behind the hydrosilylation/protodesilylation approach. 
 
 
 
Scheme 51. Possible product distribution in the hydrosilylation reaction. 
 
Only (E)-alkenylsilanes will lead to the formation of the cis-alkene after elimination of the silyl group. 
In their research Hamze et al. employed platinum dioxide as a catalyst in the hydrosilylation of 
substituted diarylacetylenes, giving only (E)-adducts. Which of the two (E)-alkenylsilanes is being 
formed is not crucial for this project since both give cis-alkenes after the elimination of the silyl group. 
The carbon-silicon bonds are readily cleaved by TBAF or other sources of fluoride ions.59a, 60 The 
alkenylsilanes are isolable compounds by flash chromatography and have been characterized by 
NMR.59c NOESY techniques have been used to prove the (E)-geometry of the silicon adduct. For our 
purposes, it meant that the alkenylsilanes could be isolated, purified and characterized before using them 
in the next step. Cleavage of the carbon-silicon bond by fluoride ions is a known reaction – the 
stereoselectivity of the cleavage, isomerisation and side-reactions were the major concerns. Keeping all 
that in mind, the reaction protocol shown in scheme 52 was tested on the methyl 2-((4-(methoxy- 
carbonyl)phenyl)ethynyl)-5-nitrobenzoate (scheme 52).  
 
 
Scheme 52. A general hydrosilylation/protodesilylation reaction sequence.  
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In the original procedure that was adopted for the hydrosilylation/protodesilylation of our substrate of 
interest, the hydrosilylation was done in neat triethylsilane, the silane functioning both as the solvent 
and a reagent. When the original procedure was tested on the methyl 2-((4-(methoxycarbonyl)-phenyl)- 
ethynyl)-5-nitrobenzoate, spontaneous evolution of gas and a small explosion accompanied by a small 
fire ensued upon addition of the triethylsilane. Dissolving the substrate and the catalyst in THF prior to 
the addition of the triethylsilane did not result in a similarly uncontrolled reaction. The hydrosilylation 
reaction was tested with different catalyst loadings, amounts of triethylsilane, reaction times and 
temperatures (scheme 53). None of the reaction outcomes were reproducible – the same conditions gave 
very different outcomes in terms of yields of the desired product – anything from no conversion to 86% 
yield was obtained. It is unclear why this happened. In cases where the reaction worked fine, one could 
see the bubbles coming from the reaction mixture, most probably hydrogen gas.61 Evolution of the 
hydrogen gas may also explain the spontaneous combustion when the reaction was performed neat. 
Platinum metal reacts very violently with hydrogen gas and since the alkyne substrate is not soluble in 
triethylsilane, the reaction mixture was not homogeneous – the heat and energy did not have any place 
to escape. In the references there was no information about this –perhaps indicating that similar 
situations did not occur in their cases.59, 60 Most likely, the alkyne substrates tested were in liquid form, 
thereby making the process of the heat transport from the reaction mixture to its surroundings more 
efficient. When the reaction did not work (conversion < 5 %), no bubbles were observed. On the 
positive side, the starting material and the alkenylsilanes adduct could be easily separated by flash 
chromatography, making the process of screening more economical and efficient. Despite the failure of 
the hydrosilylation reaction, the cleavage of the carbon-silicon bond was examined. TBAF was used as 
a source of fluoride ions together with copper iodide acting as a promoter of the protodesilylation 
reaction and buffering the activity of the TBAF.62 A summary of the hydrosilylation/protodesilylation 
experiments is presented in scheme 53, table 11, scheme 54 and table 12. 
 
 
Scheme 53. A general protocol for the hydrosilylation reaction. 
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2 7 1.5 60 2 < 5 
3 20 1.5 60 2 < 5 
4 10 10 60 2 0 
5 7 5 60 2 < 5 
6 15 1.5 70 2 < 5 
7 3 3 56 2.5 50 
8 6.5 3 55 3.5 < 5 
9 6.5 3 55 3.5 40 % 
10 5 3 58 3 64 % 
11 5 3 58 3 < 5 
12 5 1.6 56 3 < 5 
 
Table 11. The stochiometries of the reagents and catalyst in the reaction depicted in scheme 53. 
 
 
 
Scheme 54. A general protocol for the protodesilylation reaction. 
 
Entry TBAF (eq.) CuI (eq.) React.  t. (oC) React. time (h) Cis-trans ratio 
1 3.2 0 0 6 trans only 
2 2 0.2 r.t. 16 Cis (64 %) + trans (36 %) 
3 1.1 1.5 - 30 16 Cis (40 %) + trans (60 %) 
4 3 0 - 5 2 trans 
 
Table 12. The stochiometries of the reagents and catalyst in the reaction depicted in scheme 54. 
 
The TBAF was dried prior to use by dissolving it in dry toluene, concentrating in vacuo, and then drying 
for 3 days under high vacuum. As it can be seen from scheme 54, table 12, the protodesilylation of the 
alkenylsilane adduct with TBAF resulted in a mixture of the cis/trans products or only trans products. 
The yields in all cases were low – around 20 % - suggesting that a side-reaction might be involved. In 
cases where only TBAF was used, only the trans product was obtained – TBAF most probably cleaved 
the carbon-silicon bond in a stereoselective fashion, giving only the cis alkene in the first place and then 
isomerized it to the trans alkene. In cases where the CuI was used as a “buffer”, the cis isomer was also 
present. Low temperatures did not make a particular impact on a rate of the isomerization etc. The trans 
and cis analogues could not be separated by flash chromatography. The J Ha-Hb in the cis analogue was 
12.2 Hz (attachment 2, spectra 5, 7, doublets at 7.192 – 7.138 and 6.858 – 6.817 ppm; attachment 2, 
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spectra 3, 4, doublets at 7.198 – 7.136 and 6.866 – 6.805 ppm), the J Ha-Hb in the trans analogue was 
16.2 Hz. (attachment 2, spectra 8 – 11, doublets at 8.204 – 8.149 ppm and 7.187 – 7.133 ppm). In the 
reactions where the trans adduct was the only product, the product was a yellow solid. When mixtures 
of both the cis and trans-isomers were obtained, the purified product consisted of both the yellow solid 
and an oil, suggesting that the cis-isomer is a yellow oil. 
   
10.4.14 Synthesis of the cis-double bond by hydrogenation using Lindlar catalyst system 
 
The Lindlar catalyst is a catalyst system that is widely used for partial hydrogenation of acetylenic 
systems to alkenes.63 Alkyne reduction is a stereoselective process, occurring via syn addition to give cis 
alkenes. The Lindlar catalyst is a heterogeneous catalyst system that consists of 5 %wt palladium 
deployed on a porous calcium carbonate surface with a deactivating agent – lead or quinoline. The 
selectivity of the partial hydrogenation of alkynes can be divided into three stages/parts: hydrogenation 
stops at the alkene stage, no other functional groups undergo reactions and reactant/product(s) of the 
reaction do not undergo oligomerization reactions.  
 
The reduction of the triple bond with the Lindlar system could be performed on the two substrates of the 
interest – either on the methyl 2-((4-(methoxycarbonyl)phenyl)ethynyl)-5-nitrobenzoate or the methyl 5-
amino-2-((4-(methoxycarbonyl)phenyl)ethynyl)benzoate. The amino group could potentially lead to 
over-reduction of the alkyne moiety to the alkane. Protection of the amino group is a common strategy 
to overcome this issue, but the introduction of the two additional steps would be of a little practical 
value. The nitro group itself could be reduced to the amino group under the reaction conditions that are 
typical for hydrogenations with the Lindlar catalyst.64  
 
Control over the Lindlar catalyst and its activity can be achieved through the use of poison – lead or 
quinoline. The Lindlar catalyst that was available already contained lead acetate, so quinoline was 
employed as an additional deactivator of the catalyst. Quinoline acts by blocking the potential 
adsorbtion sites for dihydrogen and the alkyne.65 Hydrogen-bonding solvents can also be employed as 
deactivators of the catalyst,66 but poor solubility of the methyl 2-((4-(methoxycarbonyl)phenyl)ethynyl)-
5-nitrobenzoate in MeOH or EtOH made it impossible to use this technique. The methyl 2-((4-
(methoxycarbonyl)phenyl)ethynyl)-5-nitrobenzoate became the substrate that was tested in partial 
hydrogenation reactions employing the Lindlar catalyst system. The idea was to start with a big 
percentage of the quinoline and observe what would happen when the ratio between the catalyst/poison 
was changed. The hydrogen gas pressure was 1 atmosphere, because higher pressures could eventually 
lead to unwanted side reactions such as over-reduction. Theoretically, the reduction could give 8 
different products (scheme 55). An overview of the experiments and product distributions can be 
viewed in scheme 56, table 13. 
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Scheme 55. Probable products after the hydrogenation reaction with Lindlar catalyst. 
 
 
 
Scheme 56.  A general reaction protocol for the reduction of the triple bond employing Lindlar catalyst.  
 
Entry 
Lindlar cat. 
(mol%) 
Quinoline 
(mol%) 
Prod. distrib. (nomenclature 
as in scheme 58): 
1 5 30 Prod. 1 + prod. 3 
2 5 15 Prod. 2 + prod. 4 
3 5 15 Prod. 4 
4 5 10 Prod. 2 
5 5 5 Prod. 2 
    
Table 13. The stochiometries of the reagents and catalyst in the reaction depicted in scheme 56. 
 
In all cases, hydrogen gas was introduced into the reaction flask from a balloon via a hypodermic needle 
that was stuck through the septum. The reaction flask was flooded with hydrogen. Hydrogen gas was 
also bubbled through the solvent, after that the gas inlet was removed and the flask was sealed with 
plastic tape. Using 30 mol% of quinoline (entry 1, table 13), furnished a mixture of the starting material 
and the product 3 (scheme 58). They could not be separated by flash chromatography. The J Ha-Hb in 
product 3 had value of 12.4 Hz (attachment 2, spectra 12, 13, doublets at 7.200 – 7.139 and 6.870 – 
6.808 ppm). Upon lowering the amount of quinoline to 15 mol% (entries 2 and 3, table 13) reduction of 
both the triple bond and the nitro group was observed (attachment 2, spectra 14, 15). Upon repetition of 
the reaction, only product 4, with a cis-double bond and an amino, was formed and isolated in 96 % 
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yield. The J Ha-Hb in product 4 had value of 12.0 Hz. Further lowering of the amount of quinoline 
(entries 4 and 5, table 13) resulted only in the reduction of the nitro group, giving only product 2.  
 
Summarizing the reactions in table 13, several things can be noted. The formation of the trans product 
was not observed in any cases, meaning that the reduction proceeded in a highly cis-selective fashion 
and that no isomerization occurred. Upon lowering the quantity of quinoline, reduction of the nitro 
group was the only reaction – reduction of the triple bond did not take place at all (entries 4, 5, table 13). 
Assuming that preassociation of the alkyne bond to the metal surface is one of the first steps in the 
reduction of the triple bond, it is unclear why only reduction of the nitro group occurred. As it was 
pointed out in the literature,66 the amino group is usually protected to avoid over-reduction to an alkane, 
while in this case not even reduction to an alkene was observed. Formation of the amino group 
somehow lowered the activity of the catalyst, making it less efficient towards reduction of the triple 
bond.  
 
Chapter 11 
 
Conclusion 
 
Compounds AB74, 75, 76, 77, 78 and 81 have been docked against the DBD of the c-Myb, synthesized 
and tested in the EMSA analysis. The biological analysis revealed severe limitations of the AutoDock 
4.2 software when it came to the prediction of the inhibition constants.  
 
Compound NSC675460 has been successfully modified using the bioisosteric approach, resulting in 
three new compounds with better in silico activities than NSC675460.     
 
The synthesis of the compound NSC675460 could not be finished due to the short time that was left at 
the end of the project. The hydrolysis of the ester groups and the azo-coupling reaction with the 8-
hydroxyquinoline-5-sulfonic acid remains to be investigated.    
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Chapter 12 
 
Experimental 
 
General 
 
Chemicals were used as delivered from Sigma-Aldrich or TCI Europe. Argon (4.0) was used as delivered 
from AGA.  
 
Thin layer chromatography was done on 60 F254 silica coated aluminium plates from Merck. Flash 
chromatography was done on silica gel Merck (Silikagel 60, 0.40-0.63 mm, 480-540 m2/g, pH 6.5 – 7.5) 
with an Isco Inc. CombiFlash Companion with PeakTrak software (v. 1.4.10). Ethyl acetate and hexane 
used as eluents were of technical grade. 
 
NMR spectra were recorded on a Bruker Avance DPX200, DPX300 and DPX400 instrument at 200, 
300 or 400 MHz for 1H-NMR and 50, 75 and 100 MHz for 13C-NMR at 25 oC. Chemical shift (δ) is 
given in ppm relative to the solvent CDCl3 (7.24 ppm for 1H-NMR, 77.0 ppm for 13C-NMR), DMSO 
(2.49 ppm for 1H-NMR, 39.50 ppm for 13C-NMR). Coupling constants are given in Hz. All 13C-NMR 
spectra are decoupled. Peak assignment in 1H- and 13C-NMR spectra is based on information from 
DEPT135, DEPT 90, HMQC and COSY experiments as needed. Peaks due to solvents such as 
dichloromethane, ethyl acetate, water, hexane and THF are not included in the interpretation of NMR 
spectra. 
 
MS spectra are recorded on a VG Prospec sector instrument from Fissions Instruments at 70 eV (EI). 
HR-MS is recorded using perfluorokerosene (PFK) as reference. For electrospray (ESI) a Micromass Q-
Tof-2 mass spectrometer was used. 
  
General procedure for the synthesis of compounds AB 74, 75, 76, 77, 78 and 81 
 
To a round-bottomed flask, amine (0.483 g, 2 mmol, 1 eq.), Na2CO3 (0.101 g, 1 mmol, 0.5 eq.) and H2O 
(12 mL) were added. The mixture was stirred for 20 min. at r.t. and then cooled down to 0°C.  Then 
conc. HCl (0.34 mL) in H2O (2 mL) was added and the solution was stirred for additional 20 min at 
0°C. Then a solution of NaNO2 (0.138g, 2 mmol, 1 eq.) in H2O (0.322 ml) was added slowly at 0°C 
over 10 min. The reaction mixture was stirred at 0°C for 1 hour and then added to a solution of 8-
hydroxyquinoline-5-sulfonic acid monohydrate (0.486 g, 2.0 mmol, 1 eq.) in 1M NaOH solution (6 
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mL). The reaction mixture turned purple and was stirred for 3 hours at 0°C. Cold conc. HCl (25 
droplets) and NaCl (0.75 g) were added and the product precipitated after 30 min. The product was 
vacuum filtered and collected. The crude product was dried overnight at r.t. Purification was done by 
dissolving crude product in minimum amount of 1M NaOH, filtrating it and then precipitating product 
by careful addition of 12M HCl. The precipitated purified product was collected by vacuum filtration. 
The product was purified two times by the same method.  
 
Purity of the compounds was checked by HPLC using a Spectra SYSTEM P2000 pump with a Spectra 
SYSTEM UV3000 UV detector with a reverse phase column – Kromasil 100-5-C18, 250 x 10 mm. 
Eluent system was acetonitrile / ammonium acetate buffer (pH=10), flow = 2,5 ml/min, acetonitrile 
0→100% over 20 min. 
 
 Synthesis of sodium (E)-8-hydroxy-7-((6-sulfonaphthalen-2-yl)diazenyl)quinoline-5-
sulfonate 
 
 
          
The compound was prepared and purified according to the general procedure. 
 
Yield: 0.2073 g (22%) 
 
 
 
1H NMR (300 MHz, DMSO-d6 as solvent, in ppm): δ 9.554 - 9.525 (1H, d, J = 8.7 Hz, H1); 9.083 - 
9.070 (1H, d, J = 3.9 Hz, H2); 8.677 (1H, s, H10); 8.481 (1H, s, H4); 8.310 - 8.275 (1H, dd, J = 1.8 Hz, 
J = 8.7 Hz, H8); 8.244 (1H, s, H6); 8.152 - 8.107 (2H, dd, J = 4.8 Hz, J = 8.7 Hz, H7, H9); 8.062 - 
8.017 (1H, dd, J = 4.8 Hz, J = 8.7 Hz, H3); 7.847 - 7.814 (1H, dd, J = 1.5 Hz, J = 8.7, H5) 
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13C NMR (75 Mhz, DMSO-d6 as solvent, in ppm): δ 152.01 (Ar-C); 149.36 (Ar-C); 147.34 (Ar-C); 
145.88 (C2); 142.71 (C1); 135.46 (Ar-C); 135.22 (Ar-C); 134.98 (Ar-C); 133.74 (Ar-C); 132.97 (Ar-
C); 130.06 (C7); 129.18 (C9); 127.85 (Ar-C); 127.43 (C10); 125.10 (Ar-C); 124.30 (C6); 124.14 (C3); 
117.55 (C8); 116.87 (C4). 
 
MS (ESI, TOF MS ES-) m/z (relative intensity): 480.1 (100%) 
 
HR-MS (ESI, TOF MS ES-): Calculated value for C19H11N3NaO7S2-: 479.9936. Found: 479.9925 (- 
2.32 ppm) 
 
HPLC: 7.8 min; 93% pure 
 
Synthesis of sodium (E)-8-hydroxy-7-((5-sulfonaphthalen-2-yl)diazenyl)quinoline-5-
sulfonate 
 
 
 
The compound was prepared and purified according to the general procedure. 
 
Yield: 0.4958 g (34%) 
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1H NMR (300 MHz, DMSO-d6 as solvent, in ppm): δ 9.610 - 9.577 (1H, dd, J = 1.2 Hz, J = 8.7 Hz, 
H1); 9.125 - 9.104 (1H, dd, J = 1.2 Hz, J = 4.8 Hz, H2); 8.996 - 8.965 (1H, d, J = 9.3 Hz, H9); 8.707 - 
8.701 (1H, d, J = 1.8 Hz, H10); 8.503 (1H, s, H4); 8.314 - 8.276 (1H, dd, J = 2.1 Hz, J = 9.3 Hz, H8); 
8.162 - 8.049 (3H, m, H7, H6, H3); 7.597 - 7.546 (1H, t, J = 7.8 Hz, H5). 
 
 
 
13C NMR (75 Mhz, DMSO-d6 as solvent, in ppm): δ 152.06 (Ar-C); 148.46 (Ar-C); 145.94 (C2); 
144.36 (Ar-C); 142.70 (C1); 135.46 (Ar-C); 135.23 (Ar-C); 135.13 (Ar-C); 133.90 (Ar-C); 131.05 
(Ar-C); 130.51 (Ar-C); 129.08 (Ar-C); 127.85 (Ar-C); 127.58 (Ar-C); 126.39 (Ar-C); 125.90 (Ar-C); 
124.11 (C3); 116.93 (Ar-C); 116.71 (C4). 
 
MS (ESI, TOF MS ES-) m/z (relative intensity): 480.1 (100%) 
 
HR-MS (ESI, TOF MS ES-): Calculated value for C19H11N3NaO7S2-: 479.9936. Found: 479.9925 (- 
2.31 ppm) 
 
HPLC: 7.3 min; 91% pure 
 
Synthesis of sodium (E)-8-hydroxy-7-((6-sulfonaphthalen-1-yl)diazenyl)quinoline-5-
sulfonate 
 
 
 
The compound was prepared and purified according to the general procedure.  
 
Yield: 0.2297 g (24%) 
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1H NMR (300 MHz, DMSO-d6 as solvent, in ppm): δ 9.712 - 9.684 (1H, d, J = 8.4 Hz, H1); 9.145 - 
9.130 (1H, d, J = 4.5 Hz, H2); 8.806 - 8.776 (1H, d, J = Hz, J = 9 Hz, H6); 8.606 (1H, s, H4); 8.362 
(1H, s, H8); 8.224 - 8.043 (3H, m, J = 7.9 Hz, H9, H10, H3); 8.072 – 8.043 (1H, d, J = 8.7 Hz, H7); 
7.703 - 7.650 (1H, t, J = 8.15 Hz, H5). 
 
 
 
13C NMR (75 MHz, DMSO-d6 as solvent, in ppm): δ 151.67 (Ar-C); 145.95 (Ar-C); 145.78 (Ar-C); 
145.55 (C2); 144.07 (C1); 136.27 (Ar-C); 135.34 (Ar-C); 133.89 (Ar-C); 133.32 (Ar-C); 133.06 
(C10); 130.15 (Ar-C); 128.01 (Ar-C); 126.71 (C5); 125.62 (C6); 125.02 (C8); 124.57 (C9); 122.26 
(C7); 117.24 (C4); 114.18 (C3). 
 
MS (ESI, TOF MS ES-) m/z (relative intensity): 480.1 (100%) 
 
HR-MS (ESI, TOF MS ES-): Calculated value for C19H11N3NaO7S2-: 479.9936. Found: 479.9925 (- 
2.29 ppm) 
  
HPLC: 7.6 min; 95% pure 
 
Synthesis of sodium (E)-8-hydroxy-7-((5-sulfonaphthalen-1-yl)diazenyl)quinoline-5-
sulfonate 
 
 
 
The compound was prepared and purified according to the general procedure. 
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Yield: 0.3421 g (32%) 
 
 
 
1H NMR (300 MHz, DMSO-d6 as solvent, in ppm): δ 9.674 - 9.641 (1H, dd, J = 1.5 Hz, J = 8.7 Hz, 
H1); 9.136 - 9.103 (2H, m, H2, H8); 8.898 - 8.870 (1H, d, J = 8.4 Hz, H5); 8.49 (1H, s, H4); 8.229 - 
8.206 (1H, d, J = 6.9 Hz, H7); 8.166 - 8.120 (2H, m, J = 7.2 Hz, H10, H3); 7.774 - 7.712 (2H, dt, J = 
2.4 Hz, J = 7.2 Hz, H6, H9).  
 
 
 
13C NMR (75 Mhz, DMSO-d6 as solvent, in ppm): δ 151.31 (Ar-C); 146.28 (Ar-C); 145.77 (C2); 
144.38 (Ar-C); 143.36 (C1), 136.17 (Ar-C); 135.58 (Ar-C); 134.43 (Ar-C); 132.06 (C8); 131.10 (Ar-
C); 129.94 (Ar-C); 127.79 (Ar-C); 126.30 (C6); 125.69 (C9); 125.18 (C3); 124.17 (C10); 123.72 (C5); 
116.49 (C4); 112.78 (C7) 
 
MS (ESI, TOF MS ES-) m/z (relative intensity): 480.1 (100%) 
 
HR-MS (ESI, TOF MS ES-): Calculated value for C19H11N3NaO7S2-: 479.9936. Found: 479.9925 (- 
2.33 ppm) 
 
HPLC: 6.9 min; 90% pure 
 
Synthesis of sodium (E)-8-hydroxy-7-((4-sulfonaphthalen-1-yl)diazenyl)quinoline-5-
sulfonate 
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The compound was prepared and purified according to the general procedure. 
 
Yield: 0.395 g (33%) 
 
 
 
1H NMR (300 MHz, DMSO-d6 as solvent, in ppm): δ 9.653 - 9.626 (1H, d, J = 8.1 Hz, H1); 9.141 - 
9.128 (1H, d, J = 3.9 Hz, H2); 9.020 – 8.992 (1H, d, J = 8.4 Hz, H9); 8.873 - 8.845 (1H, d, J = 8.4 Hz, 
H10); 8.55 (1H, s, H4); 8.146 - 8.123 (3H, m, H6, H5, H3); 7.815 - 7.767 (1H, t, J = 7.2 Hz, H7); 7.720 
- 7.672 (1H, t, J = 7.5 Hz, H8). 
 
 
 
13C NMR (75 Mhz, DMSO-d6 as solvent, in ppm): δ 151.95 (Ar-C); 148.00 (Ar-C); 147.45 (Ar-C); 
146.70 (C2); 143.94 (C1); 136.96 (Ar-C); 136.39 (Ar-C); 135.65 (Ar-C); 131.63 (Ar-C); 130.78 (Ar-
C); 128.96 (Ar-C); 128.75 (C9); 128.00 (C8); 127.30 (C7); 125.34 (C5); 125.09 (C6); 123.00 (C10); 
117.38 (C4); 112.47 (C3) 
 
MS (ESI, TOF MS ES-) m/z (relative intensity): 480.1 (100%) 
 
HR-MS (ESI, TOF MS ES-): Calculated value for C19H11N3NaO7S2-: 479.9936. Found: 479.9925 (- 
2.32 ppm) 
 
HPLC: 7.4 min; 93% pure 
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Synthesis of sodium (E)-8-hydroxy-7-((7-sulfonaphthalen-1-yl)diazenyl)quinoline-5-
sulfonate 
 
 
 
The compound was prepared and purified according to the general procedure. 
 
Yield: 0.1973 g (21.5%) 
 
 
 
1H NMR (300 MHz, DMSO-d6 as solvent, in ppm): δ 9.750 - 9.724 (1H, d, J = 7.8 Hz, H1); 9.191 - 
9.176 (1H, d, J = 4.5 Hz, H2); 9.056 (1H, s, H10); 8.528 (1H, s, H4); 8.268 - 8.216 ( 2H, m, H5, H7); 
8.182 – 8.155 (1H, d, J = 8.1 Hz, H3); 8.081 - 8.053 (1H, d, J = 8. 4 Hz, H8); 7.917 - 7.884 (1H, dd, J = 
1.5 Hz, J = 8.4 Hz, H9); 7.747 - 7.695 (1H, t, J = 7.8 Hz, H6).  
 
 
 
13C NMR (75 Mhz, DMSO-d6 as solvent, in ppm): δ 152.46  (Ar-C); 146.73 (Ar-C); 146.17 (Ar-C); 
145.07 (C1); 144.71 (C2); 136.03 (Ar-C); 135.49 (Ar-C); 133.78 (Ar-C); 133.63 (Ar-C); 131.82 (C3); 
128.96 (Ar-C); 128.34 (Ar-C); 128.25 (C8); 126.62 (C6); 124.85 (C7, C5); 124.74 (C9); 118.67 
(C10); 118.03 (C4); 114.14 (C7, C5).  
 
MS (ESI, TOF MS ES-) m/z (relative intensity): 480.1 (100%) 
 
HR-MS (ESI, TOF MS ES-): Calculated value for C19H11N3NaO7S2-: 479.9936. Found: 479.9925 (- 
2.34 ppm) 
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HPLC: 7.5min; 92% pure. 
 
Synthesis of methyl 4-((trimethylsilyl)ethynyl)benzoate 
 
 
                                                                      
Procedure 1 
To a round bottomed flask, methyl 4-iodobenzoate (0.524 g, 2 mmol, 1 eq.), PdCl2(PPh3)2 (0.0702 g, 0.1 
mmol, 5 mol%), CuI (0.0381 g, 0.2 mmol, 10 mol%), PPh3 (0.0131 g, 0.05 mmol, 2.5 mol%) were 
added, the flask was equipped with septum and flushed with argon. Then dry and degassed THF (5 ml) 
was added with a syringe. Then, a deoxygenated solution of ethynyltrimethylsilane (0.424 ml, 3 mmol, 
1.5 eq.) in TEA (0.418 ml, 3 mmol, 1.5 eq.) was added with a syringe. The reaction mixture was stirred 
at r. t. for 20 hours under argon atmosphere. The crude reaction mixture was diluted with Et2O (40 ml), 
filtered, washed with H2O (25 ml) and brine (25 ml), dried with MgSO4 and concentrated in vacuo. The 
crude product was purified by flash chromatography (EtOAc – hexane, EtOAc 0% → 4% over 30 min) 
affording the title compound as white or light yellow solid.  
 
Yield = 0.455 g (98%) 
  
Procedure 2 
To a round bottomed flask, methyl 4-iodobenzoate (0.524 g, 2 mmol, 1 eq.), PdCl2(PPh3)2 (0.042 g, 0.06 
mmol, 3 mol%), CuI (0.022 g, 0.12 mmol, 6 mol%) were added, the flask was equipped with septum 
and flushed with argon. Then dry and degassed THF (4.2 ml) was added with a syringe. Then, a 
deoxygenated solution of ethynyltrimethylsilane (0.339 ml, 2.4 mmol, 1.2 eq.) in TEA (1.1 ml, 7.9 
mmol, 4 eq.) was added with a syringe. The reaction mixture was stirred at 75 oC for 2 hours under 
argon atmosphere and then cooled down to r.t. The crude reaction mixture was diluted with Et2O (40 
ml), filtered, washed with H2O (25 ml) and brine (25ml), dried with MgSO4 and concentrated in vacuo. 
The crude product was purified by flash chromatography (EtOAc – hexane, EtOAc 7% over 30 min) 
affording the title compound as a white or light yellow solid. 
 
Yield = 0.450 g (97%) 
 
Rf (20 % EtOAc - hexane) = 0.48 
 
SiMe3MeOOC
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1H NMR (300 Mhz, CDCl3 as solvent, in ppm): δ 7.942 – 7.914 (2H, d, J = 8.4 Hz, H2, H3); 7.492 – 
7.464 (2H, d, J = 8.4 Hz, H5, H4); 3.867 (3H, s, H1); 0.230 (9H, s, H6). 
 
 
 
13C NMR (300 Mhz, CDCl3 as solvent, in ppm): δ 166.80 (C2); 132.23 (C6, C7); 130.08 (C3); 129.75 
(C5, C4); 128.16 (C8); 104.48 (C9); 98.02 (C10), 52.53 (C1); 0.20 (C11). 
 
The compound has been previously reported 67. 
 
Synthesis of methyl 4-ethynylbenzoate 
 
 
     
To a dry round bottomed flask, methyl 4-((trimethylsilyl)ethynyl)benzoate (0.455 g, 1.96 mmol) and 
K2CO3 (0.0414 g, 0.3 mmol) were added. Then the flask was equipped with septum and flushed with 
argon. Then dry and degassed MeOH (2.86 ml) and CH2Cl2 (1.04 ml) were added with a syringe. The 
reaction mixture was stirred at r.t. under Ar. – atm.  for 1.5 hours, diluted with Et2O (40 ml), filtered and 
concentrated in vacuo. The crude reaction mixture was then taken up in Et2O (50 ml), washed with H2O 
(20 ml) and brine (20 ml), dried with MgSO4, filterd and concentrated in vacuo. The crude product was 
purified by flash chromatography (EtOAc – hexane, EtOAc 5%) affording the title compound as a white 
solid. 
 
Rf (20 % EtOAc - hexane) = 0.44 
 
Yield = 0.282 g (90%) 
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1H NMR (300 Mhz, CDCl3 as solvent, in ppm): δ 7.974 – 7.946 (2H, d, J = 8.4 Hz, H2, H3); 7.529 – 
7.501 (2H, d, J = 8.4 Hz, H4, H5); 3.887 (3H, s, H1); 3.204 (1H, s, H6). 
 
 
 
13C NMR (300 Mhz, CDCl3 as solvent, in ppm): δ 166.34 (C2); 132.02 (C6, C7); 130.09 (C3); 129.41 
(C4, C5); 126.72 (C8); 82.75 (C9); 80.01 (C10); 52.20 (C1). 
 
The compound has been previously reported 67.  
 
Synthesis of methyl 2-iodo-5-nitrobenzoate 
 
 
 
To a round bottomed flask, 2-iodobenzoic acid (2 g, 8.06 mmol) was added and dissolved in H2SO4 (99 
%, 6 ml) at 0 °C. The mixture was stirred at 0 °C for 10 min. Then a mixture of H2SO4 (99 %, 4 ml) and 
HNO3 (99 %, 4 ml) was added slowly with a pipette at 0 °C. The reaction flask was equipped with a 
condenser and the reaction mixture was stirred at 0 °C for 15 min, then warmed to r.t., stirred for 15 
min, then warmed up to 130 °C and stirred at that temperature for  additional 2 hours. Then the solution 
was cooled to 0 °C and poured into ice. The crude product was collected by suction filtration and dried 
under vacuum over night. Crude 2-iodo-5-nitrobenzoic acid was then dissolved in H2SO4 (99 %, 6.5 
ml), cooled down to -5 °C and cold MeOH (20 ml) was added slowly and very carefully. The reaction 
mixture was stirred at 110 °C for 24 hours, cooled down to 0 °C and a large amount of water were 
added. The crude methyl 2-iodo-5-nitrobenzoate was obtained by extraction with CH2Cl2. The crude 
product was purified by slow recrystallisation from absolute EtOH.  
 
Yield: 1.56 g (63%) 
 
Rf ( 20% EtOAc - hexane) = 0.31 
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1H NMR (300 Mhz, CDCl3 as solvent, in ppm): δ 8.590 – 8.582 (1H, d, J = 2.4 Hz, H3); 8.201 – 
8.172 (1H, d, J = 8.7 Hz, H1); 7.963 – 7.925 (1H, dd, J = 2.7 Hz, J = 8.7 Hz, H2); 3.968 (3H, s, H4). 
 
 
 
13C NMR (300 Mhz, CDCl3 as solvent, in ppm): δ 164.90 (C7); 147.65 (C4); 142.78 (C2); 136.13 
(C6); 126.33 (C3); 125.50 (C5); 102.55 (C1); 53.11 (C8). 
 
MS (EI) m/z (relative intensity): 307 (M+, 100%), 276 (87.7%), 246 (11.95%), 230 (23.51%), 75 
(33.90%). 
 
HR-MS: Calculated value for C8H6INO4: 306.934151. Found: 306.934160 (- 0.4 ppm) 
 
Synthesis of methyl 2-((4-(methoxycarbonyl)phenyl)ethynyl)-5-nitrobenzoate 
      
 
 
Procedure 1 
To a round bottomed flask, methyl 2-iodo-5-nitrobenzoate (0.418 g, 1.36 mmol, 1 eq.), PdCl2(PPh3)2 
(0.0477 g, 0.068 mmol, 5 mol%), PPh3 (0.0089 g, 0.034 mmol, 2.5 mol%) and CuI (0.027 g, 0.14 mmol, 
10 mol%) were added, the reaction flask was equipped with a septum and flushed with argon. Then dry 
and degassed THF (5 ml) was added with a syringe and the mixture was stirred at r.t. under Ar. – atm. 
for 10 min. Then a solution of methyl 4-ethynylbenzoate (0.240 g, 1.5 mmol, 1.2 eq.) in dry and 
degassed THF (1 ml) and TEA (0.379 ml, 2.72 mmol, 2 eq.) were added slowly with a syringe. The 
reaction mixture was stirred at r.t. for 48 h. under Ar. atm. Then the reaction mixture was diluted with 
I
NO2
O
O1
2 3
4
I
NO2
O
O
1
2
3
4
5
6
7
8
COOMe
COOMe
O2N
	  	  101	  
EtOAc (40 ml), filtered, washed with H2O (25 mL) and brine (25 ml), dried with MgSO4 and 
concentrated in vacuo to afford the crude product. The crude product was purified by flash 
chromatography (EtOAc – hexane, EtOAc 0% - 50% over 30 min) to afford pure product as yellow 
solid.  
 
Yield: 0.373 g (81%) 
 
Procedure 2 
To a round bottomed flask, methyl 2-iodo-5-nitrobenzoate (0.482 g, 1.57 mmol, 1 eq.), PdCl2(PPh3)2 
(0.033 g, 0.047 mmol, 3 mol%) and CuI (0.018 g, 0.094 mmol, 6 mol%) were added, the reaction flask 
was equipped with a septum and flushed with argon. Then dry and degassed THF (7 ml) was added with 
a syringe and the mixture was stirred at r.t. under Ar. – atm. for 10 min. Then a deoxygenated solution 
of methyl 4-ethynylbenzoate (0.302 g, 1.88 mmol, 1.2 eq.) in dry and degassed THF (2 ml) and TEA 
(0.88 ml, 6.28 mmol, 4 eq.) were added slowly with a syringe. The reaction mixture was stirred at 58 oC 
for 24 h. under Ar.  atm. After the completion of the reaction, the reaction mixture was allowed to cool 
down to r.t. Then the reaction mixture was diluted with EtOAc (40 ml), filtered, washed with H2O (25 
mL) and brine (25 ml), dried with MgSO4 and concentrated in vacuo to afford the crude product. The 
crude product was purified by flash chromatography (EtOAc – hexane, EtOAc 0% - 50% over 30 min) 
to afford pure product as yellow solid.  
 
Yield: 0.505 g (95%) 
 
Rf (20 % EtOAc - hexane) = 0.27 
 
 
 
1H NMR (300 Mhz, CDCl3 as solvent, in ppm): δ 8.836 – 8.828 (1H, d, J = 2.4 Hz, H5); 8.345 – 
8.308 (1H, dd, J = 8.4 Hz, J = 2.4 Hz, H6); 8.054 – 8.026 (2H, d, J = 8.4 Hz, H2); 7.806 – 7.778 (1H, d, 
J = 8.4 Hz, H7); 7.662 – 7.634 (2H, d, J = 8.4 Hz, H3); 4.000 (3H, s, H4); 3.919 (3H, s, H1). 
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13C NMR (300 Mhz, CDCl3 as solvent, in ppm): δ 166.33 (C2, C15); 164.32 (C2, C15); 146.68 (Ar-
C); 135.05 (C14); 132.95 (C); 131.94 (C4, C5); 130.64 (Ar-C); 129.68 (Ar-C); 129.63 (C4, C5); 
126.77 (Ar-C); 126.15 (C13); 125.85 (C11); 98.97 (C8); 89.29 (C7); 52.85 (C16); 52.35 (C1). 
 
MS (EI) m/z (relative intensity): 339 (M+, 100%), 308 (67%), 293 (5%), 280 (11%), 262 (15%). 
 
HR-MS: Calculated value for C18H13NO6: 339.074287. Found: 339.074287 (- 0.4 ppm)   
 
                                       Synthesis of methyl 5-amino-2-iodobenzoate 
 
 
 
Procedure 1 
To a round bottomed flask, methyl 2-iodo-5-nitrobenzoate (0.5 g, 1.63 mmol, 1 eq.), Na2S2O4 (2.84 g, 
16.3 mmol, 10 eq. or 4.3 g, 24.5 mmol, 15 eq.), H2O (10 ml) and THF (5 ml) were added. The reaction 
mixture was stirred for 16 hours at r. t. under N2 – atm., diluted with EtOAc, filtered and concentrated in 
vacuo. Then it was taken up in EtOAc, washed with water and 1M HCl, dried with MgSO4, filtered and 
concentrated in vacuo. The crude product was purified by flash chromatography (EtOAc – hexane, 
EtOAc 10% → 40% over 20 min) to afford pure product as yellow oil. 
 
Yield:  0.174 g (39%) 
 
Procedure 2 
To a round bottomed flask, methyl 2-iodo-5-nitrobenzoate (1.09 g, 3.5 mmol, 1 eq.), NH4Cl (sat., aq., 3 
ml), H2O (3 ml) and THF (10 ml) were added at r.t. The mixture was stirred until all solid material was 
dissolved and then cooled to -5 oC. Zn dust (1.83 g, 8 eq.) was added in small portions at -5 oC. The 
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reaction mixture was then stirred for 2 hours at -5 oC, then was let to warm up to r.t. and was stirred for 
16 hours at r. t. under inert atmosphere, diluted with EtOAc, filtered and concentrated in vacuo in order 
to remove EtOAc and THF. Then it was taken up in EtOAc, washed with water and 1M HCl, dried with 
MgSO4, filtered and concentrated in vacuo. The crude product was purified by flash chromatography 
(EtOAc – hexane, EtOAc 10% → 40% over 20 min) to afford pure product as yellow oil. 
 
Yield: 0.866 g (90%) 
 
Synthesis of methyl 5-amino-2-((4-(methoxycarbonyl)phenyl)ethynyl)benzoate 
 
 
  
Procedure 1 
To a round bottomed flask, methyl 2-((4-(methoxycarbonyl)phenyl)ethynyl)-5-nitrobenzoate (0.166 g, 
0.491 mmol, 1 eq.), Na2S2O4 (0.854 g, 4.91 mmol, 10 eq. or 1.28 g, 7.37 mmol, 15 eq.), H20 (20 ml) and 
THF (10 ml) were added. The reaction mixture was stirred for 16 hours at r. t. under N2 – atm., diluted 
with EtOAc (30 ml), filtered and concentrated in vacuo. Then it was taken up in EtOAc (60 ml), washed 
with H2O (20 ml) and 1M HCl solution (20 ml), dried with MgSO4, filtered and concentrated in vacuo. 
The crude product was purified by flash chromatography (EtOAc – hexane, EtOAc 15% → 65% over 
30 min) to afford pure product as yellow solid. 
 
Yield: 0.062 g (41%)  
 
Procedure 2 
To a round bottomed flask, methyl 2-((4-(methoxycarbonyl)phenyl)ethynyl)-5-nitrobenzoate (0.179 g, 
0.530 mmol, 1 eq.), NH4Cl (sat., aq., 3 ml), H2O (3 ml) and THF (10 ml) were added at r.t. The mixture 
was stirred until all solid material was dissolved and then cooled to -5 oC. Zn dust (1.83 g, 8 eq.) was 
added in small portions at -5 oC. The reaction mixture was then stirred for 2 hours at -5 oC, then was let 
to warm up to r.t. and was stirred for 16 hours at r.t. under inert atmosphere. The crude reaction mixture 
was diluted with EtOAc, filtered and concentrated in vacuo. Then it was taken up in EtOAc, washed 
with water and 1M HCl, dried with MgSO4, filtered and concentrated in vacuo. The crude product was 
purified by flash chromatography (EtOAc – hexane, EtOAc 15% → 65% over 30 min) to afford pure 
product as yellow solid. 
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Yield: 0.150 g (92%) 
 
Rf (50 % EtOAc - hexane) = 0.29 
 
 
 
1H NMR (300 Mhz, CDCl3 as solvent, in ppm): δ 8.000 – 7.972 (2H, d, J = 8.4 Hz, H2); 7.574 – 
7.546 (2H, d, J = 8.4 Hz, H3); 7.439 – 7.411 (1H, d, J = 8.4 Hz, H7); 7.249 – 7.240 (1H, d, J = 2.7 Hz, 
H5); 6.781 – 6.744 (1H, dd, J = 8.4Hz, J = 2.7 Hz, H6); 3.988 (2H, br. s, H8); 3.931, 3.905 (6H, s, H1, 
H4).  
 
 
 
13C NMR (300 Mhz, CDCl3 as solvent, in ppm): δ 166.66 (C15, C2); 146.76 (C12); 135.47 (C14); 
133.18 (Ar-C); 131.25 (C5); 129.44 (C4); 128.97 (Ar-C); 128.77 (Ar-C); 117.87 (C13); 116.29 (C11); 
112.14 (Ar-C); 92.12 (C8); 90.84 (C7); 52.17 (Ar-C); 52.14 (C1, C16). 
 
MS (EI) m/z (relative intensity): 309 (M+, 100%), 278 (18%), 251 (6%), 235 (21.07%), 193 (7.33%). 
 
HR-MS: Calculated value for C18H15NO4: 309.10011. Found: 309.10018 (+ 2.3 ppm). 
 
Synthesis of 5-amino-2-((4-carboxyphenyl)ethynyl)benzoic acid 
 
 
 
To a round bottomed flask, methyl 5-amino-2-((4-(methoxycarbonyl)phenyl)ethynyl)benzoate (0.22 g, 
0.72 mmol, 1 eq), THF and H2O (4 ml, 1:1, v:v) were added. The reaction flask was equipped with 
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septum and degassed with argon. Then an aqueous solution of LiOH (0.051 g, 2.16 mmol, 3 eq., 2M) 
was added to the reaction flask with a syringe. The reaction mixture was stirred under argon atmosphere 
over the night at r.t. and then acidified to pH 2 with conc. HCl. The desired product precipitated after 
addition of the HCl. The crude product was filtered off. 1H NMR showed that the crude product was ca 
90% pure. The desired product was isolated in ca 85% yield.      
 
 
 
1H NMR (300 Mhz, DMSO-d6 as solvent, in ppm): δ 7.947 – 7.919 (2H, d, J = 8.4 Hz, H1, H2); 
7.553 – 7.525 (2H, d, J = 8.4 Hz, H1, H2); 7.445 – 7.417 (1H, d, J = 8.4 Hz, H3); 7.291 – 7.284 (1H, d, 
J = 2.1 Hz, H5); 6.948 – 6.912 (1H, d, J = 8.4 Hz, J = 2.1 Hz, H4).  
 
Attempted synthesis of (Z)-methyl 5-amino-2-(4-(methoxycarbonyl)styryl)benzoate 
 
 
 
Procedure 1. Using the Pd(OAc)2/KOH/DMF–system 
For the amount of different reagents, reaction temperatures etc., please see section 10.4.9, table 8. 
To a round bottomed flask, methyl 5-amino-2-((4-(methoxycarbonyl)phenyl)ethynyl)benzoate (1 eq), 
Pd(OAc)2 (2 - 6 mol%), KOH (1.5 eq) and degassed DMF (1,3,1 or 1 ml pr. 0.5 mmol substrate) were 
added. The reaction flask was equipped with a condenser and flushed with argon for 20 min. The 
reaction mixture was stirred for 6 h. at 145 oC or 12 h. at 100 oC under Ar. atm., cooled to r.t. The crude 
reaction mixture was washed with EtOAc and filtered.  The organic layer was washed with H2O (5 
times) and brine (3 times), dried with MgSO4 and concentrated in vacuo. The crude product was 
purified twice by flash chromatography (EtOAc – hexane, EtOAc 25 – 55% over 45 min) affording the 
desired product in ca 25% yield, ca 65% pure based on NMR analysis.   
 
Procedure 2. Using the Pd(OAc)2/PPh3/NaOMe/THF–system 
For the amount of different reagents, reaction temperatures etc., please see section 10.4.10, table 9. 
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To a round bottomed flask, methyl 5-amino-2-((4-(methoxycarbonyl)phenyl)ethynyl)benzoate (1 eq.), 
Pd(OAc)2 (5 or 10 mol%), PPh3 (5 or 10 mol%) and NaOMe (5 or 10 eq.) were added. The reaction 
flask was equipped with septum and flushed with argon for 15 min. Then dry and degassed THF was 
added with a syringe and the reaction mixture was stirred under Ar. atm. at r.t. for 12 or 48 h. or at 45 oC 
for 12 h.. The crude reaction mixture was taken up in EtOAc, filtered, washed with H2O and brine, dried 
with MgSO4 and concentrated in vacuo giving the crude product. The crude product was purified by 
flash chromatography (EtOAc – hexane, EtOAc 25 – 55% over 45 min) affording only the starting 
material in ca 85 – 90 % yield.   
 
Procedure 3. Using the hydroboration/protonolysis approach 
For the amount of different reagents, reaction temperatures etc., please see section 10.4.12, table 10. 
To a round bottomed flask, cyclohexene (4, 8, 20, 30 or 40 eq.) and THF was added. The flask was 
equipped with septum, degassed with argon and cooled down to -20 oC. Then degassed solution of 
BH3•THF complex (2, 4, 10, 15 or 20 eq.) was added slowly with a syringe. The mixture was stirred at -
20 oC for 10 min, then was allowed to warm slowly to -5 oC. Then it was stirred for 1 h. at -5 oC, during 
that time white solid was formed. Then the mixture was cooled to -10 oC. Pre-cooled solution (0 oC) of 
methyl 5-amino-2-((4-(methoxycarbonyl)phenyl)ethynyl)benzoate (1 eq.) in THF was added to the 
solution of dicyclohexylborane at -10 oC, stirred for 10 min., then warmed to -5 oC and stirred for 1-2 
hours under Ar. atm.. Then anhydrous AcOH (12, 24, 60, 80 or 120 eq.) was added slowly with a 
syringe at -5 oC and the reaction mixture was stirred at -5 oC for 0.5-3 h. The crude reaction mixture was 
taken up in EtOAc, filtered, washed with H2O and brine, dried with MgSO4 and concentrated in vacuo 
giving the crude product. The crude product was purified by flash chromatography (EtOAc – hexane, 
EtOAc 25 – 55% over 45 min) affording only the starting material in ca 90 – 95 % yield. 
 
Synthesis of (E)-methyl 2-(2-(4-(methoxycarbonyl)phenyl)-2-(triethylsilyl)vinyl)-5-
nitrobenzoate 
 
 
 
For the amount of different reagents, reaction temperatures etc., please see section 10.4.13, table 11. 
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To a around bottomed flask, methyl 2-((4-(methoxycarbonyl)phenyl)ethynyl)-5-nitrobenzoate (1eq.) and 
PtO2 • H2O (5 – 20 mol%) were added. The flask was equipped with septum and degassed with argon. 
Then, dry and degassed THF was added with a syringe. The reaction mixture was stirred under r.t. for 
15 min. and then degassed Et3SiH (1.5 – 10 eq.) was added with a syringe. Inert gas inlet/outlet was 
removed and the mixture was stirred at 55 – 70 oC for 2 – 3.5 h. After this, the reaction mixture was 
cooled down to r.t., taken up in small volume of EtOAc and filtered. The filtrated mixture was 
concentrated in vacuo. The crude product was purified by flash chromatography (EtOAc – hexane, 
EtOAc 10 – 35% over 55 min) sometimes affording the desired product as yellow oil in up to 80 % 
yield. 
 
 
 
1H NMR (300 Mhz, CDCl3 as solvent, in ppm): δ 8.746 – 8.738 (1H, d, J = 2.4 Hz, H9); 8.216 – 
8.179 (1H, dd, J = 8.4 Hz, J = 2.4 Hz, H8); 7.751 – 7.723 (2H, d, J = 5.6 Hz, H2); 7.092 – 7.064 (1H, d, 
J = 8.4 Hz, H7); 6.919 – 6.891 (2H, J = 8.4 Hz, H3); 6.867 (1H, s, H4), 3.808 (3H, s, H1, H10); 3.783 
(3H, s, H1, H10); H5 and H6 are buried somewhere between 1.246 – 0.546 ppm.    
 
       Attempted synthesis of (Z)-methyl 2-(4-(methoxycarbonyl)styryl)-5-nitrobenzoate 
from (E)-methyl 2-(2-(4-(methoxycarbonyl)phenyl)-2-(triethylsilyl)vinyl)-5-nitrobenzoate 
 
 
        
For the amount of different reagents, reaction temperatures etc., please see section 10.4.13, table 12. 
To a round bottomed flask, (E)-methyl 2-(2-(4-(methoxycarbonyl)phenyl)-2-(triethylsilyl)vinyl)-5-
nitrobenzoate, TBAF (1.1 – 3.2 eq.) and CuI (0 – 1.5 eq.) were added. The reaction flask was equipped 
with septum and degassed. Then dry and degassed THF was added with a syringe. The reaction mixture 
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was stirred at the particular temperatures for a particular amount of time (scheme X). Then the crude 
reaction mixture was taken up in small volume of EtOAc and filtered. The filtrated mixture was 
concentrated in vacuo. The crude product was purified by flash chromatography (EtOAc – hexane, 
EtOAc 10 – 35% over 35 min).  
 
Synthesis of (Z)-methyl 5-amino-2-(4-(methoxycarbonyl)styryl)benzoate by reduction 
with Lindlar catalyst 
 
 
 
For the amount of different reagents, reaction temperatures etc., please see section 10.4.14, table 13. 
To a around bottomed flask, methyl 2-((4-(methoxycarbonyl)phenyl)ethynyl)-5-nitrobenzoate (1eq.), 
Lindlar catalyst (5mol%), quinoline (5 – 30 mol%) and THF were added. The reaction flask was sealed 
with a septum and hydrogen gas was introduced into the reaction flask from a balloon via hypodermic 
needle that was stuck through septum. The reaction flask was flooded with hydrogen. Hydrogen gas was 
also bubbled through the solvent - after that the gas inlet was removed and the flask was sealed with 
plastic tape. The reaction mixture was stirred for 16 h. Then the crude reaction mixture was taken up in 
small volume of EtOAc and filtered. The filtrated mixture was concentrated in vacuo. The crude product 
was purified by flash chromatography (EtOAc – hexane, EtOAc 20 – 55% over 35 min). The desired 
product was once isolated as the only product of the reaction in 96 % yield. The desired product is 
yellow oil.   
 
Rf (50 % EtOAc - hexane) = 0.25 
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1H NMR (400 Mhz, CDCl3 as solvent, in ppm): δ 7.801 – 7.780 (2H, d, J = 8.4 Hz, H2, H3); 7.292 – 
7.286 (1H, d, J = 2.4 Hz, H8); 7.158 – 7.137 (2H, d, J = 8.4 Hz, H2, H3); 7.073 – 7.043 (1H, d, J = 12 
Hz, H4, H5); 6.928 – 6.907 (1H, d, J = 8.4 Hz, H6); 6.589 – 6.562 (1H, dd, J = 2.4 Hz, H7); 6.543 – 
6.513 (1H, dd, J = 12 Hz, H4, H5); 3.851 (6H, s, H1, H9). 
  
 
 
13C NMR (400 Mhz, CDCl3 as solvent, in ppm): δ 167.44 (C2, C15); 166.96 (C2, C15); 145.74 (Ar-
C); 142.19 (Ar-C); 132.78 (C7, C8); 132.09 (C10); 129.99 (Ar-C); 129.29 (C4, C5); 129.07 (C4, C5); 
128.82 (Ar-C); 128.02 (Ar-C); 127.33 (C7, C8); 118.67 (C11); 116.48 (C13); 52.00 (C1, C16); 51.95 
(C1, C16).  
 
MS (EI) m/z (relative intensity): 311 (M+, 100%), 280 (15.9%), 251 (10.60%), 220 (6%), 164 (35.03%). 
 
HR-MS: Calculated value for C18H17NO4: 311.11576. Found: 311.115758 (- 2.2 ppm). 
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Attachment 1 
 
NMR data 
 
AB 81 - (E)-8-hydroxy-7-((6-sulfonaphthalen-2-yl)diazenyl)quinoline-5-sulfonic acid 
 
1H NMR 
 
Expansion of the aromatic region 
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1H NMR spectrum after freeze drying (no dioxane used during the purification) 
 
Expansion of the aromatic region 
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C13CPD 
 
C13 DEPT90 
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COSY45SW, expansion of the aromatic region 
 
HMQC (1H – 13C), expansion of the aromatic region 
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AB 75 - (E)-8-hydroxy-7-((5-sulfonaphthalen-2-yl)diazenyl)quinoline-5-sulfonic acid 
 
1H NMR, expansion of the aromatic region 
 
1H NMR spectrum after freeze drying (no dioxane used during the purification) 
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C13CPD 
 
C13 DEPT90 
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COSY45SW, expansion of the aromatic region 
 
AB 76 - (E)-8-hydroxy-7-((6-sulfonaphthalen-1-yl)diazenyl)quinoline-5-sulfonic acid 
 
1H NMR, expansion of the aromatic region 
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1H NMR spectrum after freeze drying (no dioxane used during the purification) 
 
Expansion of the aromatic region 
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C13CPD 
 
COSY45SW, expansion of the aromatic region 
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HMQC (1H – 13C), expansion of the aromatic region 
 
AB 77 - (E)-8-hydroxy-7-((5-sulfonaphthalen-1-yl)diazenyl)quinoline-5-sulfonic acid 
 
1H NMR, expansion of the aromatic region 
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1H NMR spectrum after freeze drying (no dioxane used during the purification) 
 
C13CPD 
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COSY45SW, expansion of the aromatic region 
 
 
HMQC (1H – 13C), expansion of the aromatic region 
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AB 78 - (E)-8-hydroxy-7-((4-sulfonaphthalen-1-yl)diazenyl)quinoline-5-sulfonic acid 
 
1H NMR, expansion of the aromatic region 
 
1H NMR spectrum after freeze drying (no dioxane used during the purification) 
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C13CPD 
 
C13 DEPT90 
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COSY45SW, expansion of the aromatic region 
 
HMQC (1H – 13C), expansion of the aromatic region 
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AB 74 - (E)-8-hydroxy-7-((7-sulfonaphthalen-1-yl)diazenyl)quinoline-5-sulfonic acid 
 
1H NMR 
 
Expansion of the aromatic region 
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1H NMR spectrum after freeze drying (no dioxane used in purific.), expansion of the aromatic region 
 
C13CPD 
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C13 DEPT90 
 
COSY45SW, expansion of the aromatic region 
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HMQC (1H – 13C), expansion of the aromatic region 
 
Methyl 4-((trimethylsilyl)ethynyl)benzoate 
 
1H NMR 
 
	  	  129	  
C13CPD 
 
Methyl 4-ethynylbenzoate 
1H NMR 
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C13CPD 
 
HMQC (1H – 13C) 
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Methyl 2-iodo-5-nitrobenzoate 
 
1H NMR 
 
C13CPD 
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COSY45SW 
 
HMQC (1H – 13C) 
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Methyl 2-((4-(methoxycarbonyl)phenyl)ethynyl)-5-nitrobenzoate 
 
1H NMR 
 
C13CPD 
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C13 DEPT135 
 
HMQC (1H – 13C), expansion of the aromatic region 
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Methyl 5-amino-2-((4-(methoxycarbonyl)phenyl)ethynyl)benzoate 
 
1H NMR 
 
C13CPD 
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C13 DEPT135 
 
COSY45SW, expansion of the aromatic region 
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HMQC (1H – 13C), expansion of the aromatic region 
 
5-Amino-2-((4-carboxyphenyl)ethynyl)benzoic acid 
 
1H NMR 
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Expansion of the aromatic region 
 
(E)-Methyl 2-(2-(4-(methoxycarbonyl)phenyl)-2-(triethylsilyl)vinyl)-5-nitrobenzoate 
 
1H NMR 
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Expansion of the aromatic region 
 
(Z)-Methyl 5-amino-2-(4-(methoxycarbonyl)styryl)benzoate 
 
1H NMR 
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Expansion of the aromatic region 
 
C13CPD 
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C13 DEPT135 
 
COSY45SW, expansion of the aromatic region 
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HMQC (1H – 13C), expansion of the aromatic region 
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Attachment 2 
 
Miscellaneous NMR spectra 
 
Spectrum 1 
 
Spectrum 2, expansion of the aromatic region from spectrum 1 
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Spectrum 3 
 
Spectrum 4, expansion of the aromatic region from spectrum 3 
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Spectrum 5 
 
Spectrum 6, expansion of the aromatic region from spectrum 5 
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Spectrum 7 
 
Spectrum 8 
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Spectrum 9, expansion of the aromatic region from spectrum 8 
 
Spectrum 10 
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Spectrum 11 
 
Spectrum 12 
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Spectrum 13, expansion of the aromatic region from spectrum 12 
 
Spectrum 14 
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Spectrum 15, expansion of the aromatic region from spectrum 14 
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Attachment 3 
 
Complete docking tables 
 
Table 11. Results from the docking of compounds AB74 – AB 81-5 against the R2 region 
in the DBD of c-Myb 
 
Compound Chemical structure logP 
Residues 
involv. in 
H bonds 
Fr. en. of 
bind. 
(kcal/mol) 
Ki MW 
No. of H-
bond 
accept. 
No. of H-
bond 
donors 
NSC87877 
/ AB 81 
 
- 0.807 
Lys128 
Gln129 
Arg133 
- 9.91 53.99 nM 459 10 3 
AB 81-1 
 
1.97 
Lys128 
Asn136 
- 8.45 645.09 nM 379 7 2 
AB 81-2 
 
-0.516 
Lys128 
Arg133 
- 9.25 165.66 nM 443 9 2 
AB 81-3 
 
2.225 Gly93 - 8.47 620.97 nM 379 7 2 
AB 81-4 
 
- 0.62 
Lys128 
Gln129 
Arg133 
- 9.99 47.68 nM 457 8 3 
AB 81-5 
 
0.093 
Lys128 
Arg133 
Gln129 
- 9.68 79.66 nM 458 9 3 
AB 74 
 
- 0.831 
Ser116 
Lys128 
Arg131 
- 10.94 9.5 nM 459 10 3 
AB 74-1 
 
1.946 
Lys128 
Arg131 
- 8.91 296.19 nM 379 7 2 
N
SO3H
OH
N
N
SO3H
N
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N
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N
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N
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AB 74-2 
 
- 0.54 
Ser116 
Lys128 
Arg131 
- 10.27 29.84 nM 443 9 2 
AB 74-3 
 
2.201 
Ser116 
Arg131 
- 8.47 622.47 nM 379 7 2 
AB 74-4 
 
- 0.824 
Ser116 
Arg131 
- 10.6 17 nM 457 8 3 
AB 74-5 
 
0.069 
Ser116 
Arg131 
- 10.85 11.12 nM 458 9 3 
AB 75 
 
- 0.831 
Lys128 
Arg133 
Asn136 
- 9.08 221.08 nM 459 10 3 
AB 75-1 
 
1.946 Lys128 - 8.97 266.27 nM 379 7 2 
AB 75-2 
 
- 0.54 
Lys128 
Lys171 
- 8.68 436.7 nM 443 9 2 
AB 75-3 
 
2.225 
Lys128 
Gln129 
- 8.6 497.86 nM 379 7 2 
AB 75-4 
 
- 0.644 
Lys128 
Arg133 
Asn136 
- 9.31 151.1 nM 457 8 3 
AB 75-5 
 
0.069 
Lys128 
Arg133 
- 9.18 187.14 nM 458 9 3 
AB 76 
 
- 0.831 
Ser116 
Lys128 
- 9.32 148.38 nM 459 10 3 
N
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N
N
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AB 76-1 
 
1.946 
Lys128 
Arg131 
- 8.38 715.6 nM 379 7 2 
AB 76-2 
 
- 0.54 
Ser116 
Lys128 
- 9.78 68.02 nM 443 9 2 
AB 76-3 
 
2.201 
Ser116 
Arg131 
- 8.31 805.19 nM 379 7 2 
AB 76-4 
 
- 0.824 
Ser116 
Lys128 
- 10.03 44.45 nM 457 8 3 
AB 76-5 
 
0.069 
Ser116 
Lys128 
Arg131 
- 10.03 44.38 nM 458 9 3 
AB 77 
 
- 0.855 
Glu132 
Lys128 
Arg133 
- 9.9 55.67 nM 459 10 3 
AB 77-1 
 
1.922 
Asn136 
Lys128 
- 7.74 2.14 µM 379 7 2 
AB 77-2 
 
- 0.564 
Lys128 
Arg133 
- 8.68 437.63 nM 443 9 2 
AB 77-3 
 
2.201 
Ser116 
Lys113 
- 8.12 1.11 µM 379 7 2 
AB 77-4 
 
- 0.848 
Ser116 
Arg131 
- 8.96 268.58 nM 457 8 3 
AB 77-5 
 
0.045 
Lys128 
Arg133 
- 9.95 50.75 nM 458 9 3 
AB 78 
 
- 0.855 
Lys128 
Gln129 
Arg133 
- 9.97 48.92 nM 459 10 3 
N
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AB 78-1 
 
1.922 Lys128 - 8.15 1.07 µM 379 7 2 
AB 78-2 
 
- 0.564 
Lys128 
Arg133 
- 9.12 204.84 nM 443 9 2 
AB 78-3 
 
2.201 
Ser116 
Arg131 
- 8.29 835.69 nM 379 7 2 
AB 78-4 
 
- 0.848 
Lys128 
Gln129 
Arg133 
- 10.05 43.27 nM 457 8 3 
AB 78-5 
 
0.045 
Lys128 
Arg133 
Gln129 
-10.04 43.45 nM 458 9 3 
  
Table 12. Results from the docking of compounds AB74 – AB81-5 against the R3 region in 
the DBD of c-Myb 
 
Compound Chemical structure logP 
Residues 
involv. in 
H bonds 
Fr. en. of 
bind. 
(kcal/mol) 
Ki MW 
No. of H-
bond 
accept. 
No. of H-
bond 
donors 
NSC87877 
/ AB 81 
 
- 0.807 
Asn179 
Thr188 
Asn183 
- 6.63 13.73 µM 459 10 3 
AB 81-1 
 
1.97 
Asn183 
His184 
- 7.75 2.08 µM 379 7 2 
AB 81-2 
 
-0.516 
Thr188 
Asn179 
Asn183 
- 6.74 11.56 µM 443 9 2 
AB 81-3 
 
2.225 
Trp147 
Asn183 
- 6.83 9.87 µM 379 7 2 
N
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AB 81-4 
 
- 0.62 Thr188 -6.9 8.69 µM 457 8 3 
AB 81-5 
 
0.093 
Asn179 
Thr188 
Asn183 
- 6.61 14.27 µM 458 9 3 
AB 74 
 
- 0.831 
Ser187 
Asn183 
Ala180 
-7.23 5 µM 459 10 3 
AB 74-1 
 
1.946 
Asn186 
Ser187 
Asn183 
- 7.06 6.73 µM 379 7 2 
AB 74-2 
 
- 0.54 
His184 
Asn186 
Asn183 
- 7.09 6.36 µM 443 9 2 
AB 74-3 
 
2.201 NO BONDS - 6.76 11.09 µM 379 7 2 
AB 74-4 
 
- 0.824 
Asn183 
Arg190 
Asn186 
- 7.11 6.09 µM 457 8 3 
AB 74-5 
 
0.069 
Asn183 
Ala180 
Asn186 
Ser187 
- 7.04 6.86 µM 458 9 3 
AB 75 
 
- 0.831 
Trp147 
Arg190 
Ala180 
- 6.49 17.35 µM 459 10 3 
AB 75-1 
 
1.946 
Thr188 
His184 
Asn183 
- 7.9 1.61 µM 379 7 2 
AB 75-2 
 
- 0.54 
Arg190 
Ser187 
His184 
- 6.29 24.68 µM 443 9 2 
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AB 75-3 
 
2.225 
Trp147 
Ser187 
- 6.47 18.21 µM 379 7 2 
AB 75-4 
 
- 0.644 
Trp147 
Arg190 
Ala180 
- 6.63 13.77 µM 457 8 3 
AB 75-5 
 
0.069 
Trp147 
Arg190 
- 6.79 10.47 µM 458 9 3 
AB 76 
 
- 0.831 
Arg190 
His184 
- 7.5 3.19 µM 459 10 3 
AB 76-1 
 
1.946 
Ser187 
His184 
Asn183 
- 7.71 2.23 µM 379 7 2 
AB 76-2 
 
- 0.54 
Thr145 
His184 
Arg190 
Ser187 
Trp147 
- 7.12 6.03 µM 443 9 2 
AB 76-3 
 
2.201 
Trp147 
His184 
- 7.11 6.12 µM 379 7 2 
AB 76-4 
 
- 0.824 
His184 
Arg190 
- 7.6 7.71 µM 457 8 3 
AB 76-5 
 
0.069 
His184 
Arg190 
Trp147 
- 7.65 2.47 µM 458 9 3 
AB 77 
 
- 0.855 
Trp147 
Arg190 
His184 
- 7.85 1.77 µM 459 10 3 
AB 77-1 
 
1.922 
His184 
Ser187 
- 7.19 5.14 µM 379 7 2 
N
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Asn183 
Thr177 
AB 77-2 
 
- 0.564 
Ser187 
Arg190 
His184 
Trp147 
- 6.88 9 µM 443 9 2 
AB 77-3 
 
2.201 Asn183 - 6.87 9.2 µM 379 7 2 
AB 77-4 
 
- 0.848 
Trp147 
Asn183 
- 6.87 9.17 µM 457 8 3 
AB 77-5 
 
0.045 
Arg190 
Trp147 
His184 
- 7.84 1.8 µM 458 9 3 
AB 78 
 
- 0.855 
Arg190 
Trp147 
- 6.81 10.24 µM 459 10 3 
AB 78-1 
 
1.922 
Asn183 
Ser187 
- 7.64 2.52 µM 379 7 2 
AB 78-2 
 
- 0.564 
Thr188 
Asn179 
His184 
- 7.71 2.21 µM 443 9 2 
AB 78-3 
 
2.201 
Asn183 
His184 
Trp147 
- 7.21 7.35 µM 379 7 2 
AB 78-4 
 
- 0.848 
Arg190 
Ala180 
Trp147 
- 7.03 6.99 µM 457 8 3 
AB 78-5 
 
0.045 
Arg190 
Trp147 
Ala180 
- 6.93 8.36 µM 458 9 3 
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Table 13. Results from the docking of compounds ABAD1 – ABAD68 against the R2 
region in the DBD of c-Myb 
 
 
Compound Chemical structure logP 
Residues 
involv. in 
H bonds 
Fr. en. of 
bind. 
(kcal/mol) 
Ki MW 
No. of 
H-
bond 
accept. 
No. of 
H-
bond 
donors 
ABAD 1 
 
3.292 Trp115 - 10.83 11.43 nM 564 12 4 
ABAD2 
 
2.393 No bonds - 11.79 2.26 nM 565 13 4 
ABAD3 
 
2.165 
Lys128 
Arg131 
-8.17 1.03 µM 659 11 4 
ABAD4 
 
2.14 
Ser116 
Lys128 
His135 
- 10.22 32.19 nM 577 11 4 
ABAD5 
 
1.93 Gln129 - 7.98 1.41 µM 687 13 6 
ABAD6 
 
1.957 Glu132 - 8.07 1.22 µM 623 13 4 
ABAD7 
 
1.564 Glu132 - 5.58 81.62 µM 653 15 8 
N
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ABAD8 
 
3.958 
Arg125 
Lys128 
- 8.1 1.15 µM 759 13 4 
ABAD9 
 
1.245 
Lys128 
Gln129 
Lys171 
- 8.01 1.35 µM 655 15 6 
ABAD10 
 
1.675 
Glu132 
Ser116 
- 11.2 6.17 nM 625 15 4 
ABAD11 
 
3.012 Trp95 - 9.07 226.45 nM 623 13 4 
ABAD12 
 
1.488 No hydr bonds - 10.78 12.52 nM 627 17 4 
ABAD13 
 
3.216 
Lys113 
Glu132 
- 7.41 3.67 µM 497 9 3 
ABAD14 
 
1.983 
Ser116 
Arg131 
- 8.67 438.4 nM 599 15 4 
ABAD15 
 
2.282 
Glu132 
Lys128 
- 7.02 7.16 µM 593 13 8 
ABAD16 
 
1.606 
Lys128 
Arg131 
- 9.17 190.88 nM 539 13 4 
ABAD18 
 
1.403 Lys128 - 10.35 26.06 nM 723 12 4 
R2
OO HN
NNNH
N N CF3
F3C
R2
O
O
HN
NHNNH
HN N
O
O
R2
O
O R1R1
R2
O
O
HN N
NNHN
N
R2 N
N
R1
R1
R2
R1
R2
N
N
N
H
O
NN
O NH
O
O
R2
H
N
N N
N
H
NN
NH2
H2N
R2
R1
R1
R2
O
HN S
O
O
O
NHS
O
O
	  	  160	  
ABAD19 
 
- 
Glu132 
Pro174 
Trp115 
- 3.8 1.63 mM - -- - 
ABAD20 
 
4.355 
Glu132 
Arg131 
Ser116 
- 8.25 903.44 nM 599 14 5 
ABAD21 
 
4.712 
Glu132 
Ser116 
- 10.84 11.32 nM 618 13 3 
ABAD23 
 
1.685 No bonds - 9.61 89.95 nM 516 12 4 
ABAD24 
 
1.433 
Lys128 
His135 
Ser116 
- 9.55 100.22 nM 528 10 4 
ABAD25 
 
0.967 
Ser116 
Lys128 
His135 
Trp115 
- 8.83 335 nM 576 14 4 
ABAD26 
 
0.787 
Gly127 
Lys128 
Glu132 
His135 
Trp115 
- 7.17 5.58 µM 688 12 4 
ABAD27 
 
4.518 
Gly127 
Lys128 
- 9.51 107 nM 555 12 3 
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ABAD28 
 
5.234 Arg131 - 10.24 31.34 nM 631 13 4 
ABAD29 
 
2.178 
Ser116 
His135 
Lys128 
Arg131 
- 8.92 290 nM 623 13 4 
ABAD30 
 
2.365 
Glu132 
His135 
- 8.61 491 nM 621 11 4 
ABAD31 
 
8.647 
Lys113 
Asn136 
 
 
- 8.7 420 nM 725 13 4 
ABAD32 
 
8.741 
Arg 131 
 
 
- 9.87 58.17 nM 723 11 4 
ABAD33 
 
1.817 
Lys128 
Arg133 
-8.89 306 nM 445 9 3 
ABAD34 
 
 
1.458 
Asn136 
Arg133 
Ala167 
Lys128 
- 9.3 151.4 nM 475 10 3 
ABAD35 
 
3.807 
Lys128 
Asn136 
 
- 7.66 2.43 µM 525 7 2 
ABAD36 
 
3.167 
Arg133 
Asn136 
- 7.91 1.6 µM 493 7 2 
ABAD37 
 
7.367 
Asn136 
Arg131 
 
- 8.76 379.6 nM 548 10 2 
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ABAD38 
 
4.363 No bonds - 8.49 602.21 nM 524.57 12 4 
ABAD39 
 
3.848 
Lys128 
Arg131 
Trp115 
- 10.38 24.57 nM 522 12 3 
ABAD40 
 
3.453 No bonds - 6.57 15.25 µM 629 11 4 
ABAD41 
 
1.412 No bonds - 6.29 24.2 µM 568 14 4 
ABAD42 
 
- 1.842 
Arg 133 
Asn 136 
- 8.83 338.03 nM 419 14 9 
ABAD43 
 
2.369 
Trp115 
 
- 9.13 202.59 nM 565 13 4 
ABAD44 
 
2.369 
Gln129 
Lys128 
- 10.87 10.82 nM 565 13 4 
ABAD45 
 
2.369 
Gln129 
Arg133 
- 9.84 61.63 nM 565 13 4 
ABAD46 
 
2.393 
Ser116 
 
- 10.35 25.7 nM 565 13 4 
ABAD47 
 
2.393 
Ser116 
Gly127 
- 10.09 40.51 nM 565 13 4 
ABAD48 
 
1.419 
Ser116 
Arg131 
Lys128 
-10.01 45.79 nM 563 13 4 
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ABAD49 
 
0.468 
Lys128 
Arg131 
Ser116 
- 6.68 12.59  µM 561 13 4 
ABAD50 
 
4.05 
Ser116 
 
- 8.5 301.42 nM 544 13 5 
ABAD51 
 
3.867 
Ser116 
 
-10.41 23.31 nM 564 13 5 
ABAD52 
 
4.476 
Trp115 
Ser116 
- 8.52 573.08 nM 559 13 4 
ABAD53 
 
4.484 Ser116 - 10.47 21.29 nM 618 13 3 
ABAD54 
 
3.33 Arg133 - 12.87 367.91 pM 538 13 4 
ABAD55 
 
3.988 Lys128 - 10.04 43.46 nM 565 13 5 
ABAD56 
 
4.139 Trp115 - 8.58 511.22 nM 553 13 4 
ABAD57 
 
3.33 No bonds - 9.7 77.94 nM 538 13 4 
ABAD58 
 
4.95 
Ser 116 
Lys 113 
Glu 132 
- 9.25 167.2 nM 501 11 4 
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ABAD59 
 
3.63 
Gln 129 
Glu132 
- 10.94 9.6 nM 538 13 4 
ABAD60 
 
4.29 Ser 116 - 7.79 1.95 µM 555 12 5 
ABAD61 
 
-1.67 
Trp 95 
Arg125 
Arg133 
- 7.4 3.77 µM 482 16 4 
ABAD62 
 
-0.21 
Trp115 
His135 
-4.84 282.95 µM 379 12 4 
ABAD63 
 
3.94 
Glu132 
Ser116 
Arg131 
-10.27 29.69 nM 519 13 5 
ABAD64 
 
3.21 
Gly93 
Trp95 
Lys171 
-9.57 96.35 nM 498 14 4 
ABAD65 
 
2.88 
Ser116 
Gly127 
-10.31 27.87 nM 531 15 5 
ABAD67 
 
3.27 Ser116 -8.12 1.12 µM 516 13 5 
ABAD68 
 
2.24 
Ser116 
Arg131 
-8.16 1.05 µM 595 16 2 
 
 
N
OH
S
H
N
R1
R1
O O
N
H
F
PO
OH
OH
R1
R1
N
H NH
S
F
PO
OH
OH
O O
N
N
N
N
O
N
N
N
N
N
H
N
F
PO
OH
OH
N
H
N
N
N
N
N
N
OHO
O
R1
R1
OH
N
H
OHO
O O
R1
R1
OH
O
NH2O
O
R1
R1
R1
OH
P
O
O
R1
R1
OH
OH
O
R1
R1
N
N
N N
N
S
O
O
	  	  165	  
Table 14. Results from the docking of compounds ABAD1 – ABAD 68 against the R3 
region in the DBD of c-Myb 
 
 
Compound Chemical structure logP 
Residues 
involv. in 
H bonds 
Fr. en. of 
bind. 
(kcal/mol) 
Ki MW 
No. of 
H-
bond 
accept. 
No. of 
H-
bond 
donors 
ABAD 1 
 
3.292 
Arg190 
Asn183 
Asn186 
- 10.16 35.98 nM 564 12 4 
ABAD2 
 
2.393 
Asn186 
Arg190 
Thr177 
Ala180 
- 10.54 18.64 nM 565 13 4 
ABAD3 
 
2.165 Ala180 - 7.76 2.05 µM 659 11 4 
ABAD4 
 
2.14 
Arg190 
Arg191 
Ser187 
- 7.53 3 µM 577 11 4 
ABAD5 
 
1.93 
Asn183 
Trp147 
Arg190 
- 8.21 952.32 nM 687 13 6 
ABAD6 
 
1.957 
Asn186 
Arg190 
Thr177 
Thr188 
- 6.14 31.65 µM 623 13 4 
ABAD7 
 
1.564 
Asn139 
Pro140 
Asn183 
Ser187 
- 5.21 150.7 µM 653 15 8 
N
NHN
N=R1 =R2
N
OH
SO3H
OH
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N
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O
HN
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N N
H2N
NH2
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ABAD8 
 
3.958 
Asn186 
 
 
- 6.54 15.99 µM 759 13 4 
ABAD9 
 
1.245 
Ser187 
Arg191 
Asn183 
Trp147 
- 6.79 10.46 µM 655 15 6 
ABAD10 
 
1.675 
Arg190 
Trp147 
- 10.26 30.21 nM 625 15 4 
ABAD11 
 
3.012 
Asn179 
Asn183 
Lys182 
Trp147 
Asn183 
- 5.36 118 µM 623 13 4 
ABAD12 
 
1.488 
Ala180 
Asn186 
Asn183 
Arg190 
-10.56 18.06 nM 627 17 4 
ABAD13 
 
3.216 
His184 
Thr188 
Arg190 
- 6.38 21.21 µM 497 9 3 
ABAD14 
 
1.983 
Asn183 
His184 
- 8.33 786.81 nM 599 15 4 
ABAD15 
 
2.282 
Ala180 
Arg190 
- 6.35 22.34 µM 593 13 8 
ABAD16 
 
1.606 
His137 
Asn183 
- 6.97 7.76 µM 539 13 4 
R2
OO HN
NNNH
N N CF3
F3C
R2
O
O
HN
NHNNH
HN N
O
O
R2
O
O R1R1
R2
O
O
HN N
NNHN
N
R2 N
N
R1
R1
R2
R1
R2
N
N
N
H
O
NN
O NH
O
O
R2
H
N
N N
N
H
NN
NH2
H2N
R2
R1
R1
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ABAD18 
 
1.403 
His184 
Arg191 
Trp147 
- 7.41 3.68 µM 723 12 4 
ABAD19 
 
- 
Ser187 
Asn186 
- 4.1 992.9 µM - -- - 
ABAD20 
 
4.355 No bonds - 7.83 1.82 µM 599 14 5 
ABAD21 
 
4.712 His184 - 9.15 197.17 nM 618 13 3 
ABAD23 
 
1.685 
Thr188 
Asn186 
Arg190 
- 10.03 44.59 nM 516 12 4 
ABAD24 
 
1.433 
Ala180 
Trp147 
Lys182 
His184 
Arg190 
- 7.82 1.86 µM 528 10 4 
ABAD25 
 
0.967 
Arg190 
Asn183 
Ala180 
Ser187 
- 6.61 14.21 µM 576 14 4 
ABAD26 
 
0.787 
Arg190 
Asn183 
His184 
Ser187 
- 7.07 6.55 µM 688 12 4 
R2
O
HN S
O
O
O
NHS
O
O
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N
N
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N
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ABAD27 
 
4.518 
Asn186 
Thr188 
Arg190 
Asn183 
- 8.93 282.6 nM 555 12 3 
ABAD28 
 
5.234 
Thr177 
Arg190 
- 10.52 19.42 nM 631 13 4 
ABAD29 
 
2.178 
Ser187 
Asn179 
Asn183 
His184 
Arg190 
- 7.49 3.21 µM 623 13 4 
ABAD30 
 
2.365 
Asn183 
Thr177 
Thr188 
His184 
- 9.18 186.68 nM 621 11 4 
ABAD31 
 
8.647 
Trp147 
Ala180 
Ser187 
Arg190 
- 7.53 3.02 µM 725 13 4 
ABAD32 
 
8.741 
Trp147 
His184 
- 6.59 14.77 µM 723 11 4 
ABAD33 
 
1.817 
Asn179 
Thr188 
Asn183 
- 6.42 19.55 µM 445 9 3 
ABAD34 
 
 
1.458 
Trp147 
Arg190 
Ala180 
- 6.08 35.18 µM 475 10 3 
ABAD35 
 
3.807 
Asn179 
Asn183 
- 6.36 21.87 µM 525 7 2 
R1
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N S
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O
N
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ABAD36 
 
3.167 
Asn183 
His184 
Asn179 
- 6.01 39.27 µM 493 7 2 
ABAD37 
 
7.367 
Trp147 
Asn183 
 
- 8.54 552.15 nM 548 10 2 
ABAD38 
 
4.363 
Ser187 
Arg190 
 
- 7.13 5.93 µM 524.57 12 4 
ABAD39 
 
3.848 
Trp 147 
Asn186 
- 8.69 426.76 nM 522 12 3 
ABAD40 
 
3.453 
Asn 186 
 
- 7.13 5.97 µM 629 11 4 
ABAD41 
 
1.412 
Arg190 
Asn186 
Asn183 
- 5.78 57.95 µM 568 14 4 
ABAD42 
 
- 1.842 
Arg190 
Asn186 
Asn183 
- 7.43 3.57 µM 419 14 9 
ABAD43 
 
2.369 Asn183 - 9.89 56.41 nM 565 13 4 
ABAD44 
 
2.369 
Asn183 
Arg190 
 
- 10.67 14.98 nM 565 13 4 
ABAD45 
 
2.369 
Asn186 
Arg190 
Ser187 
His184 
- 11.47 3.9 nM 565 13 4 
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ABAD46 
 
2.393 His184 - 6.43 19.41 µM 565 13 4 
ABAD47 
 
2.393 
Ala180 
Ser187 
Trp147 
Asn183 
- 7.49 3.26 µM 565 13 4 
ABAD48 
 
1.419 
Asn139 
Asn186 
Trp147 
- 6.83 9.8 µM 563 13 4 
ABAD49 
 
0.468 
Asn186 
His184 
Asn139 
- 6.9 8.8 µM 561 13 4 
ABAD50 
 
4.05 
Ala 180 
Asn 186 
Trp 147 
Asn 183 
- 9.12 207.19 nM 544 13 5 
ABAD51 
 
3.867 Arg 190 - 10.41 23.22 nM 564 13 5 
ABAD52 
 
4.476 
Arg 190 
 
- 9.97 48.82 nM 559 13 4 
ABAD53 
 
4.484 
Asn 186 
 
- 10.44 22.16 nM 618 13 3 
ABAD54 
 
3.33 
Asn 183 
Asn 186 
Ser 187 
- 9.56 98.61 nM 538 13 4 
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ABAD55 
 
3.988 
Asn 183 
Asn 186 
Ser 187 
- 9.89 55.88 nM 565 13 5 
ABAD56 
 
4.139 
Asn 183 
Ser 187 
- 8.56 532.06 nM 553 13 4 
ABAD57 
 
3.33 No bonds - 8.65 457.09 nM 538 13 4 
ABAD58 
 
4.95 
Asn 186 
Thr 188 
His 184 
- 8.2 972.63 nM 501 11 4 
ABAD59 
 
3.63 
His 184 
Thr 188 
- 8.43 658.44 nM 538 13 4 
ABAD60 
 
4.29 
Trp 147 
Asn 186 
Arg 190 
Ala 180 
- 8.34 772.42 nM 555 12 5 
ABAD61 
 
-1.67 
Trp 147 
Asn 183 
His 184 
- 5.69 67.23 µM 482 16 4 
ABAD62 
 
-0.21 
Asn183 
Asn186 
 
-4.64 398.44 µM 379 12 4 
ABAD63 
 
3.94 
Asn183 
Asn186 
-7.14 5.85 µM 519 13 5 
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ABAD64 
 
3.21 Asn183 -7.01 7.16 µM 498 14 4 
ABAD65 
 
2.88 
Asn183 
Arg190 
-7.78 1.97 µM 531 15 5 
ABAD67 
 
3.27 
Thr177 
Asn186 
-6.65 13.46 µM 516 13 5 
ABAD68 
 
2.24 
Trp147 
Arg190 
-7.82 1.87 µM 595 16 2 
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Table 15. Re-docking of ABAD1, 2, 10, 12, 45, 51, and 53 against the R2 and 
R3 regions in the DBD of c-Myb 
 
X-axis: Number of the run. Y-axis: The free energy of binding in kcal/mol 
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Attachment 4 
 
AutoDock visualizations 
 
  Docking of AB81, 81-1, 81-2, 81-3, 81-4 and 81-5 against the R2 region of the DBD in c-Myb 
 
       
Fig. 68. Top 5 conformations of every compound. One can  
see that they bind in the same pocket/site. 
Fig. 69. Red and blue areas are sites that have affinity for 
nitrogen (blue) and oxygen (red). The same areas have  
affinity for both nitrogen and oxygen. 
 
          
Fig. 70. Same as fig. 69, just closer look. The sulfonic acid  
groups in all compounds are buried or lay near the areas with 
affinity for oxygen. 
     Fig. 71. AB81 – green, AB81-1 – blue, AB81-2 – red, AB81-3 – 
     black, AB81-4 – purple, AB81-5 – yellow. 
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Docking of AB81, 81-1, 81-2, 81-3, 81-4 and 81-5 against the R3 region of the DBD in c-Myb 
 
         
Fig. 72. Top 5 conformations of every compound. One can  
see that they bind in the same pocket/site. 
Fig. 73. Red and blue areas are sites with affinity for nitrogen and 
oxygen. The same areas have affinity for both nitrogen and oxygen. 
 
       
Fig. 74. Oxygen affin. map. The sulfonic acid groups are buried  
inside the areas with affinity  for the oxygen.  
         Fig. 75. AB81 – green, AB81-1 – blue, AB81-2 – red,  
          AB81-3 – black, AB81-4 – purple, AB81-5 – yellow. 
 
         
                            Fig. 76. Nitrogen affinity map.  Fig. 77. All 600 conformations represented with green    
spheres. 
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Docking of AB74, 74-1 – 74-5 against the R2 region of the DBD in c-Myb 
 
    
Fig. 78. Top 5 conformations of every compound. One can  
see that they bind in the same pocket/site. 
  Fig. 79. Red and blue areas are sites with affinity for nitrogen  
  and oxygen. 
 
    
                   Fig. 80. Nitrogen affinity map. Fig. 81. Oxygen affinity map. The sulfonic acid groups are buried 
 inside the areas with affinity for oxygen. 
 
           
        Fig. 82. AB74 – green, AB74-1 – blue, AB74-2 – red,  
          AB74-3 – black, AB74-4 – purple, AB74-5 – yellow. 
 Fig. 83. All 600 conformations represented with green spheres. 
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Docking of AB74, 74-1 – 74-5 against the R3 region of the DBD in c-Myb 
 
             
Fig. 84. Top 5 conformations of every compound. One can  
see  that they bind in the same pocket/site. 
Fig. 85. Red and blue areas are sites with affinity for nitrogen 
and oxygen. 
 
   
                     Fig. 86. Nitrogen affinity map. Fig. 87. Oxygen affinity map. The sulfonic acid groups are buried  
inside the areas with affinity for oxygen. 
 
  
    Fig. 88. AB74 – green, AB74-1 – blue, AB74-2 – red,  
    AB74-3 – black, AB74-4 – purple, AB74-5 – yellow. 
  Fig. 89. All 600 conformations represented with green spheres. 
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Docking of AB75, 75-1 – 75-5 against the R2 region of the DBD in c-Myb 
 
                  
Fig. 90. Top 5 conformations of every compound. One can   
see that they bind in the same pocket/site. 
Fig. 91. Red and blue areas are sites that have affinity for 
nitrogen and oxygen. The same areas have affinity for both 
nitrogen and oxygen. 
 
                             
               Fig. 92. Nitrogen affinity map.   Fig. 93. Oxyg. affinity map. The sulfonic acid groups are buried 
  inside the areas with affinity for oxygen. 
 
                                
     Fig. 94. AB75 – green, AB75-1 – blue, AB75-2 – red,  
     AB75-3 – black, AB75-4 – purple, AB75-5 – yellow. 
 Fig. 95. All 600 conformations represented with green spheres. 
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 Docking of AB75, 75-1 – 75-5 against the R3 region of the DBD in c-Myb 
 
             
Fig. 96. Top 5 conformations of every compound. One  
        can see that they bind in the same pocket/site. 
     Fig. 97. Red and blue areas are sites that have affinity for  
     nitrogen and oxygen.  
 
                    
                  Fig. 98. Nitrogen affinity map.   Fig. 99. Oxygen affinity map. The sulfonic acid groups are buried 
 inside the areas with affinity for oxygen. 
 
                      
    Fig. 100. AB75 – green, AB75-1 – blue, AB75-2 – red,  
    AB75-3 –black, AB75-4 – purple, AB75-5 – yellow. 
Fig. 101. All 600 conformations represented with green spheres. 
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Docking of AB76, 76-1 – 76-5 against the R2 region of the DBD in c-Myb 
 
             
Fig. 102. Top 5 conformations of every compound. 
 One can  see that they bind in the same pocket/site. 
 Fig. 103. Red and blue areas are sites that have affinity for   
nitrogen and oxygen. 
 
           
                  Fig. 104. Nitrogen affinity map. Fig. 105. Oxygen affinity map. The sulfonic acid groups are buried 
inside the areas with affinity for oxygen. 
 
                        
    Fig. 106. AB76 – green, AB76-1 – blue, AB76-2 – red,  
    AB76-3 – black, AB76-4 – purple, AB76-5 – yellow. 
 Fig. 107. All 600 conformations represented with green spheres. 
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Docking of AB76, 76-1 – 76-5 against the R3 region of the DBD in c-Myb 
 
        
Fig. 108. Top 5 conformations of every compound. One  
can see that they bind in the same pocket/site. 
Fig. 109. Red and blue areas are sites that have affinity for nitrogen  
and oxygen. The same areas have affinity for both atoms. 
 
          
               Fig. 110. Nitrogen affinity map.  Fig. 111. Oxygen affinity map. The sulfonic acid groups are buried 
 inside the areas with affinity for oxygen. 
 
                                  
    Fig. 112. AB76 – green, AB76-1 – blue, AB76-2 – red,  
      AB76-3 – black, AB76-4 – purple, AB76-5 – yellow. 
  Fig. 113. All 600 conformations represented with green spheres. 
  All conformations are located between Ser187 and Asn183. 
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Docking of AB77, 77-1 – 77-5 against the R2 region of the DBD in c-Myb 
 
                  
Fig. 114. Top 5 conformations of every compound. One  
can see that they bind in the same pocket/site. 
Fig. 115. Red and blue areas are sites that have affinity for nitrogen  
and oxygen. The same areas have affinity for both atoms. 
 
           
               Fig. 116. Nitrogen affinity map.            Fig. 117. Oxygen affinity map. The sulfonic acid groups are buried 
           inside the areas with affinity for oxygen. 
 
                            
    Fig. 118. AB77 – green, AB77-1 – blue, AB77-2 – red,  
    AB77-3 – black, AB77-4 – purple, AB77-5 – yellow. 
      Fig. 119. All 600 conformations represented with green spheres. 
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Docking of AB77, 77-1 – 77-5 against the R3 region of the DBD in c-Myb 
 
               
Fig. 120. Top 5 conformations of every compound. One  
can see that they bind in the same pocket/site. 
Fig. 121. Red and blue areas are sites that have affinity for nitrogen  
and oxygen. The same areas have affinity for both atoms. 
 
     
            Fig. 122. Nitrogen affinity map.  Fig. 123. Oxygen affinity map. The sulfonic acid groups are buried 
 inside the areas with affinity for oxygen. 
 
              
     Fig. 124. AB77 – green, AB77-1 – blue, AB77-2 – red,  
     AB77-3 – black, AB77-4 – purple, AB77-5 – yellow. 
      Fig. 125. All 600 conformations represented with green spheres. 
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Docking of AB78, 78-1 – 78-5 against the R2 region of the DBD in c-Myb 
 
                       
Fig. 126. Top 5 conformations of every compound. One 
        can see that they bind in the same pocket/site. 
Fig. 127. Red and blue areas are sites that have affinity for nitrogen  
and oxygen. The same areas have affinity for both atoms. 
 
  
           Fig. 128. Nitrogen affinity map.  Fig. 129. Oxygen affinity map. The sulfonic acid groups are buried 
 inside the areas with affinity for oxygen. 
 
            
      Fig. 130. AB78 – green, AB78-1 – blue, AB78-2 – red,  
     AB78-3 – black, AB78-4 – purple, AB78-5 – yellow. 
    Fig. 131. All 600 conformations represented with green spheres. 
	  	  186	  
Docking of AB78, 78-1 – 78-5 against the R3 region of the DBD in c-Myb 
 
  
   Fig. 132. Top 5 conformations of every compound. One 
        can see that they bind in the same pocket/site. 
Fig. 133. Red and blue areas are sites that have affinity for nitrogen  
and oxygen. The same areas have affinity for both atoms. 
 
     
              Fig. 134. Nitrogen affinity map.  Fig. 135. Oxygen affinity map. The sulfonic acid groups are buried 
 inside the areas with affinity for oxygen. 
 
         
    Fig. 136. AB78 – green, AB78-1 – blue, AB78-2 – red,  
     AB78-3 – black, AB78-4 – purple, AB78-5 – yellow. 
      Fig. 137. All 600 conformations represented with green spheres. 
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Visualization of the re-docked conformations of ABAD45 and ABAD53 
 
Re-docking of ABAD45 in the R2 region in the DBD of the c-Myb 
 
      
Fig. 138. Top conformations from every single of the 26 runs 
– 26 conformations totally. All conformations have been 
docked in the region near Lys128.  
Fig. 139. Red and blue areas are sites that have affinity for 
nitrogen and oxygen. The same areas have affinity for both 
nitrogen and oxygen. 
 
              
Fig. 140. Same as fig. 139, just a closer view.  Fig. 141. All 2600 conformations of ABAD45 represented 
with small green spheres. All the spheres are grouped near 
Lys128. 
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Re-docking of ABAD45 in the R3 region in the DBD of the c-Myb 
 
                    
Fig. 142. Top confor. from every single of the 26 runs – 26 
confor. totally. All confor. are docked in the same region. 
Fig. 143. Red and blue areas are sites that have affinity 
 for nitrogen and oxygen. 
 
 
Fig. 144. The same areas have affinity for both nitrogen and oxygen. One can see that the sulfonic acid groups and the  
tetrazole rings are  buried in the regions with affinity for nitrogen and oxygen. 
 
 
Fig. 145. All 2600 conformations of ABAD45 represented with small green spheres. All the spheres are grouped near Ser187 
and Asn183. 
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Re-docking of ABAD53 in the R2 region in the DBD of the c-Myb 
 
                     
Fig. 146. Top confor. from every single of the 26 runs – 26 
confor. totally. All confor. were docked in the same region. 
Fig. 147. Red and blue areas are sites that have affinity for nitrogen 
and oxygen. The same areas have affinity for both atoms. 
 
 
Fig. 148. Red and blue areas are sites that have affinity for nitrogen and oxygen. The same areas have affinity for both nitrogen 
and oxygen. One can see that oxygen atoms on the sulfonic acid groups and tetrazole rings are buried in the regions with affinity 
for nitrogen and oxygen. 
 
 
             Fig. 149. All 2600 confor. of ABAD53 represented with small green spheres. All the spheres are grouped near Lys128. 
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Re-docking of ABAD53 in the R3 region in the DBD of the c-Myb 
 
                   
Fig. 150. Top confor. from every single of the 26 runs – 26 
confor. totally. All confor. were docked in the same region. 
Fig. 151. Red and blue areas are sites with affinity for nitrogen  
and oxygen. The same areas have affinity for both atoms. 
 
 
Fig. 152. Red and blue areas are sites that have affinity for nitrogen and oxygen. The same areas have affinity for both nitrogen 
and oxygen. One can see that oxygen atoms on the sulfonic acid groups and tetrazole rings are buried in the regions with affinity 
for nitrogen and oxygen. 
 
 
Fig. 153. 2600 conformations of ABAD53 represented with small green spheres that are grouped near Ser187 and Asn183. 
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Attachment 5 
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